%PDF-1.4%‚„œ”
62 0 obj
<</Metadata 64 0 R/PageLabels 10 0 R/Pages 55 0 R/Type/Catalog>>
endobj
64 0 obj
<</Length 1664/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 4.2.1-c043 52.389687, 2009/06/02-13:20:35        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/">
         <xmp:CreateDate>2008-01-23T14:58:47Z</xmp:CreateDate>
         <xmp:CreatorTool>QuarkXPress(tm) 6.52</xmp:CreatorTool>
         <xmp:ModifyDate>2015-04-18T04:36:43-07:00</xmp:ModifyDate>
         <xmp:MetadataDate>2015-04-18T04:36:43-07:00</xmp:MetadataDate>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/">
         <pdf:Producer>QuarkXPress(tm) 6.52</pdf:Producer>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/">
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">Layout 1</rdf:li>
            </rdf:Alt>
         </dc:title>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:pdfx="http://ns.adobe.com/pdfx/1.3/">
         <pdfx:XPressPrivate>%%DocumentProcessColors: Black&#xA;%%EndComments</pdfx:XPressPrivate>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/">
         <xmpMM:DocumentID>uuid:e3270548-1dd1-11b2-0a00-1e0a273dd000</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:e327054c-1dd1-11b2-0a00-09f600000000</xmpMM:InstanceID>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>
endstream
endobj
10 0 obj
<</Nums[0<</S/D/St 278>>]>>
endobj
55 0 obj
<</Count 6/Kids[56 0 R 57 0 R 58 0 R 59 0 R 60 0 R 61 0 R]/Type/Pages>>
endobj
56 0 obj
<</Annots 65 0 R/Contents 66 0 R/MediaBox[0 0 612 792]/Parent 55 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 67 0 R/GS2 68 0 R>>/Font<</T1_0 14 0 R/T1_1 18 0 R/T1_10 69 0 R/T1_2 22 0 R/T1_3 26 0 R/T1_4 30 0 R/T1_5 34 0 R/T1_6 38 0 R/T1_7 42 0 R/T1_8 46 0 R/T1_9 50 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
57 0 obj
<</Annots 70 0 R/Contents 71 0 R/MediaBox[0 0 612 792]/Parent 55 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 72 0 R/GS2 73 0 R>>/Font<</T1_0 34 0 R/T1_1 14 0 R/T1_2 22 0 R/T1_3 18 0 R/T1_4 38 0 R/T1_5 30 0 R/T1_6 69 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
58 0 obj
<</Annots 74 0 R/Contents 75 0 R/MediaBox[0 0 612 792]/Parent 55 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 76 0 R/GS2 77 0 R>>/Font<</T1_0 34 0 R/T1_1 38 0 R/T1_2 14 0 R/T1_3 18 0 R/T1_4 22 0 R/T1_5 54 0 R/T1_6 30 0 R/T1_7 69 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
59 0 obj
<</Annots 78 0 R/Contents 79 0 R/MediaBox[0 0 612 792]/Parent 55 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 80 0 R/GS2 81 0 R>>/Font<</T1_0 34 0 R/T1_1 38 0 R/T1_2 14 0 R/T1_3 54 0 R/T1_4 22 0 R/T1_5 18 0 R/T1_6 69 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
60 0 obj
<</Annots 82 0 R/Contents 83 0 R/MediaBox[0 0 612 792]/Parent 55 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 84 0 R/GS2 85 0 R>>/Font<</T1_0 34 0 R/T1_1 14 0 R/T1_2 38 0 R/T1_3 30 0 R/T1_4 18 0 R/T1_5 22 0 R/T1_6 54 0 R/T1_7 69 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
61 0 obj
<</Annots 86 0 R/Contents 87 0 R/MediaBox[0 0 612 792]/Parent 55 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 88 0 R/GS2 89 0 R>>/Font<</T1_0 54 0 R/T1_1 22 0 R/T1_2 18 0 R/T1_3 14 0 R/T1_4 34 0 R/T1_5 69 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
86 0 obj
[90 0 R]
endobj
87 0 obj
<</Length 12519>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
318 745 234 10 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.02499 Tc 0.013 Tw 8 0 0 8 347.0937 749.5293 Tm
(Prolonged QT Interval, Syncope, and Delirium with Galantamine)Tj
ET
0 0 0 0 k
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
10 0 0 10 267.483 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 5 0 0 5 400.608 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 413.7891 23.9116 Tm
[(2008 February)55 (, V)110 (olume 42    )]TJ
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 5 0 0 5 524.3189 25.4116 Tm
(n)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 10 0 0 10 537.5 23.9116 Tm
(283)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
0 0 0 0 k
60 135.941 492 602.059 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
-0.008 Tc 0.008 Tw 8 0 0 8 73.5 732.5292 Tm
(head-up tilt testing and the additional yield of drug provocation. Heart\)Tj
-0.02499 Tc 0 Tw 0 -1.25 TD
[(1996;76:406)-25 (-1)35 (1.)]TJ
-0.004 Tc 0.004 Tw -1.6875 -1.375 Td
[(21.)-496 (Bordier P)110 (, Lanusse S, Garrigue S, et al. Causes of syncope in patients)]TJ
-0.019 Tc 0.019 Tw 1.6875 -1.25 Td
[(with Alzheimer)-35 (\325)56 (s disease treated with donepezil. Drugs Aging 2005;22:)]TJ
-0.02499 Tc 0 Tw T*
(687-94.)Tj
-0.015 Tc 0.015 Tw -1.6875 -1.375 Td
[(22.)-485 (Bednar MM, Harrigan EP)110 (, Anziano RJ, Camm AJ, Ruskin JN. The QT)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.25 Td
[(interval. Prog Cardiovasc Dis 2001;43:1)50 (-)-125 (45.)]TJ
0 Tc 0.02499 Tw -1.6875 -1.375 Td
[(23.)-500 (Martins JB, Zipes DP)110 (, Lund DD. Distribution of local repolarization)]TJ
-0.02499 Tc 0.006 Tw 1.6875 -1.25 Td
[(changes produced by ef)20 (ferent vagal stimulation in the canine ventricles. J)]TJ
0.013 Tw T*
[(Am Coll Cardiol 1983;2:1)35 (191)50 (-9.)]TJ
-0.002 Tc 0.002 Tw -1.6875 -1.375 Td
[(24.)-498 (Inglis F)80 (. The tolerability and safety of cholinesterase inhibitors in the)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.25 Td
[(treatment of dementia \(letter\). Int J Clin Pract Suppl 2002;Jun:45)-25 (-)-75 (63.)]TJ
-0.035 Tc 0.008 Tw -1.6875 -1.375 Td
[(2)-10 (5)-10 (.)-485 (Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the prob\-)]TJ
0.013 Tw 1.6875 -1.25 Td
[(ability of adverse drug reactions. Clin Phar)-25 (macol Ther 1981;30:239)-25 (-)-125 (45.)]TJ
ET
0 0 0 1 K
114 575.029 m
240 575.029 l
S
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 9 0 0 9 60 550.5292 Tm
[(Prolongaci\227n del Intervalo QT)75 (, S\222ncope, y Delirio con el uso de la)]TJ
0 Tw 0 -1.22223 TD
(Galantamina)Tj
ET
BT
/T1_4 1 Tf
0.013 Tw 8 0 0 8 60 525.5292 Tm
(AA Fisher y MW Davis)Tj
ET
BT
/T1_1 1 Tf
8 0 0 8 60 509.5293 Tm
[(Ann Phar)-25 (macother)]TJ
ET
BT
/T1_4 1 Tf
0 Tw 8 0 0 8 121.9947 509.5293 Tm
[(2008;42:278)-25 (-)-25 (83.)]TJ
ET
BT
/T1_4 1 Tf
7.5 0 0 7.5 60 484.0293 Tm
(EXTRACT)Tj
0 Tc 4.41532 0 Td
(O)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 6 0 0 6 60 470.5293 Tm
(OBJETIV)Tj
-0.02299 Tc 4.19462 0 Td
(OS:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 96.7354 470.5293 Tm
(Describir un caso de prolongaci\227n del intervalo QT)Tj
-0.0251 Tc 19.33697 0 Td
(,)Tj
-0.02499 Tc 0 Tw 0.46237 0 Td
(s\222ncope,)Tj
-0.0251 Tc -24.12115 -1.11765 Td
(y)Tj
-0.02499 Tc 0.01199 Tw 0.7123 0 Td
(delirio asociado al uso de la galantamina, y analizar casos similares)Tj
-0.03999 Tc -0.7123 -1.11765 Td
(reportados al Comit\216 Consejero de Reacciones Adversas a Medicamentos)Tj
-0.02499 Tc 0 -1.11764 TD
(Australiano, con el uso de los inhibidores de la acetilcolinesterasa.)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 0.013 Tw 6 0 0 6 60 429.5293 Tm
(RESUMEN DEL CASO:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 123.6132 429.5293 Tm
(Un paciente de 85 a\226os de edad con historia de)Tj
-7.48391 -1.11765 Td
(demencia leve de etiolog\222a mixta \(Alzheimer y vascular\) hab\222a es\tado)Tj
T*
(recibiendo galantamina de liberaci\227n prolongada en dosis de 8 mg)Tj
0 -1.11765 TD
[(diarios por un a\226o y medio. T)35 (res meses antes de su admisi\227n a la sala de)]TJ
0 Tw 0 -1.11764 TD
(emer)Tj
0.01199 Tw 1.87827 0 Td
(gencia, el paciente hab\222a tenido un episodio de s\222ncope con baja d\e)Tj
-1.87827 -1.11765 Td
(presi\227n arterial y bradicardia. Dos meses m\207s tarde, la galantamin\a fue)Tj
0 -1.11765 TD
(suspendida pero en el transcurso de 2 semanas, el paciente present\227)Tj
0 -1.11764 TD
(marcado deterioro cognitivo, de comportamiento, y funcional por lo que)Tj
0 -1.11765 TD
[(la galantamina fue recetada de nuevo al paciente. T)36.4 (res semanas m\207s)]TJ
T*
(tarde, el paciente desarroll\227 s\222ncope, delirio, hipotensi\227n, pr\olongaci\227n)Tj
0 -1.11764 TD
(del intervalo QT con arritmias card\222acas serias, adem\207s de v\227mi\to y)Tj
0 -1.11765 TD
[(diarrea. Su contaje sangu\222neo y bioqu\222mico era nor)-23.9 (mal y no hab\222a)]TJ
T*
(indicio de infecci\227n. La galantamina y el irbesartan fueron suspendid\os.)Tj
0 -1.11764 TD
(En 6 d\222as su delirio se resolvi\227 completamente, y en 4 d\222as el \intervalo)Tj
0 -1.11765 TD
(QT se acort\227 de 503)Tj
0 Tc 7.73245 0.00001 Td
(\320)Tj
-0.02499 Tc 0.62491 0.00001 Td
[(443 milisegundos \(corregido con la f\227r)-24 (mula de)]TJ
-8.35735 -1.11766 Td
[(Bazett\), y per)-25 (maneci\227 en un valor nor)-25 (mal desde entonces.)]TJ
ET
BT
/T1_3 1 Tf
-0.024 Tc 0.013 Tw 6 0 0 6 60 274.5292 Tm
[(REPOR)37 (TES AUSTRALIANOS:)]TJ
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 142.0802 274.5292 Tm
(La galantamina estuvo asociada a 18 casos de)Tj
-9.65649 -1.11764 Td
(delirio/confusi\227n, 8 de s\222ncope, 13 de bradicardia, 6 de otro tipo\ de)Tj
0 -1.11764 TD
[(arritmias o anor)-25 (malidades en la conducci\227n, y 6 de hipotensi\227n. El)]TJ
0 -1.11765 TD
(donezil estudo asociado a 56, 15, 26, 15, y 5 casos, y la rivastigmina a\)Tj
0 -1.11764 TD
(21, 8, 6, 2, y 2 casos, respectivamente. Cinco de los casos reportados)Tj
T*
[(con la galantamina fueron fatales, 1)35 (1 con el donepezil, y 3 con la)]TJ
0 -1.11765 TD
(rivastsigmina, incluyendo 3, 6, y 0 casos de muerte repentina,)Tj
0 Tw 0 -1.11764 TD
(respectivamente.)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 6 0 0 6 60 195.5293 Tm
(DISCUSI\356N:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 95.8463 195.5293 Tm
(Este caso junto con otros reportados previamente y los)Tj
-4.21721 -1.11765 Td
(identificados mediante la base de datos australiana ilustran que los)Tj
T*
(inhibidores de la acetilcolinesterasa pueden conllevar a delirio, s\222n\cope,)Tj
T*
(hipotensi\227n, y arritmias serias. La escala de probabilidad Naranjo in\dic\227)Tj
0 -1.11765 TD
(que la galantamina era probablemente responsable por la prolongaci\227n)Tj
0 -1.11764 TD
[(del intervalo QT)75 (, s\222ncope, y delirio en este paciente.)]TJ
ET
BT
/T1_3 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 318 732.1874 Tm
(CONCLUSIONES:)Tj
ET
BT
/T1_4 1 Tf
-0.0251 Tc 8.5 0 0 8.5 368.0652 732.1874 Tm
(La)Tj
-0.02499 Tc 0.01199 Tw 1.2422 -0.00001 Td
(administraci\227n de la galantamina y otros inhibidores)Tj
-7.13222 -1.11764 Td
(de la acetilcolinesterasa requieren de la vigilancia y evaluaci\227n de)Tj
T*
(factores de riesgo que puedan precipitar una prolongaci\227n del interva\lo)Tj
0 -1.11765 TD
[(QT)75 (, s\222ncope, y delirio.)]TJ
ET
BT
/T1_4 1 Tf
0.013 Tw 8 0 0 8 439.675 687.1874 Tm
[(T)35 (raducido por Encar)-25 (naci\227n C Su\207rez)]TJ
ET
BT
/T1_4 1 Tf
0.01199 Tw 9 0 0 9 318 661.1874 Tm
[(Prolongation de l\325Intervalle QT)75 (, Syncope, et Delirium Suite \210 la)]TJ
0 -1.22223 TD
(Prise de Galantamine)Tj
ET
BT
/T1_4 1 Tf
0.013 Tw 8 0 0 8 318 636.1874 Tm
(AA Fisher et MW Davis)Tj
ET
BT
/T1_1 1 Tf
8 0 0 8 318 620.1873 Tm
[(Ann Phar)-25 (macother)]TJ
ET
BT
/T1_4 1 Tf
0 Tw 8 0 0 8 379.9947 620.1873 Tm
[(2008;42:278)-25 (-)-25 (83.)]TJ
ET
BT
/T1_4 1 Tf
-0.0251 Tc 7.5 0 0 7.5 318 594.6874 Tm
(R)Tj
-0.02499 Tc (\203SUM\203)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 6 0 0 6 318 581.1874 Tm
(OBJECTIF:)Tj
ET
BT
/T1_4 1 Tf
-0.0251 Tc 8.5 0 0 8.5 350.6682 581.1874 Tm
(D)Tj
-0.02499 Tc 0.01199 Tw [(\216crire un cas de prolongation de l\325intervalle QT)75 (, de syncope,)]TJ
-3.84332 -1.11765 Td
(et de delirium li\216s \210 la prise de galantamine et comparer \210 d\325\autres cas)Tj
0 -1.11764 TD
[(rapport\216s au Comit\216 australien d\325ef)20 (fets ind\216sirables des m\216dicaments)]TJ
T*
[(concer)-25 (nant les inhibiteurs de l\325ac\216tylcholinest\216rase \(AchE\). )]TJ
ET
BT
/T1_3 1 Tf
-0.024 Tc 0.013 Tw 6 0 0 6 318 540.1874 Tm
(SOMMAIRE DU CAS:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 377.7539 540.1874 Tm
[(Un homme de 85 ans souf)20 (frant de d\216mence a \216t\216)]TJ
-7.02987 -1.11765 Td
(trait\216 par la galantamine \210 lib\216ration prolong\216e \210 raison\ de 8 mg par jour)Tj
T*
[(pendant 18 mois. T)34.8 (rois mois avant la pr\216sente hospitalisation, il a)]TJ
0 -1.11763 TD
(pr\216sent\216 un \216pisode de syncope avec hypotension et bradycardie.\ Deux)Tj
0 -1.11765 TD
(mois plus tard, la galantamine a \216t\216 cess\216e mais en moins de 2 \semaines,)Tj
0 -1.11764 TD
(le patient a pr\216sent\216 une d\216t\216rioration marqu\216e au niveau\ fonctionnel,)Tj
0 -1.11765 TD
(comportemental, et cognitif ; la galantamine a donc \216t\216 r\216intro\duite.)Tj
0 -1.11764 TD
[(T)35 (rois semaines suite \210 la r\216introduction de la galantamine, le pati\ent a)]TJ
T*
(fait une syncope avec hypotension, un delirium, une prolongation de)Tj
0 -1.11765 TD
[(l\325intervalle QT)75 (, et de graves arythmies cardiaques en plus de)]TJ
0 -1.11764 TD
[(vomissements et de diarrh\216e. \313 l\325admission, la for)-23.2 (mule sanguine et tous)]TJ
0 -1.11765 TD
[(les tests de biochimie \216taient nor)-25 (maux. Aucune infection n\325a \216t\216)]TJ
T*
(d\216tect\216e. La galantamine ainsi que l\325irb\216sartan ont \216t\216\ cess\216s. Le)Tj
0 -1.11764 TD
(delirium est compl\217tement disparu apr\217s 6 jours et l\325intervalle\ QT est)Tj
T*
(pass\216 de 503)Tj
0 Tc 4.88416 0 Td
(\320)Tj
-0.02499 Tc 0.6249 0 Td
[(443 millisecondes \(corrig\216 selon la for)-23.3 (mule de Bazett\) 4)]TJ
-5.50906 -1.11765 Td
[(jours apr\217s l\325arr\220t de la galantamine et est demeur\216 nor)-25 (mal par la suite.)]TJ
T*
(La galantamine a \216t\216 associ\216e \210 18 cas de delirium ou de con\fusion, 8)Tj
-0.0251 Tc 0 -1.11765 TD
(cas)Tj
-0.02499 Tc 1.43918 0 Td
(de syncope, 13 cas de bradycardie, 6 cas d\325arythmies ou de troubles)Tj
-1.43918 -1.11765 Td
(de conduction, et 6 cas d\325hypotension. Le don\216p\216zil a, quant \210\ lui, \216t\216)Tj
0 -1.11764 TD
(associ\216 respectivement \210 56, 15, 26, 15, et 5 cas tandis que la)Tj
0 -1.11765 TD
(rivastigmine l\325a \216t\216 dans 21, 8, 6, 2, et 2 cas respectivement.\ Cinq cas de)Tj
T*
[(d\216c\217s ont \216t\216 rapport\216s avec la galantamine, 1)35 (1 avec le don\216p\216zil, et 3)]TJ
0 -1.11764 TD
(avec la rivastigmine, incluant 3, 6, et 0 morts soudaines respectivement\. )Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 318 318.6874 Tm
(DISCUSSION:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 357.0317 318.6874 Tm
(Ce cas, en plus des cas pr\216c\216demment publi\216s et de ceux)Tj
-4.59196 -1.11764 Td
(rapport\216s dans le cadre du programme australien de d\216claration des\)Tj
0 -1.11765 TD
[(ef)20 (fets ind\216sirables des m\216dicaments, montre que les inhibiteurs de)]TJ
0 -1.11764 TD
(l\325AchE peuvent provoquer un delirium, une syncope, de l\325hypotensio\n,)Tj
T*
[(et des arythmies potentiellement mortelles. L)90 (\325\216chelle de probabilit\216 de)]TJ
0 -1.11765 TD
(Naranjo montre que la galantamine \216tait la cause probable de la)Tj
0 -1.11764 TD
[(prolongation de l\325intervalle QT)75 (, de la syncope, et du delirium observ\216s)]TJ
0 -1.11765 TD
(chez ce patient. )Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 318 239.6873 Tm
(CONCLUSIONS:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 364.2133 239.6873 Tm
(La prise de galantamine et d\325autres inhibiteurs de)Tj
-5.43686 -1.11764 Td
(l\325ac\216tylcholinest\216rase doit \220tre suivie rigoureusement et un\e \216valuation)Tj
T*
(des facteurs de risque pouvant pr\216cipiter une prolongation de l\325in\tervalle)Tj
0 -1.11764 TD
[(QT)75 (, une syncope, ou un delirium doit \220tre faite. )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 8 0 0 8 468.1624 194.6873 Tm
(T)Tj
-0.02499 Tc 0.013 Tw 0.55068 0.00001 Td
(raduit par Denyse Demers)Tj
ET
BT
0 g
/GS2 gs
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 299.75243 11 Tm
( at UNIV OF MICHIGAN on April 18, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
54 0 obj
<</BaseFont/HBYZVQ+Times-BoldItalic/Encoding 51 0 R/FirstChar 32/FontDescriptor 53 0 R/LastChar 121/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 722 0 667 722 0 389 0 0 0 889 0 0 611 722 0 556 611 0 0 889 0 0 0 0 0 0 0 0 0 500 0 444 500 444 0 500 556 278 0 0 278 778 556 500 500 0 389 389 278 556 444 667 0 444]>>
endobj
22 0 obj
<</BaseFont/AOGMZT+Times-Italic/Encoding 19 0 R/FirstChar 32/FontDescriptor 21 0 R/LastChar 121/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 0 250 0 500 0 500 0 500 0 0 0 500 0 0 0 0 0 0 0 0 611 0 0 0 0 611 0 0 0 0 0 0 0 0 0 611 0 0 0 556 0 611 0 0 0 0 0 0 0 0 0 0 500 500 444 0 444 278 0 500 0 0 0 278 722 500 500 500 0 389 389 278 500 0 667 0 444]>>
endobj
18 0 obj
<</BaseFont/CLWRCQ+ZapfDingbatsITC/Encoding 15 0 R/FirstChar 110/FontDescriptor 17 0 R/LastChar 110/Subtype/Type1/Type/Font/Widths[761]>>
endobj
14 0 obj
<</BaseFont/OHABFE+Times-Bold/Encoding 11 0 R/FirstChar 32/FontDescriptor 13 0 R/LastChar 251/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 0 0 0 499 499 499 499 499 499 499 499 499 499 332 0 0 0 0 0 0 721 666 721 721 666 610 0 0 388 499 0 666 942 721 776 610 0 721 555 666 721 721 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 776 0 0 0 0 0 0 0 0 0 0 0 0 332]>>
endobj
34 0 obj
<</BaseFont/PWMQHS+Times-Roman/Encoding 31 0 R/FirstChar 32/FontDescriptor 33 0 R/LastChar 213/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 833 0 0 333 333 0 0 250 333 250 278 500 500 500 500 500 500 500 500 500 500 278 278 0 564 0 444 0 722 667 667 722 611 556 722 722 333 389 722 611 889 722 722 556 722 667 556 611 722 722 944 722 722 611 333 0 333 0 0 0 444 500 444 500 444 333 500 500 278 278 500 278 778 500 500 500 500 333 389 278 500 500 722 500 500 444 0 0 0 0 0 0 0 0 611 0 0 0 444 444 0 0 0 0 0 444 444 444 0 278 0 0 0 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 722 0 0 0 0 500 0 444 444 333 333]>>
endobj
69 0 obj
<</BaseFont/Helvetica/Encoding/WinAnsiEncoding/Subtype/Type1/Type/Font>>
endobj
31 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 37/percent 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon 61/equal 63/question 65/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X/Y/Z/bracketleft 93/bracketright 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 131/Eacute 135/aacute/agrave 142/eacute/egrave/ecircumflex 146/iacute 150/ntilde/oacute 203/Agrave 208/endash 210/quotedblleft/quotedblright/quoteleft/quoteright]/Type/Encoding>>
endobj
33 0 obj
<</Ascent 684/CapHeight 662/Descent -215/Flags 34/FontBBox[-168 -218 1000 899]/FontFile3 32 0 R/FontName/PWMQHS+Times-Roman/ItalicAngle 0/StemH 0/StemV 84/Type/FontDescriptor/XHeight 677>>
endobj
32 0 obj
<</Length 9986/Length1 9986/Subtype/Type1C>>stream
  PWMQHS+Times-Roman   @¯ ¯¯¯¯˚<˚n˙|˙
 ãã
 ãã   ˚   ˜  ≤¨  &· }àç002.000Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku RomanTurku  Z  D F U Z M I P J O T S B  C 	 " $ * 
 V E N G  [   5 H Q W X  Y 1 L 4 2 8 % 3   )      ' . &  (    6 0  / R K 9 - #   i w :  + 7 ,   < > A ; ÿ ” œ ◊ » o À ≤ Æ “ – \   O ≠ ˘q©\∑,ª(∂πY∫#Zõ}/å£‚		5	Å
K
Ÿ:“óíç,êå˙e∂ÔiŒ1ü	Ü°á¥V≠|‹I¥Iè.Q≠|Í#k«K∑‡
?~Z„ ¢![!r")"’#f#Ì$s˚bÅ”¯®§◊¯0˜(}ì`HapQã1K›˜ƒ‘ÿ≤ñÇcóëwïkö|£ã¶ûù•¡E∫<˚+!˚!˚⁄/˜ﬂ∆∫˜¿˚bÅ–˜o´˜Ø§–F“˜cÒÙ¯<˜1{ìW<dpJã.Pﬁ˜Ö˜À˜P…&˚7(˚&˚ —6˜	ÎÕø˜ΩÏ˚˜-˚cŸöÆØ«∆•m7ó¸Åø¯´–ﬂ˜™Õ~ñvrzÅtãg|¶ ˜≥´&˜ñâéÖU<midpÑÜâàãÖãáåâéãø˚¬5©b…∏≤§æ¨˚*˚m¯Àwô¯`¯n¯Iô˚}ØàóÑzÑéîqB<˚q˚˜êÇûãíãñúííΩëô˚a}®ÜóÑîw˜˚ä¶PÆJ|tpG{rt|z||wuùloxzpk™r¥“µº˜*ƒ˜/¯-ñ©ôò°é¸†vÏﬂ˜îõMå~ó√¯ÁáéHwvÖEy{åôíãó∞ìÄY¸pV{}Ná{˚*†v¯+¡”ﬂ˜Nﬂ¯zõXêÇó–˜[ˆa¿9R_rQ`â˜¬Öè\{òè kzåìëãè∞ìÇa¸kFÇUÜ{˜kõTç~úŒ˜Öπµ´ù±∫¶eF˚ZGÄ}Rá{˚*Ç¶¯4ß®‰˜ö‰¯i˜~˜0È˚˚0+˚˚Á'˜˜ÍÛ˜2h˚^FA8O˜˜*ÁºÃ–ﬂ«*˚¸†v¯^w˜$◊8ﬂ˜E˘ßt¢opttop°tßß¢¢¶÷˝õËKèÅñ”˜˜ÜèWwZyVy|é©åãì¶î{_˚{CÅGà{˚*†v¯)¬åw⁄‹:ﬂ˜Eﬂ‘¯xõ]}õº˜yË^ƒB[p|ID€¨ÑçYxà@tyéôëåì¶ì{[˚ãS}z\â{˜göYê{ò≠˜≠Ãª√õî¨ª£kJ˚eN}xZà{˚ôÇ°êv¯Zwí¢æ»˜:—ú˜˜ªt´M∞ Ànú|§ã©Ø≠®∂≈Æd6úõ¨á˜ÉÜáâÖÜÑåéÖúôcçs:QXDO™e·Z≈j≠xùqãn_koYEiØÚs{\˚/òîíêéîìïäàñúÅ¥§á•Ÿ ƒ”˚—†v¯`w†w÷ﬂ–˜‚¯+¨wühblsH]â‰∞ÜéJqwÑMu{éöìåï§ï{_˚éYÇÉNÅ{˜ÉõKvùƒ˜súò§ûûôòôìîíìáÉîx†ìáõ°õû•˚bñvåƒ¯§∞„˜6›x¯O≥•{tÖà}rÖóª˜W˜`π˚ 1CYNrûw¢¢°†°òáòãò®™ü∑π¶lWNOuBqWg]kxjãZãN∑`…ã∏ã∏¢¬Ω∏Tëùx∑™ßõ≠ß˚0ﬂsàÄÉx{yb{sfo≠π»∫µ˜±¸$˚*Å´¯Àœﬂ˜w‰¯h˜á˜?Ë$SWlXpâ˜¡Üéa{U{[~{åïíãèÆîÅc¸úm„i⁄˜Ú˜˜!2b˚	]L5[\££˜ê∂µ¨ƒ◊ø;˚˚—˚1v˘Íwª‡˜ƒ˚6˚·Z˜˜l˜[∂Ò˜ÓÇõ˚@˚@˚ã˚L˚µ#Î%≤aßt≤t”ãû˜[¥¯4wö˘G˘Vü^ç}òl”˚ç¯Ãw˚d¸O˚!}xYáw˜Zü\äuô™ïéïëõπ˜
˜ö¥*ïtîlãpzÉWwÜ˜ó˚{˜˜ßú}∑¯Ov˜M≤ß˜˘˜yú=AOp5ã˚+,˜˜K˜SÂ˜	˜(ˆ“N˚∞°Ç˜tvÉu|wåÅå{éxíbôYìaã˚Zã˚!˚#ã˚]ã˚f˜˚˜_ã˜ã˜ øæ◊˚—ãû˘û˜Ò˜Ãü8é~ó÷¯O÷òóﬁéü˚∫wﬁàò@¸O@~8àw˚—˚1v˘Íw˜\‡˜±˜ä˜aÛ+Òdµo¢d¢{˜5º˚˚l˚[`%˚(î{˜@˜÷˜ã˜L˚*Åƒ¯(w—ﬂ˜Fﬂ=ŸË¯rØôYäñ∫˜Ï˚2{ÀáïÇY˚ÅràÄÉÅuy^wlcjÆµ˜€˚%{ªàò~[˚è;∫Y◊Ø±õ¶¶Ë∑∂9çàŸßîéæô˚*Åø¯ß¶·˜wﬂ¯µõÉÇäãáfÇó∏¯ÀÜéUx|á=v{åòëãêØìÇa˚0¨crïb˚.˚˚˚◊2˜¿µ†∂™çNêàŸßoÅÎ≠˚+»m^l_9Sﬁ˜˜æ◊‘¬ª\U˜†v¯-øåw·ﬂ˜Lﬂ˜Kﬁ‹˘ôõRåïª˜c˜d∆=SXpSU≈xk§SbvÇXFÜáÉÜÅÉ÷ºÉéZyåã1pyéõêåñ§ïx^˚íV}}Sâ{˜rõYyô∞˜Øéïïóï‹£®´ó™ª°iC˚mU~Sà{˜sõSå|ú»˜ê∏´™ú∫¡ûn9˚gSÑÉPÑ{˚—†v¯7´˜_®Úﬂ7ﬁ¯˘´\ßU˚QA˚2ä:k‹˚œBÅÄBá{˜òõ:çñ÷˜œ˜´Ë˚˜∆ùß≤†îÖoük°îÑú¢ûû¢˚—†v˜UÀ≤˜ä˜±˜UÀ˚äK˚bã©¯©¶¯¯6˜yèv*|~/ã˚˜¢¯*ö˚Ôà˚ú’ïôö»˜˚ù¸*|¯˚—⁄˜ ˜o¯ﬁøh≤\jrskk¢wØîñèãìîåëÜäÅâhohVgïwŒ≠∏»≈¸$Ä˜—˜˜I∑™r§mlrrlm§r™©§§©dãû¯Ì∂ü°˜gÒ˜|v¯„¯ÅÑ˜>¸ƒÑ˚>§˜°†õ˜¡¸í@~8àw˜∫ü8é~ó÷¯í¡˜†{˚°˚*˚nƒ˜&÷@‘Ê§˜k≤êßß–nﬁ˜EŸ•®›¿¯i¯≤?u~çìwù]têm*AE-L§h–gCKyvtuö|≤{æ¿FZnfgTÿ`Ô˜˜ŸÊ ]¥@é˚êTçsïãùîòûôòóòôìîúêÜ®ÁœÕ‰®áû|∞P˚Snf_›¿MaÃÌ»¶Æªƒ∏B.Û˚ﬁR?b˚ﬁ¿3M©µ£ïú≤π¨Ñéõâ§àªâ¿âà°Äãi˚*˚Vv˜a´¯«åw’ﬂ˜v‡Ï¯i˜à˜F‰*R_sVaâç‘‹ÖéTvää4m{åóéãó´ëÅ[¸gUÑÑMÑ{˜ÖõAå}ó…˜0m´©≤˜Ê˜˜$6f˚YAArmóûs}óÇóï˜äÏØìª™∫’º>˚˚*ív¯ewû¯\¯o¯Gõ˚{´äöÄv|Çoy]=˚[%˜îÜòáúãíúòî¨çõ˚W{üäïÜó§s˜˚ø£NéÇòeîãíãèíù∑˜˜‘¶Œíî©ç”ív°v¯dw†˘4p˘I¯Gõ˚{™àòÅy~áu~l0˚r<˜kt…çÑãò£ôì∂èõ˚^{µäôv≠%/˚\k‚H˜CãÜõäìíüòî¨çõ˚G{¢äîÄüX˜˚Èkòëíëëî©ô˜˜ÉÂ˚∞^úãåíìååªû˜˜Óúµêíûê¸$õv£v√˜ †˜Xñøh≤\jrskl¢wØ`ôêéãîïêáÅäâiogVgïxŒ≠∏»ƒ˚*†v¯Wwú¯b¯sõhçyòn∑˚˜Xﬂ˜û¶ßõ≠åö˚3}¨áíá}~uU?~üèÖs≥x™Ñöãìãõïë´çô˚b}µäêá∞SÍ˚%˚˚9pd}Ålä{˜%õnÄêóìêóô°€˜‹˚õsãäãÄ{ÄÑrá{-ãû˜°≥˜Ω±xûÓÚ$Ò˜{˜⁄¯±¯w˜$—˚3˚öw’ÉìÇD¸FCäp9âw˜¨ü<å|ö’˜Hä§¢äû⁄≈ñ°≤»≠Æ«œ˚â!S\˚ÊzÅãçt˜ôßíë≠˜ÕY-˚*†v›ﬂ¯çõ`çi°dº˚.˜V®¶ÔËΩÆÃâô˚_}ìêäãè¢äîáå~åÅÉÉ{|˚˚âç¯3ÜéOxzÜ>w{åòïãíØîZ¸uUââBÄ{˜~õMç~î¥˜Iç˜˚LûrçáãÖÉÇÖy{-~Ø¯¯¥—·˜~Ô¯~˜<€\ƒ˚’Q≠"º‹¿µ≤∆Â–L˚ ¶§u˜hvsÖÇÅzÑ|éê}üOwëq"?D)9≠a˜C˜>¨hNGZ\C0M¿˜Wu©˚h††çñóùØ´jÁ˜
„ÿÛ”˚Fû˜Gw˘Ø≠˜¯?˜˘P˚Eù˚å=∂5˜ ˜2•Ú˜ã˜Eã˜_˚˜#˚Sã˚Tã˚˚#ã˚_ã˚¡˚‚SÆu©}•ÖπT=Õ˜_˜,íåãå≤˚¯ê˚T:˚	˚˚:˜	˜T˜R›˜˜˜ﬁ˚˚R˜∫ñv˘"ûê˙1˙6˘ü˚Zw¬ÜôÇl|ÑkÇs˚˚Ë˚˜Èp–ãäãó§°ï¬ü˚üw áèá≠:≠9 ˚Ø˚%¯É†àïãò°óë¿êü˚àw…Çéá“˚SÃ˚CçÜË˚°ö˜.¯;ëyë|éÇë|°U™;±*ú[™4ôŸ˜Éñ™Ã˜H¶‘ö≥ñ©öµõóªë”ãûx∞¯·∞xûÚÒ¯˜ú˘?˜‚˜b˚)˜˚é˚†w’áò~C¸QC~~Aáw˜Ø˜Ç˜&˜˜cl˚Ö˚U#)˚a\~î´¯ê≠îë¡˜Q˜	˚˚Lúãû˜¡§˜ÆØxûÒÒ˜}˜‹˘'üdçvóp¨˚b˜ë˜¢ƒ¿Ë˜/ ˚7˚ßw‘Üó~D¸D4ÖÑ=Éw˜®ü=íó“˜X√é˜Ç˚…N¯"Kc˚=ä˜äÏ®óíΩ˜≈]1˚*~ß˘ß√÷F’˜o–T◊‘¯Q˜0ÿiª˚ÊÿÓ¡ÆµŒﬁC≈#!;H0J¢iÒ4‰˚<ulG&ÿI˜	˜
ÿÕÚÿ1¯PuiCVTØEø‘ƒ∏≥ œ∂_G‰ô¸-G__IAU«›Œû±…æ™tîÑãËE£rN˚*~∞¯‚‡Ÿ˜˘—¯J˘?ÇëyuÉáwã˚e˚˚Ääâäàãâáçâëä˜É˜5Y˚.&O?;uÑé´^°l}êpr}~tb∑u›˜5˜ Ú˜.˜@˚ƒ˚)¶µ‡˜Xúéåíé”ãû˜º∑˜±ûıÒ˜√Ò˘PüAè~ò”¯Q”òò’èü˚®w’áò~C˚W˚√˜W”òò’èü˚®w’áò~C¸QC~~Aáw˜®üAè~ò”˜b˜√˚bC~~Aáw˚*ã◊¯§‘˜Â·¯n˜~êmdÜpPã˚Ñ˜=˜D‚Ê≥⁄ã⁄Ì:Ÿ&˚HK˚lüÜØÍ≤Ø”ã›ƒP6?\*95˚F˚P~¯˚*†v˜i·¯ö=åyñ∫¯ÌÇç˚G0~•ïúíúèîã¢ï}j¸m\yÄ=ä|˚*}Ø¯Á∆˜—⁄g“–¯C˜lÍkπ+∑‡œπ§∞≈⁄K¬/,MX˚döá≥÷∏´ ãÃ∏^L^r_cnpwvÅWyû¡¶Üz™–ªp®XO8QICqvì†h£cÇéys}~ug∑v÷˜1˜Î˜˚*}ß¯∫˜Çö≠Á˜ë‰¯h˜m˜Bﬂ˚[wÑeL™˜1ÓÍ˜;´áö˚vá˚M˚;˚˚D‰˚˜˜·Í˜2j˚ cME4SÈ˜'≤ê≠îô°ò∑ù¥ÂæC˚˚*~•˘•£Î˜òÎ¯p˜ﬂ˜c˜E∆§ndò[[d~rnFPb˚˚˚≥˚—Or®≤~ªª≤ò§®—«≥˜˜+˚h`!44`ı˜h˜i∂ı‚‚∂!˚i-ãû˜»µb¥˜ì≤xûÓ˜î¢¥¢œ¯µ¯úà˜#¸¶w’áò~C¸QC~~Aáw˜´ü@é{ö“˜p˜&âﬂäñÅö7¢˜|t6|Å8˚&˜q∑®êêß˜˜û~0ù˜Éãû˘ûˆ∑¯ú˘ÔüFçyù–¯Q”ôô‘éü˚[˚o¸é˚{¯é˚Zw›Üò~D¸+&|x;Ñw˜}ü@éx•Ì¯$ç˜é¸∑ô˜ê¯Œç¸V9Ä~<Üwdã±eû˜»µb¥˜ì≤xûÓ˜ú¢¨¢´Ä¯Ë˜>o˚ ^]s˚7#Åè≤˜å˜.âﬂäñÇö6¢˜|t6|Å8˚.˜q®êêß˜˜û~0ù§á˜#¸•WÄw’áò~C¸QC~~Aáw¯Ø¸ív˘FwÇ˜∫˜±˘8I˚x˝FŒ”}≥˜…û˜Æ≥´˜¯Î˘W˜„û˚íxŸáïÅ@˚4iOq?˚3'˜
˜O˜KÏ˜˜%Ù–U˚µ£É˜fuuÑ{ÄsÖÄçéÄ°Ejë\˚[˚"˚&˚b˚|˜A!˜K˜˜¬ù˜\≈ôö√é˚*âw˜ó∂¯ß©Á˜ÄÔ+ÎÙ¯^¯!˜5/˜
˚˚4'˚ ˚
‘:ˆ¿ªù±π¯åàm˚%˚˚>qçw˜Öõ˜3˜<ã˜Ù+bváÇÅuod}j>\’˜˜± œ‰∏4˚;˚*ôv¯Ë‘ü¯@¯T˘ö¸|_`%úÉ≤Ã¢õ¡ã˜m˚Z¸ËÃ˚*†v˜;À¯Qw˜∑⁄>ÿË¯k˜;À&¯Q_˚Œ¸QK˜≠˚;ÿ˜;<À˚Ñ˜Ç˜Èç”}∑¯˙ûÚÚ˜¸∂˘S˘ü˚{w÷âûr(˚¢=Å`slakTtJO\ùÆnnÆÇ∞€˜‘‘ññ⁄èü˚Æy⁄ÉïÅB˚À˚@›6˜:˜HŸ›˜P˜ôõ†Ÿè”}Ø¯˛Ø≠˜¯?˜˘C˜ﬁ˜_˚˜#˚S˚T˚˚#˚_˚]˜˚#˜T˜S˜˜#˜]˚å˚T:˚	˚˚:˜	˜T˜R›˜˜˜ﬁ˚˚R˜Kìvò™˜óÆö´˜g§œw»◊˜r§Ã÷˜q•¿˘ó˜ö—f≥H˚˚ ˚˚;ªW’ÛÎ˜˜˚¯2eYYbyDd{í†oür{ëo˚ ˚	˚BæQÕıÔ˜˜ôâñáûÉ£óâ£∑ßí†∞çâø¿˚˝∫¿¯Ö˜£˚:˚<du•∑œÀ˜?‚≤™f^¸˜º˚:˚<cu£∏»∞ÊπΩ£°°òúëçäÑíïÅöÑ®Éëéwã}”ïvñû˘û˜ ∏¯1∑x˘T˘ü˚~wÂÑëk4˚„â¸¯u˚?w∂åñÑµ[¸M%~y8Éw˜ü>éz£¯ç∏¯J¸πú¯§Ôöü⁄ë˚*˚Vv˜a…¯ß£‡˜|ﬂ¯|˚kõ]çzö¥¯ÍÜêNgU™|ê_ã˚,˚˚&˚Õ4Ï¿¿§ªπçä˚NT|~AÑ{‰˜ÎkÑ~t~srÖs>W◊˜˜	¡Ÿ‹Õ™kF¸˚Xv˘7w˜$Á8ﬂ˜U˘ßt¢pottop¢tß¶¢¢¶Ëå˝¯^ÜèXwXyWy|é©åãì¶î{_¸!Äjg}ÇêóÄ≥iÜéwwwywk≤t¬˜∆÷˜"”ãû˘ûï˘H‡˘RüWêwòe¬˚S˜¶˜%˜K≈’§öÃèü˚Äw≈àñÜr|É}kd˚˚`∆CÓ~¶ã¢£öë»ü˚¡w–Ö¢w„˚˜˚5˚0˚U;)~ÅWÜw˜}‡ûVçsñå°åúò§∞∏˜˜(Í˚!´\ùgã}‡uwÉSäwdã≤dû˘ûÓ∞¯Ë˜Bs˚
Siz˚I0Åè∞¯n”òò’èü˚ßw’áò~C¸QpC~~Aáw¯≠úã∞fû˜»≥c≤˜ó±xû˜Ò˜Ü;˜¶Ä¯Â˜D≈oΩ\ßröyíZôçg Ë°≤∂⁄˜.«˚<˚¨wﬁàòA¸QA~8àw˜‚¶Ä˜%Ï“Ùß ˚˜Ã<Yb)äõ -ä˜yßèç√˜»]0¶Ä†˚»*O]˚O|ì¨˜ç˜Vå–d˚5†v˜Õ˜Õ©¯ã¯©˜’Õ¸ãI¯ã˚]Õ¸ãI¸õv£v˜Û˜€˜ ˚˜h˜T¯)©r§lmrrml§r©™§§™∞ß¸øh≤\jrskl¢wØpïîéãîïêáÅäâiogVgïxŒ≠∏»ƒ˚b†v¯E˜ ∂˜ Ê˜ ¯2¯}´tügÅÅáãÉÇäÜêïçÆßÆ¿ØÅüHh^OQWÆd∫¨§£´˚{´tügÇÄáãÉÇäÖêåïçÆßÆ¿ØÅüHi^NQWÆd∫¨§£´˚b†v¯Õˆ©˜ Ê˜ ¯%¯›øh≤\jrskl¢wØïîéãîïêáÅäâiogVhïwŒ≠∏»ƒ˚{øh≤\jrskl¢wØïîéãîïåêÜäÅâiogVhïwŒ≠∏»ƒ”ãû˘û˜œÒ˘R˘ü˚owæåùÇtÅáÄÅ{˚!˚x˚)˜tÄõÖöãò°ôëƒü˚¨wØâôÑßiüt≤W•e˜˚T˚M>~Ä2âw˜∆ü2ç~ñÿ˜U˜'˜w¡ﬂ®¢¬ë¸Ä˜˜ç˜‹˜˜T¯)©r§mlrrml§r™©§§™˚˝™r§mlrrlm§r™©§§©˚ôív˘&û˜CÒ¯˘ü˚¥w⁄âô}C¸d\Äwq|Üë£Ñ≤|õqqutp_≤n∆˜ »”˜¯”ôô⁄ç”ïv˘#ûõ˘;‡˘K˘ü˚`‡x∆ÜôÇm}Ñqm˚&¸˚,˜ÊmÕÅ©ãô§ñê èû˚ù‡wΩàú{±6˜ã¸∫ö˜p¯∆®’õõ∫ç”ãû˘û˜Ò‡˘eüXzñÎ2˚|˜é˜Q˜Q««£óŒêü˚òw«áíàtrxs4:tu∫∂˚@˚0˜W‡ﬁñóŸëû˚¨xŸÖñ8¸;8Ä=Öx˜¨û=ëÄóﬁ˜D•°ı!ÿ>¿Fãt‡yÇàOâw˚bÑÛ¯π®˜MÛ´Ë¯2¯õÊ?Ã .EM9dút©•õõ§ôÖò}ö}õáíï©ª™ª∆∫UGb}PuVoIy`ÄXä\ùï÷ö©œ‡¿Õ¢Ωãº˚¸n®t¢nnttnn¢t®®¢¢®˚—˚/§˘î§„ÿ˜¿˚/§1l}ô©˘<©ôô™Â§˚h˝∆˚—˚/§˘î§˜=ÿ˜ä˚/˘∆˚hrÂ™ô}m˝<m}}l1r˚—˜˜ ˜ì¯~™tügÅÇàãÇÅÜèïåç≠ßØ¿ØÅûHi^NRWÆd∫¨§£´dã±¯ﬂ±î¯ﬁ¯Á˜Dt˚hjq%˚ñ¯C¯ˆö¸°x˚>§Úü∞®˜˜q¸H¸ˆ|¯∆˚*Ç¶¯4ß®‰∆˜rx‰ﬂ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸#˝Ë¯i˜~˜0È˚˚0+˚˚Á'˜˜ÍÛ˜2h˚^FA8O˜˜*ÁºÃ–ﬂ«*˚¸†v¯bwÃ˜r˚Uﬂo ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú˚≥˝–˜êõKèÅñ”˜˜ÜèXyWxXx|é©åãì¶î{_˚{CÅGà{˚bÅ–˜o´˜Ø§–F“¿˜rGÒ√˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸˝Ú¯<˜1{ìW<dpJã.Pﬁ˜Ö˜À˜P…&˚7(˚&˚ —6˜	ÎÕø˜ΩÍ˚˜-˚cŸöÆØ«∆•m7ó˚*†v¯)¬åw⁄‹:ﬂ<˜›Bﬂﬁ˜ﬁ˘mf{~r~tëì{tóvñsëuãUhiI}®™ìùößïòàÑô°ÄØy¢Ö¢ã¡©©÷†¸1˝“¯xõ]}õº˜yË^ƒB[p|ID€™ÑçYxà@tyéôëåì¶ì{[˚ãS}z\â{˜göYê{ò≠˜≠ ª√õî¨ª£kJ˚eN}xZà{˚bñvåƒ¯§∞„§˜r6›ƒ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸˝t¯O≥•{tÖà}rÖóª˜W˜`π˚ 1CYNrûw¢¢°†°òáòãò®™ü∑π¶lWNOuBqWg]kxjãZãN∑`…ã∏ã∏¢¬Ω¥Tëùx∑™ßõ≠ß˚0ﬂsàÄÉt{yb{sfo≠π»∫µ˜±˚*†v˜]ºã¯à¯à˜]º¸àZ˚bñvåƒ¯§∞„Y˜rÅ›√˜Ö¯è˚'˜)|ö}í|ãz}}zzî}û˜.*˚ï¸èt¯O≥•{tÖà}rÖóª˜W˜`π˚ 1CYNrûw¢¢°†°òáòãò®™ü∑π¶lWNOuBqWg]kxjãZãN∑`…ã∏ã∏¢¬Ω¥Tëùx∑™ßõ≠ß˚0ﬂsàÄÉt{yb{sfo≠π»∫µ˜±dã±eû˜»µb¥˜ì≤xûÓ¨˜rî¢¨¢˜ ˜i ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸[˝™¿¯Ë˜>o˚ ^]s˚7#Åè≤˜å˜.âﬂäñÇö6¢˜|t6|Å8˚.˜q®êêß˜˜û~0ù§á˜#¸•V¿w’áò~C¸QC~~Aáw¯Ø”ãû˜[¥¯4wö˘G¸Ä˜r˜W˜i˜Ö¯è˚'˜)|ö}í|ãz}}zzî}û˜.*¸ ˝d˘Vü^ç}òl”˚ç¯Ãw˚d¸O˚!}xYáw˜Zü\äuô™ïéïëõπ˜
˜ö¥*ïtîlãpzÉWwÜ˜ó˚{˜˜ß˚bÅ–˜o´˜Ø§–F“v˜rëÒ√˜Ö¯è˚'˜)|ö}í|ãz}}zzî}û˜.*˚ï¸èÚ¯<˜1{ìW<dpJã.Pﬁ˜Ö˜À˜P…&˚7(˚&˚ —6˜	ÎÕø˜ΩÍ˚˜-˚cŸöÆØ«∆•m7ó˚bÅ–˜o´˜Ø˜jw§–F“t˜ ;Ò…˜’¯ê˚˜:K˚˚:¨˜Ú˜$˚Ú¸êÈ¯<˜1{ìW<dpJã.Pﬁ˜Ö˜À˜P…&˚7(˚&˚ —6˜	ÎÕø˜ΩÂ˚˜-˚cŸöÆØ«∆•m7óu°¯Wñ˜\öíã˜öî¸}é¶
ﬂ
_˜é˘
endstream
endobj
11 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma 48/zero/one/two/three/four/five/six/seven/eight/nine/colon 65/A/B/C/D/E/F 73/I/J 76/L/M/N/O/P 82/R/S/T/U/V 238/Oacute 251/ring]/Type/Encoding>>
endobj
13 0 obj
<</Ascent 912/CapHeight 676/Descent -203/Flags 262178/FontBBox[-168 -218 998 934]/FontFile3 12 0 R/FontName/OHABFE+Times-Bold/ItalicAngle 0/StemH 0/StemV 25/Type/FontDescriptor/XHeight 921>>
endobj
12 0 obj
<</Length 3393/Length1 3393/Subtype/Type1C>>stream
  OHABFE+Times-Bold   @¯ ¯¯¯¯˚<˚n˙z˙:
 ãã
 ãã   ˘   ı  <∞   }áå002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku BoldTurku                Ñ 0 # + & 5 * 7 4  3 6 . /  % - $ " 1 ª ' "   Y ÖJä˙QØÄÕ\·.£(|˝4®Äﬂ‚	F	ç	Ú
S
Ω1ò˚+ã˜¯M˜˜Ω˜¯q˜hrEo|Ç(˚*˜3˜.ﬁ€´«ã÷˜@◊˚*DI˚Y¶ƒ•∂´ø–ºV@YwSaN^K]U˚˚s¯3˚+†v¯Ø˜ú¯^¯o˘8¸3`˚r§Àú£†√˜b˚Z¸ØÍ˚+~™˘ßß˜˚˜˜9˜˚˜
ÿ¯j˜M„b«˚“‘‚£ºΩÃ„A√˚
˚ 6H˚A≥UÔPË"l]X5&·H˜˜Á⁄˜‘˚˜ÙaÇgjeR®Cƒ“∂±±∑¬≠]?ËÖ¸+Gi_XOe¡‡≈ï™≥∆˜C£kD˚+ã§˘+w˜O˜&¯N§1çxõ◊¯Õz˚è˚q†ƒôèô§óu\¸:wz(är¸$öv£v≤˜L‡˜sµÕ`∫O[jj[[©k∑‡ííéãìóìÇ}fkd>Sñt…∞¢û¶©¨±†æª˚+}˜(˚(Ω¯œ€˜≠˜&@˜®¯f˜ã‹b«:Ø∞À±û©«ﬁMø(&@Y$U†Æ«∞§¿ã«≤bMIig,mxË˜ `«P+EdZT®DqÌã7iprlS«gÈ˜9˜˜˜&˚+†v˜#˜¯Ew˜ù˜&˚$˜$Ë¯m˜#˜M¯E;dYk_xr˚˚4êë#˚2˚˜ä˚#˜&˜#Ë˚$˜˚c˜a˜ªËç˚+É«O˜(˜S˜‹˜¯	ÿ∏¯i˘8˚’+˚Ì˜
Å∫ÉªuŒm¥VTU^\X¯DZ„ãBgqrhV»hÂ˜4˜	˜‹fÕH≥V´eì˚î°‹˜©˚+~¶˜˛π˜Ñ•ß¯R¯n˜p˜Aﬁ˚ kxá}e≥˜*—–˜/≤•˚®j˚8˚/˚w˚BÊ˚˜"˜ÊÓ˜˚-K˚nZuyñ°Ä|¶Ç⁄Âµç®ë∫íå†ìùÃ¢Q˚6˚+~•˜Ñπ˜˝¶•¯R¯l¯&˜>.˜˚˚1*˚˚’9ˆ∞£êô®]˚0DD˚(kq˜ù§˜C˜8˜v˚1¶häoÉSÜsÖxMt≈˜5˜ó®ª°ùÅxïõoñ62˚+~ß˘ß£¯V¯n˜ﬂ˜b,˜*˚˚,˚+˚a˚ZÎ˚&˜˜Î˜&˜Z˚2˚ ˚'wN\\w»˜'˜y˜&ü»∫∫üN˚&˚“†v¯£ª˜ª«ª˜∫˜£˘∆]∫PQ[[QQª[≈∆π∫∆\kqqkkq•´´••´´•qk˜x¨˘¨Æ˘V˘y˜„˜d˚'˜(˚b˚b˚'˚(˚d˚b˜(˚(˜a˜a˜(˜(˜b˚Eå˚hO˚˚˚	P˜˜h˜_À˜˜˜Ã˚˚_õã§r´˜ °˜Æ©r§Ú˜3˜L˜?Æ¯˝˜NÂH ˚£ç˜∞≤∞ÿÚ/ƒ˚;˚«rŒàüzX¸yXÅ@Çr˜’˜?˜”˜˛˚[˜Ÿ˚ lp˚à˜tÆöô±—¨`/ß˚›&cZ8`yù∂˜ç©ÙºX˚˚+,¨˘]§é˜"›˜5¯p˘§˚Ûr‹â†}U¸¿Myr_qvòù£¶îã´≤iÆddmj`D’SÍ˜#‘‘˜&¯H‘õõ”çõã™l§˜ƒ¨˜≠¨r§Ú˜5˜6•˜§∑˘˜dp˚QBZ˚Kwòµ˜á˜
Ñ©nô˚•˜Áqz˚kn˚à˜}¥óíœ˜#ƒ`˚†§˜\¸“ˇr–Öù|Y¸wW~ÄAÇr¯€õã§¯ˇ´¨¶˜U˜6˜T¶˘¯oà˜]¸Íá˚]®°˜±≠˜î¸£BÄ6Ñr˜¯§7ê}ò’¯£˜Äæoû˚˚öã§˘§˜˜4¯§BétúΩ¯x¿¢ù‘å§˚Òr“â°zV¸xZuzDár“çv˘2§õ˘?˘O˘§˚hr´à¡åa{àÅz]˚˚‹˚˜–pÃàîãõßòë‘è§˚„rΩÇóÅ°X˜î¸Ï¶˜v¯ﬂ£…óñ¡ï,x≠v˘:´Æ®w˜˜Ö˜
Ï¯î˜SŸa—G≠˚'÷9µw†ãº»∂≤ Á—I˚≠ß˜mmoÉÖÖxgg≠1˚7<˚1ºO˜PÕlÁ_†rãTHY_?Ù$Bÿ˜on˚å®Ï¢êîïõ≠±iÌ˜(Ô‡˜˚“ìv¯yw›˜<˜é¯πf±]\ee]\±e∫π∞±∫˚—∫f±]\ee\]±e∫π∞±π“ã§¯˛¨r§˜˜5˜K˜>¯˘]§tçÇèÇò˚]˜≤˜∞∂πﬂ˜
,»˚O˚”r‘áô{D¸NBÉÇ<Är˜Â§@ï}ö–˜V•˜c˚ÕY¯à˚dj˚$ä˜î¯´öï∫ﬁ±^)“xº˘§Ì˜2˜’∑˘O˘§˚pr€ÉùyB˚ƒ˚*TG˚(]…˜˜·÷úõ€å§˚ÂrÕÜõyF˚·/ù\ø`aºœv‡◊€©∂≤Ø≥üœ·˜”∆ôõÀî˜∏ã§˘§s£Ûµ¯¶˜.¯˙+§<ïÅñ“¯O”ôö‘ê£˚è˚[¸l˚\¯l˚è¯r’ÉôÅW¸pOÄÇ<Är˜~§7ìyù‘¯fç˜é¸‚¶˜ç¯Òç¸çS}@Ñr“évù§˘§Ú∂¯B∑¯˘N˘§˚kr’ÑûvD˚√â˚Ó¯?˚fr£áô∫S¸oT|}CÅr˜v§>ïxüœ¯%ç¯¯Q¸≤¶¯·ƒòôÃî¸$“ã§rÆ¯Û≠r§Î˜6˜ï˜A‹˘D˜Î˜e˚˜˚}˚√rÃÖú}\¸Å^vzNár˜Œ˜p˜ ˜˜f¸˚A{˚VH)˚a|ö∂¯ä∞òïª˜“˚˚]õã™l§˘§Û˜6˘˜xn˚*KO\˚Dxó∏¯lÿôó‚ç§˚rŒáù|X¸yXÇÉ?r¯’“y∫˘	≠áwº˜E˚E˘`§Ù˘A˜m§;4Ig;ã˚IÒ˜a˜k»ˆ˜Á€E˚«§Ù˜~pk~}yËoBΩã#˚V˚)˚0˚`˚d˜%˚"˜j˜ŒÆ˜Ó“ã§˜@≤¯Zwî˘9˘B£]èÅóW˜˚s¯¢n˚p¸∏e.ÇYr˜_§Oètó§öò±´Ÿ˜sßQûRt~ÉÅ|àÄàéãYÜrû˜Ä˚VË˜ácã§˜™Æ˜ƒ≠r§Ó˜5˜:˜?‹¯È¯Å˜0À˚>˚”rŒÑö{G¸N=záIÄr˜·§>îó”˜M∞ˆ¬ñ¶ª≈≠´¡À˚?à˚gj˚˜†¸•õï±Ÿ≠]!˜xv˘ÑvÆ˘V˘y˜„˚b˚(˚(˚a˚a˚(˜(˜b˜d˜'˜(˜b˜b˜'˚(˚d˚Eå˜_J˜˚˚K˚˚_˚h∆˚˜	˜«˜˜hz¯±vÅ~mx˚#4T˜˜0õùûïüã§üwscã§˜ƒ¨˜≠¨r§Ú˜5˜.§˜£ﬁ¯Ÿ¯o˜]¸…r–áù}W¸zY}CÉr˜˚§2éuô¿˜~ıà¨iô˚	§˜Êrx˚	jk&â˜~˛≤óì«˜#∆\˚ùxû¯aó˜_õ˜pî˜üì¸ué§
§å
_˜é˘
endstream
endobj
15 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[110/a73]/Type/Encoding>>
endobj
17 0 obj
<</Ascent 1667/CapHeight 1667/Descent -293/Flags 4/FontBBox[0 -143 976 814]/FontFile3 16 0 R/FontName/CLWRCQ+ZapfDingbatsITC/ItalicAngle 0/StemH 0/StemV 0/Type/FontDescriptor/XHeight 0>>
endobj
16 0 obj
<</Length 178/Length1 178/Subtype/Type1C>>stream
  CLWRCQ+ZapfDingbatsITC   6ã˚πœÉ
 à?ãã
 à?ãã   h   e   kë   ¨ a73    á %<¯
˙0˚π…˝Ã˘7˘Ã˝YV¯Á˙¸Á‰˙!—ç˙s˙sçç¯Õ˘
endstream
endobj
19 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma 46/period 48/zero 50/two 52/four 56/eight 65/A 70/F 80/P 84/T 86/V 97/a/b/c 101/e/f 104/h 108/l/m/n/o/p 114/r/s/t/u 119/w 121/y]/Type/Encoding>>
endobj
21 0 obj
<</Ascent 684/CapHeight 654/Descent -205/Flags 98/FontBBox[-169 -217 1009 884]/FontFile3 20 0 R/FontName/AOGMZT+Times-Italic/ItalicAngle -11/StemH 0/StemV 23/Type/FontDescriptor/XHeight 677>>
endobj
20 0 obj
<</Length 3450/Length1 3450/Subtype/Type1C>>stream
  AOGMZT+Times-Italic   C¯ ¯¯¯¯Ä˚=˚m˙Ö˙
 ãã
 ãã      ¸  ;¨  Y }âé002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku ItalicTurku    5 I F  " O B M T P G 1 S N D U Q Z    ' C V  7  X     Y ÏLO≥Eø|¡>≥ﬁ+ü ≠Zﬁ	W	º
L
z
œæﬁ-†v¯ˇÆ∆¯—˘˘"¸ßa˚.ùá°∫ú§•ü§¨¶ë˜˚#¸•}YszFÑ{˜∂õ9ëÇè´ïë•í•˜ ¯á¡÷®rKÅäÇâxúä˚*óv©v¯Ovû¯]¯pÙó_QvwzãÉÑíïñëôçìƒ˜eïÆë©ãò≤pßfKFM˚#-âç˜
¯KÖêL}wÜBÉz§åúå§âãtuj|P˚¸ã÷±˜)õµ≤∆¡‹Õ∆ÆãõãóÄã}ãÜåãÉnW˚S}WÇapú{ßæ∑Æ⁄ª˚bÅ∏¯¢™·˜yÃ¯/¯
∏o¢T˚˚2˚9˚&3æV‡Œ’≤œ…óCQk{`ãSe∞¡ôéüí•®è˜,†Ú◊ã‚Jí7+G˚vù∑∞Êœ‘¿é†åö{t¸$d†v˜vØ¯+vX¯˚¯»õSéÉï”,¯Ãq˚µ¸âA˚}{bÉ{˜Oõ\ê~í¢òì•ó¢≈˜˜pü˚åÅåÇãÅgx~Pä{æ˜ö˚V˜(˜òç˚*óv©v¯Nvô¯`¯nÛ|òUFÅÅyãÇÖíîíê†ï±∑˜4ó∑î¥ãö∞q§e,4˚&H^âçÀ˜eáç˚tëå[Ç{æâòÜx~ÇnÖvãÉl@˚ß÷¥˜$¢√º— „±¨ØãòãïãzãÄÖlÅf`˚7{PäÉ|lõ{´π©§„À˚*Äº[ª¯°úﬁ¯pÔñ~~YSyãÑÜêìïê¶ñµÿ˜∆ÖéLÑÄ[äåÄÆoûdã˚˚1˚J˚-=ÆbŒ—≤©˜„çà{LÜqãwoò®±¨•ﬂÕ˚˜î3,˚z!drß∑ÂÈ˜q˜Æ¢qd¸ïv¥˜Ç˜´˘;ÜêQ{à9{§ç∑ärÑèñv>"¸v;à}ãziõy™¡ß¢Ò—îUCwxuãÅÜëïíéöì©˚ôìv¢v¯A£åv˜ ‘πÿ|¯¯O}}ÇÑá~|nqúãcC[aJ-˜?ã@[nkaRl≥Ïz|¸w˚4öõíëêñ|≠™xã±ﬂ…¬÷Í˚Ÿã‘¨¢ü≠Ω´g=ï|õ˚*ïv¯Yv¶ﬂ˜¶ﬁ¯h˜πËU√2˚(˚*˚0˚-/¬WÎ˜ ˜*˜<˜8´)B˚m˚[k∞¬Ó›˜p˜∂ßfP¸˚Mv¯Ô´˜x°ØÍ¯:¯˙±g¶Xaexdjibu\j#0ÉkÂ3¸9t˚lX_ãÑëïîîêãô†zösw}zsi¨q∑Â–Ï˜Mµ‘˜’˜ ë´ ˜0¶±”¬ôïÜÑäÜÅÄã|sö{°¢ùù°d†v˜≈∞˜Æ©¯âÚ¯¯äÓB¿˚˚åz´Ü±è`}áv`˚
¸={RÑÖPÄ{˜âõSíìßöéóî≠¿˜U∂Ö§â±ã˜,Û€˜	$ë˚OW˚xtçè{—˜ãë†óì®ãÊ¥g;˚ô†v˜ËÒåv∏¯¯0¯™xünX@7(^Çwäçº˜[àéWÅWÇWÇ{éûìåì†òÅy~ÖiÅh:˚π◊∂˜ ö¥Æ–∞’µ¿†ã†fã∂®úû´”óv©v¯ø\∫ó˘Fx˘RÙ}óZOxyzäÉÜêïîåêí£ƒ˜gî≠ë©ãòØsßk24˚Haâç¶„ï±ãúØt£iO?D˚8àéƒ˜[àé$vååPÄ{¿äñázÉçë{M8˚ ÷™üﬂ…„x—º¬ª®òìÇ|Éåç|Tãâ;˚∫◊≤˜,†¬ªœ∫œ¡ª¶ãóãîÇã}ãÜåéÄ^Z˚Z}Qáz~¯oö{¶π∫∞ÿ¿˚bÄØ¯5w©‡¯<˜¸Ωa´H˚%˚ ˚'˚.)øUÎ‘…Æ‘¿{îcZSk[ãSh∏“˜$Ï˜Ò£öÉ{|Çãruõ|£¶ûû•¸ñv¯+¨Ø˜ò˜º¯B;ßÚåçãçãçêàèÖÖääÄÇ\Sbib{mÄáàãÅãÇãîãÇ÷B˚ßt5åéãÇuä†y¶§£ñü¢ùõòú≥ƒ~ërlpj{}ãÅÖëñêåçèõﬂ˜“ﬂ˚*˚Mv˜Wû¯∂¯Â¯i˜…ﬂaºBL[l=TâéßÓáí˚0uéz©é≠àãpÑÜsÇj˚¸N~YÖÖ[Ü|˜bö\yî°©®ìÆ}¶òà®˜!˜0˜=˜+1ì˚(˚ ˚5'ltö°πª˜(ùπÃ§ƒºø≥°mW˚b˚Lv˘v˜‡Èc≥–¯>¯≤u£h‡v{|w–Z¡óãdP,˚/p]w˜Ö¨N˜qyãvE}ÅVzéüìåî¡§Y˚lºöGïV~{Ñ|tmxqplwwÄÖÇãwã}®pãtãz{ãuãpüy™ã∞ãº≤–‡˜	˜#˜˜Éã⁄˚*ã÷¯•‘¯‡¯W¯éÌF‘-*?Q%güÑ≤Õµß…ã“¿WDP`C%˚˚e˚tz˜˜Ω˜zírXv~Uã˚Rê˜U˜U˜
˜
©∫ãœ˚*Ñß˘ß´⁄˜»Ÿ¯Ö¯H˜*OÊ(˚.˚,˚|˚~˚Œ0Í˜1˜&˜j˜y=‚˚*T˚]J5_jjvhUjΩ‹˜Ω˜U¡Ó∆¨∑≠∑ø™\<˚*Ñ°˘¢©œ≥Ÿ˜-÷xœÙ¯Å¯´ﬂC≈%˚CO0Fπ\¥Z˚fA@4(›E˜
¯˜ÁÿÚŒfŒ=◊Ù˜≠¿º–GéJto0^N»i™√…µ∑« ∑\F¯S¸<RO@9Rƒﬁ‡∫«Ò∏ùwõzã’;ôvVd†v˜€Æ˜ó¨ì˘˘˘"¸Ü{œÖïÜn}ÜpÖt˚¸O{RÉÑRÄ{˜êõQèyñ®ñåèì©…˜s≈ä¡äπéãYxâ|ÖsúÖ◊˜xëZ,ìè˚BàÃ˜}ë¢ïéÕã˜,™~M}ãÇâxüâ˚*Å°¯º¯‡¯n˜‘‘[ºD2V:J^äç¯ÜêUÇêã#|{†â∏ënyfá{˚¸äàr’n…˜)˜:˜B˜06~#˚˚S˚h|ó¶ÏÎ˜â˜µßiW˚*Ä¿mv¯Nv™v˜‡˜∏¯o˜ }î[Nyy|ãÑÖëïóçåòºãê†Ÿ˜ºAa˚rT`HP/XUnãqãç•çìÊ¯ ∏àéQ}zà@Ä}†â≤ílÉãäÇgY˚W\ÜpãzgùxØ–ææ˜O˜çh˚Éhw¯lúy©œØ–ªÆ¸$á˜˜¨≥sßinvxpzíù{ö}êÉrurVgïx‡º∂¡ã∆dév˘4v◊¯¯˘D˘õ˚N{øÑñÖuy|hfK˚^˚ÛáI¯Jäëãëãê´öî…íõ˚Ö{¿ÑëÉô9Á¸√û¯¯˝õ¶ôï•ç˚*†v˜EÕKÀå¯q∞¯r˘:c¸5¸CwG˜ôZ˚G⁄∫˜EÓöÕ,ô˜◊,˚◊˚iç˜≈˜’úév¯`v°v˜’˜: ˜Hª¸˘¯¨v†jt}|xj∂Üãf]_I˚˚&k˜˝ãèáçÜãáâäÉÜ˚S˚ƒâÖÁÉÊzÂ¸ØÑâêÉ¸âàãäà[ÅzáVÇ}°åéããßåìÖìtïmö˚ë#ê4Äåäfôìëî∑§˜:˜∫ç®˚–çqéÖíåëìí¢û…÷˜=˜]Ô¸$Ä˜¶˜˜∑™r§mlrrlm§r™©§§©xû¯Aô˜g¢íã˜°ç¸sé°
¢
_˜é˘
endstream
endobj
51 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma 65/A 68/D 70/F/G 73/I 77/M 80/P/Q 83/S/T 87/W 97/a 99/c/d/e 103/g/h/i 108/l/m/n/o/p 114/r/s/t/u/v/w 121/y]/Type/Encoding>>
endobj
53 0 obj
<</Ascent 700/CapHeight 669/Descent -204/Flags 262242/FontBBox[-200 -216 992 921]/FontFile3 52 0 R/FontName/HBYZVQ+Times-BoldItalic/ItalicAngle -11/StemH 0/StemV 79/Type/FontDescriptor/XHeight 685>>
endobj
52 0 obj
<</Length 3935/Length1 3935/Subtype/Type1C>>stream
  HBYZVQ+Times-BoldItalic   C¯ ¯¯¯¯Ä˚\˚l˙t˙-
 ãã
 ãã  	    JØ  ; }éì002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku Bold ItalicTurku    "  ' J T I F S B O E . 8 % W 1 P M H 2 5 * U  4 Z D Q V N X ( !   _ b ‚O≈>°Ûk‹gÒu„BºM°Û	?	å	±
+
©
ˆw∑-´úã§˜L≤¯Hw¯˜ ¯/˘@s¸¸‡m\x{hÉr˜Y§Zézì§ñëùîõ«Ú˜jãö7ã_d|ÄKÖr˜√§KèÑì~’˚\¯±˚â˚M¸$úã§˜Õ¨˜û´s£~˘3ÿ˘&˘1¸ßsÕÇíár|ásÖu˚¸U~[|}WÅr˜ª§Tê{î®öçåô¿¿˜]ıä©xãGäàußÜ’˜•oè\0s}˚ã{«˜r¯Øïñì∑»Ω~sß¶sîpK•Ö¸óv¯√˜˜˜˜V˘@fmmff©m∞∞©©∞∞m©f®˚r/zÖä#ÅqπäóÖrÜâÑá{S˚lÄbávã|e¶q¥«√∏ÂøuôjWqoxãÉÑíìîäãîÆã»˜z™˜˚ôìvå®¯1´äwπÎ¥Í\˜ﬂ¯ao{ÉÖÜ}|nv°ã^:VZ?TônŒ=≥[õmrlrsjYj∫·~qé¸u˚:•ôììëô|°§xã∑‰»¬Ÿı˚‹ã“ßü¢´∏©c<ò\¶à-óv©v¯bw˜Ù˜p˜π˘O.zná6Çq£≤èhÅâ}Öv˚.¸À˜¶Ïß›°∏∏Ë ”ØãôãîÖã{ãa3˚Sã8h¶r∞·¥‘…µvõeSrp}ãÉÑíìùÂ˜ã»∏n®^GT^˚4âå˚b~À˜´˜l¨ê˜#˚#˜˜>ÁÙ˜(˜j˜´æ‡∫ùîu(AM8v˜<CLegocÏ^uß¡úåîê¢Âî˜:Œ˜Ω`ØO˚'˚"˚<˚13 L‚Ÿ¬≥Ìƒ˚ô†v˜◊˜ v¯-˜w¯cQ|âã˚ ~p∂äñÜw}V~]>˚°˜Ω˜2©Î ˆ•ãúìeãÆÆ£©∑¥u§h\`X˚JÜé˚*ívç—˜ˇµv˜p˜û¯9¢äôxnIH˚å1rx¢™Ã‹˜çﬁÜ˜PØ˚ÖySâ∑Ös£b˚˚)˚R˚3=µ[Œ«∑≠Á√çåÄbâÉã}dßp≥∏Ω∂ﬁ¡vöfWxx|ãÉÜëïßë®ßÁ-óv©v¯bw˜wp˜Ö¯aS~YÑ.Öp†´åoqj äÜãÉlP˚h˜˜Ë‚Ω•òñÇ~i4˚[ã:b£u∏ƒº¥ÂæuòeP}{zäÉÑíï§„˜iã÷Ωp¢X6N/*Jâç˚*”D“˜˝µv˜p˜¢¯9¢öwkbD˚†/rz£ÆÕ€˜Ä‚˜ä˜´FyWÜ4Öp†ßòÇwÑázÖue˚t£wîpã˚
˚/˚S˚1B∏U«ÃπØÊ¿çÇcäÇ{pd°u±ººµﬂΩuõmZwu{äÖäÜëì¢∫˜:î¨˜Éîvó§¯ˇ§n˙E˘A¯Ω˚¸\}Vu|Kár˜Ã§Rç|î´óè†ë°˜¯VôøúöΩè§˚i˚«¸päT¯p˚rrß∏íb~ásÖv˚¸	f˚É~T|r˜c§Nëwö≤ûéóú Ô¯ åÕ¸øß¯¯Ã˜Éév˘*§Ã˘ˇ¯Œy˜≥¯„§øúô¥ê§˚OræâóÑm{àÅr˚.˚Ÿâj˜πà¶à©ãô±ìí¡ë§˚†r√ÜöwE˚(˚»äc˜ÓäëãëãëÆöó∏è§˚®r ÑêÖïE⁄¸◊®˜y¯{å«¸{”ã≠¯Ò©r§¯¨˜'Á˘1rœÉëÑoÄâÖ{P˚¸?}X{|YÑr˜≤˜ï˜N˜9˜x˜D˚Ô˚TIGßíõïÆ˜¿N˚˚f˚WCBWBf5ayñ£ååòããó∑˚bìv¯pw„˜ﬁ˜B‘Ë˜~˜^˜U„˜Ê±p™inqqlË_∂~ãijbN6.à˜VÖ√v‡W}rá=Äqõüå{ïörò0â!ããâ˚âMdã§˜πÆ˜±™s£¯e˜&Ë˜‡¯Â±ïìí¨æ™iRWyMrhmud|SÄÑãçxÇká≤úä§˜7˜ Ÿ˜
ÚDø˚"˚≤¯sœÇëào~áuÖt˚¸V}YUÅr˜∫§Qè~ì©óé¢ë°˚*}©¯5®à˜˜`˜˜Ø¯b˚'˚˚3˚;5œKÁ˜%˜˜0˜9ËL….Én©äövaBS˚¨+iy°∑÷ø˜≠ˆÜ¸óvç˜≥˜µ˘P3ymá1Çq¢≥èjw}\Ñq'˚ˇ}WÑjãzb§sµ‹º÷«≤uöiUqqyãÇÖíïóí¨ö¿˚*˚_≠˜Kv˜4´˜ã™W‚ã˜˜˜ @˜	ˆ˜ÑùÿoÇù•~öwt`_qEC^©ª∑»≥õı˜!¯K®útcWi˚En|ü±æ¨˜–˙˚C¸>+uipSN◊`˜ ˜&Î«Ê«g¨˚™VöiïyôãõõúùòöôÉã†ı˜Í⁄ÌúäíáûŒ√˚•ikìa˚$9*V¶d¿v9]}}emùw¥|”˚c„≠˘¨¶˜%¯
˜$¯S˘ »à±\C˚+¸˚CJe∫€˜Ì¯˜EÇ¸7˝ƒôs∫ü≠ì´ãﬁœ\ãËÙ◊∂Û’vü\U[rOãq{çòbbòkïvèbèNíìàêéòò´™äòîãë˜_˜c˜Å˜}˜&Ì˚!˚k˚b˚y˚É æ>Îh®Äåãàâççuxdã§¯ıÆi≠Ω¯Î˘˘1¸∫e˚?§ÑπÏ…¥˜ë˚'¸Ø|UrzIãr˜ﬂ§CéÄë™òê®ë†˜¯éÓÜ™hì˚¶â˚ôã£˘ §k¯H˜õ£Sè|îßôãìô¿ãí¢˜¯.ôæ†ù∫ç§˚ΩrÃÑîÜr~ÜqÜx˚¸W}X{|ZÑr˜ª¸óv¯4∂Ä˜∑˜ã¯ÁhZ>^f2dhæL˚pÇmxFãn`•r∏≈ª≥Î∆uôgStsyãÉÑíìöìØú»»˜oﬁ∂C¸$≈‡\˚I˜πŸÊﬁ√h≥Ybnl`M—éãbeZ[Fl-y≠˘Æáw˜˜˜¯˜≈¯@Gø}ü∑Õ±≥À‹µY˚ï¶á¯≥˜\nyÅÑu¯]l®ãA˚26!˚?˜â_ã˚!FVVC!^·Òàmåh˚s©ßóííûØ∑hÊ˜‰€˜ﬁi»˚Ì˚b˚a‹:˜¯ªw†wÙ˜∑˜KÀ™ò¯0µñâ˚T≤•˚ïJjWQIjÍqmÆãgntsli¶p∞„‰„˜Eı‚˜&æ˜ÕΩiûmÏnqpk˙V¬èãb]I˚ygâ~‘w˜w‰rŸK|vàJÑ˚b~Ã¯¨Ü˜˜)˜˜—˜!GYov`_nØƒœƒ˜mÂôîÑÇ}vzãpm§t™≤£¶∂¬^ÆE˚˚%˚:˚//…LÁ◊º≠Ò“˚*˚`•˜:Æ¯”˜‘˜˜k¯c*{£é˚|pπäìáwÅÑnÉj˚¸>~X}Ä_äq˜å•Xå}í•ß•Ÿï∫{´õÜ°˜˜"˜J˜<Ÿb∫IZ\p;RâèÔ™£ôxlAD˚à*uzõ†¨¥˜ô¥€ß∫∏≤-óv¯_w´wö¯p–¯{¯V˚
a˚&wUgGfFZXnã}ãÉîãõãñê°ï¨È˜…EÅI|Bâpªáìáu}ÜsÄf_˚+ÇkÖjãxV£s¿¬≥¶ÿ√ìñèë™∂çâ{\Öopc°w∑ƒ≈∫‹∑vòfUxx|ãÅáëò–ôìØöæ˜óv©v¯‘äw¯⁄˜h˜}¯aO~~â˚q∑äïÜwÑåÑk˚ãÉkM˚q˜˜˜Ê˜≠ññíÇ|Çâ~Ü|ãG˚oi˚˜∞˜µ˜·˜πãôïÅ~b3˚Oã8Ë_¢vπ«¥≠Ï√uóeQ|z|ãÇÑíì∞„˜LãÁ∫m®YXL`˚?éú∏ê°®¯¥q§b-D˚H]àçúìv¯ow†w˜¬Ô˜÷ÿ˜È~÷€˜X˜e˜±r¶hmqolc¥wãineQ:/¯l˜·o˚-˚•âÿà˜Ç◊v—WÇXÇWÅq∞äëàìv£Mì˚FâDâ6¶ƒ·¥…≠–ØÃå¢˚Æ”y±˜±§˜‘Ø†˘?˘:˘BntÄ~Ñzl`©4˚5kG>*6R˚˚˚5˜˚˜G“˜ †§Ωßôª˜Hû“êë¡ë§˚≤râòñäë≠áïÇrp_˚?}{y{f_(N—˜˜/Ë˜∫˜SÂ∏P˚é®Üxû¯Vò˜bõöã˜úñ¸vé§
⁄å
_˜é˘
endstream
endobj
1 0 obj
<</OPM 1/Type/ExtGState>>
endobj
88 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
89 0 obj
<</OP false/OPM 0/op false>>
endobj
90 0 obj
<</A 91 0 R/Border[0 0 0]/Rect[259.007 9.0 300.752 16.0]/Subtype/Link/Type/Annot>>
endobj
91 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
82 0 obj
[92 0 R]
endobj
83 0 obj
<</Length 14577>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.01601 Tc 0.01601 Tw 10.5 0 0 10.5 60 730.8196 Tm
(diac channelopathy could not be excluded. A silent muta-)Tj
-0.008 Tc 0.008 Tw 0 -1.23333 TD
[(tion may predispose to QT)70 (c interval prolongation, which)]TJ
-0.02499 Tc 0.015 Tw T*
(manifests only after exposure to a specific drug and/or oth-)Tj
-0.015 Tc 0 -1.23334 TD
(er risk factors.)Tj
ET
BT
/T1_1 1 Tf
-0.013 Tc 0 Tw 6 0 0 6 118.1886 695.2697 Tm
(22)Tj
ET
BT
/T1_0 1 Tf
-0.015 Tc 0.015 Tw 10.5 0 0 10.5 126.6384 691.9697 Tm
(Increased vagal tone due to the increased)Tj
-0.017 Tc 0.01601 Tw -6.34651 -1.23333 Td
(amount of acetylcholine in the synapses is the most likely)Tj
-0.02299 Tc 0.02299 Tw 0 -1.23333 TD
[(explanation for QT)70 (c interval prolongation and arrhythmias)]TJ
-0.036 Tc 0.021 Tw T*
[(w)-15 (i)-15 (t)-15 (h)-15 ( )-15 (A)-15 (C)-15 (h)-15 (Is. In a canine model, vagal nerve stimulation pro-)]TJ
-0.03999 Tc 0 -1.23334 TD
(longed the QT interval by 1 msec for each 0.82 msec prolon-)Tj
-0.037 Tc T*
[(gation of ef)20 (fective refractory period.)]TJ
ET
BT
/T1_1 1 Tf
-0.03439 Tc 0 Tw 6 0 0 6 199.1725 630.5197 Tm
(23)Tj
ET
BT
/T1_0 1 Tf
-0.037 Tc 0.021 Tw 10.5 0 0 10.5 207.2026 627.2196 Tm
(Data from studies per-)Tj
-0.026 Tc 0.011 Tw -14.0193 -1.23333 Td
[(f)1 (o)1 (r)-24 (med by phar)-25 (maceutical companies did not show statisti-)]TJ
-0.015 Tc 0.381 Tw 0 -1.23333 TD
[(cally significant dif)20 (ference between galantamine- \(or)]TJ
-0.017 Tc 0.002 Tw T*
(rivastigmine-\) and placebo-treated patients with respect to)Tj
-0.03799 Tc 0.02299 Tw 0 -1.23334 TD
[(QT)70 (c, PR, RR, and QRS intervals.)]TJ
ET
BT
/T1_1 1 Tf
-0.036 Tc 0 Tw 6 0 0 6 189.0848 578.7198 Tm
(24)Tj
ET
BT
/T1_0 1 Tf
-0.03799 Tc 0.02299 Tw 10.5 0 0 10.5 197.1018 575.4197 Tm
(Our observation and oth-)Tj
-0.015 Tc 0.071 Tw -13.05731 -1.23333 Td
(er case reports are therefore important for postmarketing)Tj
-0.02 Tc 0.005 Tw 0 -1.23333 TD
[(safety surveillance. The full spectrum of adverse ef)20 (fects of)]TJ
-0.03 Tc 0.015 Tw T*
[(AChIs manifests only when a lar)20 (ge number of patients with)]TJ
-0.019 Tc 0.004 Tw T*
[(dif)20 (ferent comorbidities not present in the original trials are)]TJ
-0.01801 Tc 0.002 Tw 0 -1.23334 TD
(treated. The Naranjo probability scale indicates that in our)Tj
-0.03101 Tc 0.01601 Tw 0 -1.23333 TD
(patient, galantamine was the probable cause of QT)Tj
-0.0309 Tc 18.79954 0.00001 Td
(c)Tj
-0.03101 Tc 0 Tw 0.64792 0 Td
(interval)Tj
-0.032 Tc 0.017 Tw -19.44747 -1.23334 Td
(prolongation, syncope, and delirium because these reactions)Tj
-0.015 Tc 0.08099 Tw T*
(have been previously reported, the events appeared after)Tj
-0.03799 Tc 0.02299 Tw T*
(galantamine was readministered and improved after removal)Tj
-0.036 Tc 0.021 Tw T*
[(of the drug, no alter)-28.9 (native causes were identified, and the re)]TJ
0 Tc 21.95292 0 Td
(-)Tj
-0.03999 Tc 0.013 Tw -21.95292 -1.23334 Td
[(actions were confir)-21.6 (med by objective evidence.)]TJ
ET
BT
/T1_1 1 Tf
-0.03799 Tc 0 Tw 6 0 0 6 237.3361 436.2698 Tm
(25)Tj
ET
BT
/T1_0 1 Tf
-0.01801 Tc 0.01801 Tw 10.5 0 0 10.5 70.5 420.0198 Tm
(Spontaneously reported adverse drug events are impor)Tj
0 Tc 20.95294 0 Td
(-)Tj
-0.021 Tc 0.021 Tw -21.95294 -1.23334 Td
(tant means of postmarketing surveillance, especially when)Tj
-0.008 Tc 0.008 Tw T*
(the events are rare. Analysis of the ADRAC database re)Tj
0 Tc 21.95293 0 Td
(-)Tj
-0.013 Tc 0.013 Tw -21.95293 -1.23333 Td
(vealed that, in addition to well-known gastrointestinal ef-)Tj
-0.006 Tc 0.005 Tw T*
(fects, use of AChIs carries the risk of delirium, syncope,)Tj
-0.02499 Tc T*
(arrhythmias, other cardiovascular disturbances, and sudden)Tj
0.011 Tw T*
[(death. Clearly)65 (, the reporting rates are not synonymous with)]TJ
0 Tc 0.09 Tw T*
[(incidence rates. Despite obvious limitations of sponta)2.1 (-)]TJ
0.037 Tw 0 -1.23334 TD
(neous adverse event reporting \(underreporting, missing)Tj
-0.00101 Tc 0.00101 Tw 0 -1.23333 TD
[(clinical infor)-25 (mation, failure to identify comorbid condi-)]TJ
0 Tc 0.129 Tw T*
[(tions\), this infor)-25 (mation should not be ignored. Galan-)]TJ
-0.006 Tc 0.006 Tw T*
(tamine had the highest rates of reported arrhythmias and)Tj
0 Tc 0.054 Tw 0 -1.23334 TD
(sudden death in comparison with 2 other AChIs, while)Tj
0.03 Tw 0 -1.23333 TD
(rivastigmine demonstrated the highest rates of delirium)Tj
0.021 Tw 0 -1.23334 TD
(and syncope. As the total number of reports for each of)Tj
-0.01401 Tc 0.01401 Tw 0 -1.23333 TD
(these 2 newer drugs is about 2 times higher than the rates)Tj
-0.02499 Tc 0.013 Tw T*
(for donepezil, some reporting bias could not be excluded. )Tj
ET
BT
/T1_2 1 Tf
0 Tw 10.5 0 0 10.5 60 184.8198 Tm
(Conclusions)Tj
ET
BT
/T1_0 1 Tf
-0.007 Tc 0.007 Tw 10.5 0 0 10.5 70.5 163.8198 Tm
(Our case, along with previously published reports and)Tj
-0.02499 Tc -1 -1.2381 Td
(cases identified from the ADRAC database, illustrates that,)Tj
-0.004 Tc 0.004 Tw 0 -1.2381 TD
(in addition to gastrointestinal adverse symptoms, AChIs)Tj
-0.00301 Tc 0.00301 Tw 0 -1.23809 TD
[(may lead to delirium, syncope, and prolongation of QT)70 (c)]TJ
-0.013 Tc 0.013 Tw 0 -1.2381 TD
(interval, thereby increasing the risk of life-threatening ar-)Tj
-0.024 Tc 0.024 Tw T*
[(rhythmias. Such adverse ef)20 (fects may appear simultaneous-)]TJ
-0.02499 Tc 0.002 Tw 0 -1.23809 TD
(ly after galantamine readministration, as in our patient. Ad)Tj
0 Tc 21.95296 0.00001 Td
(-)Tj
-0.00301 Tc -21.95296 -1.2381 Td
(ministering, discontinuing, and restarting AChIs require)Tj
-0.007 Tc 0.007 Tw 0 -1.2381 TD
(vigilance and careful assessment of risk factors that may)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(precipitate such events.)Tj
ET
BT
/T1_2 1 Tf
-0.01801 Tc -0.00999 Tw 8.5 0 0 8.5 318 731.8055 Tm
(Alexander A Fisher)Tj
ET
BT
/T1_3 1 Tf
8 0 0 8 394.5556 731.8055 Tm
(MD FRACP PhD Doc Med Sci, Associate Pro-)Tj
0.008 Tc 0.005 Tw -9.56945 -1.125 Td
[(fessor)55 (, Australian National University Medical School; Consultant)]TJ
0 Tc -0.028 Tw 0 -1.125 TD
(Geriatrician, Department of Geriatric Medicine, The Canberra Hos-)Tj
-0.01401 Tw T*
[(pital, W)18 (oden, Australia)]TJ
ET
BT
/T1_2 1 Tf
-0.005 Tc -0.02299 Tw 8.5 0 0 8.5 318 693.8055 Tm
(Michael W Davis)Tj
ET
BT
/T1_3 1 Tf
8 0 0 8 385.5823 693.8055 Tm
[(MBBS FRACP)129 (, Associate Professor)55 (, Consultant)]TJ
0 Tc -0.028 Tw -8.44779 -1.125 Td
(Geriatrician, Department of Geriatric Medicine, The Canberra Hos-)Tj
-0.01401 Tw T*
(pital, and Australian National University Medical School)Tj
ET
BT
/T1_2 1 Tf
-0.01601 Tc 0 Tw 8.5 0 0 8.5 318 664.8055 Tm
(Reprints:)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tw 8 0 0 8 356.0462 664.8055 Tm
[(D)1 (r)56 (. Fisher)54 (, PO BOX 1)74 (1, Department of Geriatric Medicine,)]TJ
-0.009 Tc -0.01801 Tw -4.75577 -1.125 Td
[(The Canberra Hospital, W)18 (oden, ACT 2606, Australia, fax 61-2-6244)]TJ
0 Tc -0.01401 Tw T*
[(4036, alex.fisher@act.gov)74 (.au)]TJ
ET
BT
/T1_3 1 Tf
0 Tw 6.5 0 0 6.5 318 626.8055 Tm
(W)Tj
0.00549 Tc 0.93167 -0.00001 Td
(e)Tj
0.006 Tc 0.008 Tw 0.85332 0 Td
(thank Dr Patrick Parcell for providing ADRAC data and Robyn Muscat-Prest\i)Tj
0 Tc -0.011 Tw -1.785 -1.23077 Td
[(and L)37 (yn Cridland for their excellent secretarial assistance in preparation of\ this ar-)]TJ
0 Tw 0 -1.23077 TD
(ticle.)Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 10.5 0 0 10.5 318 582.8055 Tm
(References)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.024 Tw 8 0 0 8 322 564.8354 Tm
[(1.)-500 (Birks J. Cholinesterase inhibitors for Alzheimer)-35 (\325)55 (s disease. Cochrane)]TJ
-0.02499 Tc 0.013 Tw 1.1875 -1.24625 Td
(Database Syst Rev 2006:CD005593.)Tj
-0.00101 Tc 0.00101 Tw -1.18889 -1.37125 Td
[(2.)-499 (Farlow MR, Cummings JL. Ef)20 (f)1 (e)1 (c)1 (t)1 (i)1 (v)1 (e)1 ( )1 (p)1 (h)1 (a)1 (r)-24 (macologic management of)]TJ
-0.02499 Tc 0.013 Tw 1.18889 -1.24625 Td
[(Alzheimer)-35 (\325)55 (s disease. Am J Med 2007;120:388)-25 (-97.)]TJ
-0.00999 Tc 0.00999 Tw -1.19729 -1.37125 Td
[(3.)-490 (Arias E, Gallego-Sandin S, V)60 (illarroya M, Garcia AG, Lopez MG. Un-)]TJ
0 Tc 0.01601 Tw 1.19729 -1.24625 Td
[(equal neuroprotection af)20 (forded by the acetylcholinesterase inhibitors)]TJ
-0.03999 Tc 0.007 Tw 0 -1.24625 TD
(galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells:\)Tj
0.013 Tw T*
[(role of nicotinic receptors. J Phar)-25 (macol Exp Ther 2005;315:1346)-25 (-53.)]TJ
-0.022 Tc 0.022 Tw -1.20914 -1.37125 Td
[(4.)-478 (Thompson S, Lanctot KL, Herr)-25 (mann N. The benefits and risks associat-)]TJ
-0.01199 Tc 0.01199 Tw 1.20914 -1.24625 Td
[(ed with cholinesterase inhibitor therapy in Alzheimer)-35 (\325)56 (s disease. Expert)]TJ
-0.02499 Tc 0.013 Tw T*
[(Opin Drug Saf 2004;3:425)-25 (-)-125 (40.)]TJ
-0.017 Tc 0.017 Tw -1.20454 -1.37125 Td
[(5.)-483 (Rowland JP)110 (, Rigby J, Harper AC, Rowland R. Cardiovascular monitor-)]TJ
-0.01199 Tc 0.01199 Tw 1.20454 -1.24625 Td
(ing with acetylcholinesterase inhibitors: a clinical protocol. Adv Psych\)Tj
-0.02499 Tc 0.013 Tw T*
[(T)35 (reat 2007;13:178)-25 (-)-24 (84.)]TJ
-0.019 Tc 0.019 Tw -1.20609 -1.37125 Td
[(6.)-481 (Suleyman T)75 (, T)70 (evfik P)110 (, Abdulkadir G, Ozlem S. Complete atrioventricu-)]TJ
0 Tc 0.02699 Tw 1.20609 -1.24625 Td
(lar block and ventricular tachyarrhythmia associated with donepezil.)Tj
-0.02499 Tc 0 Tw T*
[(Emer)20.8 (g)]TJ
0.013 Tw 2.75769 0 Td
(Med J 2006;23:641)Tj
0 Tc 0 Tw 7.32734 0 Td
[(-2)25 (.)]TJ
0.006 Tw -11.27253 -1.37126 Td
[(7.)-500 (Nelson MW)90 (, Buchanan R)55 (W)90 (. Galantamine-induced QT)70 (c prolongation)]TJ
-0.02499 Tc 0.013 Tw 1.1875 -1.24625 Td
(\(letter\). J Clin Psychiatry 2006;67:166)Tj
0 Tw 14.45751 0 Td
(-7.)Tj
-0.022 Tc 0.022 Tw -15.66714 -1.37125 Td
[(8.)-478 (W)80 (alsh E, Dourish J. Prolo)1 (nged QT interval with rivastigmine \(letter\))-1 (. )1 (B)-1 (r)]TJ
-0.0251 Tc 1.20963 -1.24625 Td
(J)Tj
-0.02499 Tc 0.013 Tw 0.60138 0 Td
(Psychiatry 2002;180:466.)Tj
-0.009 Tc 0 Tw -1.79837 -1.37124 Td
(9.)Tj
-0.00999 Tc 0.009 Tw 1.22155 0 Td
(Luo S, Michler K, Johnston P)Tj
-0.0096 Tc 11.58706 0 Td
(,)Tj
-0.00999 Tc 0.49026 0 Td
(Macfarlane PW)Tj
-0.0096 Tc 6.09764 0 Td
[(.)-250 (A)]TJ
-0.00999 Tc 1.45271 0 Td
(comparison of com)Tj
0 Tc 7.57748 0 Td
(-)Tj
-0.015 Tc 0.015 Tw -27.22971 -1.24627 Td
[(monly used QT correction for)-25 (mulae: the ef)20 (fect of heart rate on the QT)70 (c)]TJ
-0.02499 Tc 0.013 Tw T*
[(of nor)-23.9 (mal ECGs. J Electrocardiol 2004;37\(suppl\):81)]TJ
0 Tw 19.78093 0 Td
(-90.)Tj
0 Tc 0.20799 Tw -21.46844 -1.37126 Td
[(10.)-500 (Mason JW)90 (, Ramseth DJ, Chanter DO, Moon TE, Goodman DB,)]TJ
-0.002 Tc 0.002 Tw 1.6875 -1.24625 Td
(Mendzelevski B. Electrocardiographic reference ranges derived from)Tj
-0.02499 Tc 0.013 Tw T*
[(79,743 ambulatory subjects. J Electrocardiol 2007;40:228)-25 (-)-25 (34.)]TJ
-0.024 Tc 0.024 Tw -1.6875 -1.37125 Td
[(1)35 (1.)-476 (Loy C, Schneider L. Galantamine for Alzheimer)-35 (\325)56 (s disease and mild cog-)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.24625 Td
[(nitive impair)-25 (ment. Cochrane Database Syst Rev 2006:CD001747.)]TJ
0 Tc 0.155 Tw -1.6875 -1.37125 Td
[(12.)-500 (Minett TS, Thomas A, W)40 (ilkinson LM, et al. What happens when)]TJ
-0.013 Tc 0.013 Tw 1.6875 -1.24625 Td
(donepezil is suddenly withdrawn? An open label trial in dementia with)Tj
-0.011 Tc 0.011 Tw T*
(Lewy bodies and Parkinson\325)Tj
-0.0108 Tc 11.11118 0.00001 Td
(s)Tj
-0.011 Tc 0.62807 0 Td
(disease with dementia. Int J Geriatr Psy)Tj
0 Tc 15.49039 0.00001 Td
(-)Tj
-0.02499 Tc 0.013 Tw -27.22965 -1.24627 Td
[(chiatry 2003;18:988)-25 (-93.)]TJ
0 Tc 0.10699 Tw -1.6875 -1.37124 Td
[(13.)-500 (Bickel U, Thomsen T)75 (, W)80 (eber W)90 (, et al. Phar)-25 (macokinetics of galan-)]TJ
0.002 Tw 1.6875 -1.24625 Td
(thamine in humans and corresponding cholinesterase inhibition. Clin)Tj
-0.02499 Tc 0.013 Tw T*
[(Phar)-25 (macol Ther 1991;50:420)-75 (-)-25 (8.)]TJ
-0.009 Tc 0.009 Tw -1.6875 -1.37125 Td
[(14.)-491 (Marino MR, V)110 (achharajani NN. Drug interactions with irbesartan. Clin)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.24625 Td
[(Phar)-25 (macokinet 2001;40:605)-25 (-14.)]TJ
0 Tw -1.6875 -1.37125 Td
[(15.)-475 (Iraqi A, Hughes TL. A case report of paranoid delusion with galantamine)]TJ
0.013 Tw 1.6875 -1.24625 Td
[(use \(letter\). J Am Geriatr Soc 2005;53:2036)-25 (-7.)]TJ
0.01601 Tw -1.6875 -1.37125 Td
[(16.)-475 (Brembilla-Perrot B, Regent MC, Hanesse B, et al. [Paroxysmal atrioven-)]TJ
-0.015 Tc 0.015 Tw 1.6875 -1.24625 Td
[(tricular block due to anticholinesterase therapy]. Arch Mal Coeur V)110 (aiss)]TJ
-0.02499 Tc 0 Tw T*
[(2004;97:1265)-25 (-7.)]TJ
0.013 Tw -1.6875 -1.37125 Td
[(17.)-475 (Inouye SK. Delirium in older persons. N Engl J Med 2006;354:1)35 (157-)-75 (65.)]TJ
0 Tc 0.04401 Tw 0 -1.37125 TD
[(18.)-500 (Baraka A, Harik S. Reversal of central anticholiner)20 (gic syndrome by)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.24625 Td
[(galanthamine. JAMA 1977;238:2293)-25 (-)-125 (4.)]TJ
-0.021 Tc 0 Tw -1.6875 -1.37125 Td
(19.)Tj
0.021 Tw 1.66605 0.00001 Td
[(W)80 (ang MH, T)70 (seng CD, Bair SY)130 (. Q-T interval prolongation and pleomor-)]TJ
-0.01401 Tc 0.01401 Tw 0.02145 -1.24626 Td
[(phic ventricular tachyarrhythmia \(\324T)70.4 (orsade de pointes\325\) in or)20 (ganophos-)]TJ
-0.02499 Tc 0.013 Tw 0 -1.24624 TD
[(phate poisoning: report of a case. Hum Exp T)70 (oxicol 1998;17:587-90.)]TJ
-0.015 Tc 0 Tw -1.6875 -1.375 Td
(20.)Tj
0.015 Tw 1.68964 0.00001 Td
(Fitzpatrick AP)Tj
-0.0152 Tc 5.55309 0.00001 Td
(,)Tj
-0.015 Tc 0.48475 0 Td
(Lee RJ, Epstein LM, Lesh MD, Eisenber)Tj
-0.0152 Tc 15.86827 0.00001 Td
(g)Tj
-0.015 Tc 0.73477 0 Td
(S, Sheinman)Tj
-0.017 Tc 0.017 Tw -22.64302 -1.25002 Td
[(MM. Ef)21.1 (fect of patient characteristics on the yield of prolonged baseline)]TJ
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.024 Tc 0 Tw 10 0 0 10 60.5 23.9116 Tm
(282)Tj
ET
BT
/T1_4 1 Tf
0 Tc 5 0 0 5 84.2499 25.4116 Tm
(n)Tj
ET
BT
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 97.431 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 230.556 25.4116 Tm
(n)Tj
ET
BT
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 243.737 23.9116 Tm
[(2008 February)55 (, V)110 (olume 42)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
0.013 Tw 8 0 0 8 60 749.5293 Tm
(AA Fisher and MW Davis)Tj
ET
BT
0 g
/GS2 gs
/T1_7 1 Tf
0 Tc 0 Tw 5 0 0 5 299.75243 11 Tm
( at UNIV OF MICHIGAN on April 18, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
38 0 obj
<</BaseFont/DNFGOS+Helvetica-Bold/Encoding 35 0 R/FirstChar 32/FontDescriptor 37 0 R/LastChar 122/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 278 0 278 278 556 556 556 556 556 0 0 0 0 556 333 0 0 0 0 0 0 722 722 722 722 667 611 778 722 278 556 722 611 833 722 778 667 778 722 667 611 722 667 944 0 667 0 0 0 0 0 0 0 556 611 556 611 556 333 611 611 278 0 0 278 889 611 611 611 0 389 556 333 611 556 0 556 556 500]>>
endobj
30 0 obj
<</BaseFont/OQKIVY+Helvetica/Encoding 27 0 R/FirstChar 32/FontDescriptor 29 0 R/LastChar 213/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 584 278 333 278 278 556 556 556 556 556 556 556 556 556 556 278 278 0 584 0 0 1015 667 667 722 722 667 611 778 722 278 500 667 556 833 722 778 667 778 722 667 611 722 667 944 667 0 0 0 0 0 0 0 0 556 556 500 556 556 278 556 556 222 222 500 222 833 556 556 556 556 333 500 278 556 500 722 500 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 556 1000 0 0 0 222]>>
endobj
27 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 40/parenleft/parenright 43/plus/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon 61/equal 64/at/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 208/endash/emdash 213/quoteright]/Type/Encoding>>
endobj
29 0 obj
<</Ascent 717/CapHeight 687/Descent -194/Flags 32/FontBBox[-166 -224 1000 931]/FontFile3 28 0 R/FontName/OQKIVY+Helvetica/ItalicAngle 0/StemH 0/StemV 88/Type/FontDescriptor/XHeight 737>>
endobj
28 0 obj
<</Length 5608/Length1 5608/Subtype/Type1C>>stream
  OQKIVY+Helvetica   @¯ ¯¯¯¯˚:˚t˙|˙7
 ãã
 ãã   Û   Ô  ä¨  « Äà002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki  J  " M F Y B O E S  ' J T I . D 8 % W V U P G N Q  5 C 2 H  Z X [ 	 $ * 
 3      L / (     #   K R    1 0 + , &  6   o ) â - 4 7 9 ! L   < Q Æ ÎwπQTwôM®˙>É´Èaö˘]mä‰P“Nå≥Ï	I	^	ö	¸
|
”
Íhõ∆0®Ôiû
;VåÎ$AzºDuöJmëß÷ÌÖÆÍ°ú†v˜d‚¯:wô˘˘ ˚ò˘a˚˚†˝aÓ÷˜d˜≥“˚d!˜ª˚r˜˜–ç¸@†v˘awŒ„˜/˘a3˝a-|◊˜@—˜/€≥Ë˜¥‚8ÊÙ¯ò˜}˜V:˜˚%˚1.˚ ˚K˚6Á'˜*¯˜ÿ»˜
ß4J{YeC.W√˜ÜÙ˜∏—˚∏Ïî«≈›Ô∞@;è˚*†v¯üwò¯r¯˚L˜†˜E˜ì˚ ˚˚M˚˜M˚˜B˚ì˚K˚†˜˜˜Y˜˚Y-|‘[v˜âÕ˜8‘Ø‰L€˜Ö„6‡µ¯§Àá~ÉäÑvÉî°˜¡Ê@¬˚˚HT˚
Ñ€—ï∞©Ÿ÷∑kSi{wlá˚$yπ$~SQ.0ÕOÌ◊√§«ƒˆQë§t√ûñçî°∫˚%˜HK>Q5Qf´ø¿Ø©ÿî˜òÜä≥ü-†v¯^€|wÃﬁ8‰˜è‚Ù¯Ä˜˜˜IŒ˚EZpM_âÙ’8¸üÏ‰˜∞˜¿ÃÂ’≠`.˚÷-|◊cv¯_Ÿ˜HwÆÂ˜±„4‚:‹y¯Ü˘a˙4˚°âŒ[d°E˚7&˚5˚E‰˚˜!œªß≈≠yçD¸Ñ˜â˚TD24Uÿ˜˜∫ÀÍÊø>˚˚—†v¯PÈ|wÿ›9„˜ﬂ¯PÊç~ÑåáQamB]â„9¸üË„˜ƒ‹√∆Ÿ¸d†v˜Ÿ·˜p··Ï¯⁄˘·¸Ñ˝aÏ˜Ÿ˜Ù·˚Ù˜p¸@†v¯üw˜ÌŒ„˜/¯ˇÌ3)„¸ˇ¯ü3¸ü˚*|÷˜2ŸV÷˜$◊´ﬂGﬂ˜y‡D„’¯c˜2‘c± ¶ˆ4°<üyòã±∑µ® ‹±pNê‡˜ ÇF√˚˚=J%I≥a›wŸrﬁv†}ãdW]k@2d©ŸÅ7éTíqùp´\”oÊã˜ãﬁ–ãÛ-†v¯_€˜FwÃ„˜è‚¯˜˜˜
KÕ˚HbtLYâ˜ú3˝a„˜±˜¬ Î–™f:˚È˜K†v˘aw‘Ë.Ê¯äÈ/Á‰˘å˘a˚˚_¸Òâ˚a¯Ò˚˝aË¯<‘«â∆ã«Ëç˜_¸ÔÎ˜]¯‰çËä˚	ä∫;ããã¸Z˚*{ÿ¯"⁄©È˜†‡7ﬂË¯q˜L7<y]_I1Z“˜˜¬’Áœ±h>ö‡˜}GÃ˚˚)*˚˚?˚8Á ˜"˜€÷˜ô˜∫†v˘awõ˙"˙2˘a ˚¸€â˚4¯€"˚6¸€â˚¯€#˜O˝a˜:¯Áéå˜7¸ËÒ”ã›¯Ω›‹Ì¯Ó˘5¯˜g˚˜˚J˚∑˝a˜≥˜R˜˜˜z(Ö˚A< ˚˚O¯Ω˜I˜5¿˚˚˚*†v¯üwì¯w¯¯ü+˚(¸=âä˚¯>'˜R¸üË-|◊cv¯üwœ‚˜â„8ﬁÙ¯|¯ü¯3˚¥ TH2Hi≤◊˜Ô4¸%…Oˆ€¥¢—∏Ùç=¸Ñ◊¯’ﬂ„˜ï–mezó®˜Áﬂ’7˜&3˚&EA—˚Ï?¨g–úôåë≥-}◊¯$◊ÆÊ˜ƒÊ¯ù˜ö˜7'˜˚#˚#'˚˚7˚8Ó˚˜$˜$Ó˜˜80˚P=..PŸ˜˜∆ŸËË∆=˚¸†v¯U’˜awﬂ„˜ò¯U’3Ã∂õû∞ìîäâù⁄åwÄåÇ/_f=1EA—¸U„¯U˜K†v¯_⁄|wÃﬁ8„˜q„˜n„ˆ˘î˜˛˜KŒ%Lp|EJ≈o^¶IGYoNcâˆ’8¸üÓ„˜±Ù¡–ﬂæ´fO˚˛„˜”Ÿ¡…ŒÃ´c:˚Ê-˚Lv˜R◊¯#⁄{w≈ﬁ8„3ﬂ˜±ÂÈ¯ô˜®˜24Ù˚H^qL`â˘‘8˝lÂ„˜òçWµÆy»˜#„˜˜H1Ö˚X?0„2U–˜˜!º’ÁÍºJ˚¸ãı‚Û˜Sı#!d†v˘‡˜ïÎ¯Á˘‡¸Ÿ6˜á˝Î˘-{ÿcv¯`Ÿ˜Gw≈„3ﬂ˜±Âz¯ô˜®˜24Û˚MZqTcâ˜ò3˝aﬁÃçˆN∏ØwŒ˜Â˜˜D1É˚W?13T“˜˜Ω◊ÊÍºI˚˜x‚¯‹‡≤Ó¯âÓ˘v˜˚˜u˚!˜-˚d˚e˚!˚-˚u˚v˜ ˚,˜f”√ö¨√˜6º≈)÷—÷≠Ëã˜(/o>WU1—ZO’Ra{qÜeã˚(%˜
˜A˜DÔ˜	˜+˜*Ô˚	˚D-˚n”˜◊¯!€|w≥Ê@„˜ü„7ﬂ9›‘Ä¯á∂¯t9@˘ âÃ^^§H˚4"˚0˚D‰˚˜“µ†¿´ˆ çu˚cZ˚Hg§ƒ}3"úÕZ˜˜7’›˜G˘ 7˜b˚WH/5Uÿ˜˜ªŒÁÈΩC˚¸ãı6v‚ÛXæ–˜SìÌ‡#!–¿‡äHscÅ]”õ´ªÊ˚*˚j⁄˘&wñ¯q¯|¯ü+˚!¸?â˚¯?(˜V¸¨b˚Çdãv|éëv<ÖõóàúÚõ†˜_ÿÔ˜úêñﬁ˜Ç”†v¯üwõ˘I˘Y¯ü4 ¸.â&¯.)&¸.â'¯.,˜+¸üÂÒ¯)çÙ¸)Ê˚*ã”¯’™¯I¯h”˚’˜Õ¯’¸)A˜∂˚Œ¸F˚—˚Mv˙>wœË˜ø˚b<˜2P˜˜J˜D≥˜Î˜;O˚˚B]˚˚=˚V—˚Ú˚0”w·¯›‡∑Ó¯HÁ5ÈË˘;˜ú-˚qCH˚˚&8˜˜R˜GÁˆ˜+ÔœV*§Á˜*s!‡˚7˚a˚˚%˚x˚Ç˜˚%˜\Ë˜?˜	ı˜F§¸†v˘awÊÏ˜P˘a*˝a˚—˚Nv˙>w˜@Ë˜ù˜ù˜VE˜$˜0Q⁄˚2∆˚˚J˚Dc˚+˚;«˜˜Bπ˜˜=”†v˜«ﬁ˜ä‹„Î¯Ó˘>õoöÖóâ∏Ö˜á◊y©Kß÷π§∂ã‡ã˜6–˚*ã˚ﬂ˝aÎ˜«˜ÊÆi.çé˚å}òRÇ¯ô6[a*˚v˜ä˜áﬁ∏a>-x⁄˜¢◊˜oŸ±ËEÊ˜åÊGËÍ¯ò˜`Ÿh¿;≤ÏÀ¨•¥Œ˜5’˚˚7?˚I®aÕmÚ5ck[/˚Ó4˜!˜$È„˜Ï˚˜—HV[BEWªÃÃπ¥—‹æcKÚ¢˚⁄5XZ1.Q¡‚◊«¿‡ÂƒV9-x◊˜–⁄˜*·´Â˜ΩË¯î˜x˜(Î˚Tfk^™˜V˜Ω·˚ˇW¸÷ÜµºÆù¿ãÊÃK1*LJ/;\≤Ÿ|1˚ú◊K˜˜1ÏÈ˜-˚—†v˜{Â∑˜à˜¥˜{Â˚à1-†v¯Ü“˜w˜úÍ¯Ü˜7¸ÜÍ˘REp$qx˚Ä-ã›¯±⁄•Ó:‚˜ØÁË¯é›¸òÀª≥∆´‘≥Ô¬„º˜˜3ﬁ˚ÿ˚3?$˚)‚˜ë∏¡Â‡ƒW=Dmk&Q/VË˚Fc5Ö˚˚*†v¯üw˜jwŒ‡¯â˚h˜€˜\˜X˚˚v˚q¯36˝a‡˜Z‘Õ˜7˚ú”†v˘aw◊Ë¯Í˘˘a,¸◊â˚˙¯◊˚˝aË¯ÿç¯¸ÿ˜xﬁ`v˜¡ﬁ˜ü‡ªÔ¯eÂ|˘S¯˚Œ8˜tà@Ågqf¸PcJm8˚09Ò˜V˜EÈ˜˜'˜ –Y&´Ë˜(o˚„˚7˚b˚˚,˚˚o˜˚)˜TˆÿÆÿ…|£.-x⁄˜…⁄˜E⁄±‰2Ú˜ß‡AÂÚ¯ô˜q˜1Ë˚@VpOdàçï˜?«ÊÒãÏÀ≥fCò‡Ü«~´i≠e≤Q¢Rã˚5ã*˚#ã˚ã˚v·˚˜7ãÍ˜ÏÒ˜1Ü0RJ94OÀÁÁƒ»‡„√P--w€¯«⁄∞Ë˜∫Ë¯ô˜È˜}6˜˚/˚/6˚˚}˚z‚˚˜-˜-‚˜˜z.˚KX)++XÌ˜K˜OΩÍÏÏΩ+˚N-x⁄˜ú‘˜w⁄≠Á˜™ÂIÈÙ¯û˜bﬁiª8≠ç¯√†¨øŒ˜6’˚˚(FD˚3É·˜ ì≤∂„›Ω`DAYd,~Öãçz?åõìãéÙ˜¬c39MU+*`π˜á/˚6ô”C˜(˜/Ó„˜-†v˜>◊¯]w˜ﬂ„¯ù˜>◊%¯]B˚’¸R4˜∆˚>„˜>3◊˚u˜t˜‘åúãﬁ˜êŸ˜r›‘Ï˜ÿÎMÎ¯˘˜l‡gª-±Õ≠©ª–ˆ:”˚˚Œ˝a˜ Ù˜%Î·˜¯˚˜À?Ye(˚C˜r˜CÔºgCÙ≠˚Õ7U\*˚c˜ê˜R˜≈b;¸@†v¯¯Ù¿ÛXæ–˜1˘ Ï‡#"–¿‡äHscÅ]”õ´ªÊ¸çv˘áwz˜Ã˜ª˘tI˚ä˝áŒ¸@˚eŸ˘"w˜ÌŒ„˜/¯ˇÌ3)„˝L¯Ï3¸‚UÅÅTyAáúêãöË¥¥Ê-˚Nv˜T◊¯"⁄|wÆÊ˜≠‚7ﬂ8ﬁŸ¯Ç˚c˘n8Aâ¸…a\¶G˚4"˚1˚G„˚˜!»≥üº≥ç˚ô˙é¯Y˚UF14Vÿ˜˜∫ÕÁÈæA˚¸†v¯/ı‚ÛXæ–˜S¯/ı‡#!Û¸'Ì#!–¿‡äHscÅ]”õ´ªÊ¸ãı˜≈ı‚Û˜S¯/ı#!Û¸/ı#!-†v¯Ì·˜Í¯û¯ˆÿ¸y5¯@1W:U˚O˚l/}#Í≠˜4¢“¡˜ ƒ˜¿⁄–ÿú†v˜¬ﬁ˜é›·Ì˜ÁÓ˘¯ò˜6€˚˚◊˝aÌ˜¬˜u˜··˜(â6Y_+˚U˜é˜XÈºb;˜x‚¯‹‡≤Ó¯âÓ˘v˜˚˜u˚!˜-˚d˚d˚"˚-˚u˚v˜ ˚,˜f˜e˜ ˜,˜v(˚A%˚
˚(˚)%˜
˜A˜EÔ˜˜+˜*Ô˚	˚D˚*x›˘"wúÂ˜sÏ¯?˜V¯ü*¸•7fb>Bg≤⁄Ω1D˚ÿG˜˜÷Ÿ˜ú†v˘aw÷Ï˘)˚«¯@˜æ˜µ˚˚Ô˚˜*˝aÏ˜è˜˜˜è˚¸úã·˜Ö‡˜p‡·Ï¯¸·¸E˜Ö¯‡¸˜p¯<‡¸ù˝a-x‘˜I⁄˜ÀŸµÂ9‚˜¶Ò4‚Ú¯ï¯˜k7˜˚6˚1+˚%˚‡2˜Ÿ¡¶ƒÆçân˚X`H)ãÍEa¥’Ñ4˚î‘I˜÷∆®≈µΩŒ®˜˜Ù%Ì#XR.6Y¡ÁÒø ﬂ‚√P0”x·˘w⁄Ï¯Î˘˜ë¯d+¸Y˚FC˚˚I”˜¯V*¸r˚1˜ &˜<˜F˜Ú˜=I†v˜‘˜‘≤¯å¯≥˜“‘¸åB¯å˚`‘¸åBI†v˜l”˜î”¯≥˜l”˚k˜mC˚m˚mC˜m˚l”˜l-†v˜É’ã¯¿¯¿˜É’¸¿A”†v˜·‚˜ΩwÿÏ*Ì¯
ÏÙ˘˘a*˚Ω¸˜Ω*˝aÏÌ˜·¯
˚·˜Ú†v˜É’ã˙|˙|˜É’˛|A-ã·˘w◊Ï¯¨·˚ˇ˘*˝aúxﬁ˜ãŸ`Â˜nﬁºÊGË˜ÍÊCË’¯ˇ˜YÔQœ#£ˆ˚a∫Qòn¨ãΩ÷ ∫˜«Z*îÊ˜/Ä3’˚B˚2,7˚3øSÒsŸ˜&h˜
oØpãN4L_˚˚D∆ˆà0åçDïe©dGøŸi˜ ˜Kˆ€˜ú†v˘awü˘˘˘a˚˚^¸˜â˚b¯˜ ˜ö˝aÚú†v˘awû˘˘˚è¯˜É˜Ò˚˚J˚¶˚J˜¶˚˜Ñ˚Ò˚î¸˜˜[˜º˜U˚º¯x…ËÃJ‘˜∏”Ò»˜'‘◊ﬁ¯:Ãﬂ˘ˆ¯>˜C˚*˜˚V˚e˚:˚:˚d˚k˜:˚:˜l˜˜Œ˜ I@H8d/˚B˚˜˜C˜K˜˜˜A˜3˜˚˚$ F˚Cyäöö§ßÈ»˜cGwMlƒj†Wã˚$˚˚,5ÕAÿ∂¨òΩªçaè†v±Æ¿¢¨¥“∆±›Ëˇ˚ìy*>%A[j≥ƒÏ’Ì‘π≤`Yu°¯üö˜)õôü˜°ñ¸}ö◊
„
_˜™˘
endstream
endobj
35 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma 46/period/slash/zero/one/two/three/four 57/nine/colon 65/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W 89/Y 97/a/b/c/d/e/f/g/h/i 108/l/m/n/o/p 114/r/s/t/u/v 120/x/y/z]/Type/Encoding>>
endobj
37 0 obj
<</Ascent 750/CapHeight 717/Descent -205/Flags 262176/FontBBox[-170 -227 1001 963]/FontFile3 36 0 R/FontName/DNFGOS+Helvetica-Bold/ItalicAngle 0/StemH 0/StemV 140/Type/FontDescriptor/XHeight 737>>
endobj
36 0 obj
<</Length 4493/Length1 4493/Subtype/Type1C>>stream
  DNFGOS+Helvetica-Bold   @¯ ¯¯¯¯˚>˚w˙}˙W
 ãã
 ãã      y≤  f Äçï002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki BoldHelsinki  8  $ B T F  3 Q P S U 0 # + & 5 * 7  " 4 6 . : % / - , 8 C M   )  1 2 D N Z G V  J O [ ' E H I     ( W  Y :   T ‘>†£s∫ˇ;ç?kç§Œı0ΩÛ3_¶’"çÌ2Gqó‹	C	ë

I
Å
»
ÂUÇ´ÜÕBè‰`∆Ò=u”x˜¯É˜∑˘˘?˜â˚)*n_f6˚HÁ˜,˜4ÕÊ˜
ﬁµi1ß˜(˜-~˚˚A˚]˚˚'˚|˚|˜˚$˜^˜;ˆÊ˜A∞-}ÔJv˜z‹˜˜®˜˜Q˜|¯°†uíÇ£ø˜¥Î;≈˚˚0FU˚Ä˜Ωèß£¿ ®x`t|}iÜ˚x${XRã*¸.ÀMÎ”≤ù∆…|åqçÅîp¸z˜SRS[K`q§≤ª°û“ò–òàä©ú-}ı˜ı©˜#˚˜˚˜˜a˜ ‘¯ö˜9˜d˚·?ãÍ©´ù¿«®uZë˜˜Ñ;≈˚-˚;D ˚X˜› ã3ggxVÃ=h¢¬à‰˚#˚çÎE˜0˜#Ê–˜-}˜˜Ê˜˜¢˜#˚#˜ ˜p˜#Ù¯¢˜x§˜P2Ù˚5˚4.%˚D˚IÁ&˜9˜⁄¬˜Ø˚#cyny\ÏAdµ‰ÑÙ˜pÊ˚m⁄ò´¨  Øf@ï¸”†v˜Æ˜˜T˜◊˜(˜∏˜(˘9ûsîÑù¿˜HÄ©:Ø’©Øƒﬂ˜3⁄˚˚ˇå˝a˜'˜Æ˜/Óöy˚
çåFéoòZè¯ÜIgn:˚C˜T˜OŒ±hMd˚Nv˜U˜˜Ÿ˜{w…˜˚˜!˜{˜#Í¯’˜§˜82˜˚AcsF^â˙ÿ˚˝vÊ˜!˜¶çå≠Rπr–ã˜·˜˜D˚#Ç)^KEÍ?\∆È˜¥∆Ÿ÷∑O$d}˜	˜Ÿ˜
≠˜#˜ï˜#¯’˜û˜?!˜˚9˚:!˚˚?˚AÛ ˜<˜;Û˜ ˜@˚# _S76_√ˆÙ∏ƒﬂﬁ∏R"˚ô†v¯(˜"|wÀ˜˚˜ ¯¯%˜"éÜãÅJgp<_âÊ˚¸ßË˜ ˜®ﬂ∑∑ﬂñîäâü˚—Öı˜ﬂÔ›˜ ˜»àıâ|Ñä^Ñë±˜≥·Ô5˜%˚ ˚%C'”˚’7≥kÚùûôåç´˜x˜¯ä˜∑˘F˘r˜˙˜m˚˜6˚v˚u˚˚4˚o˚n˜	˚3˜x˜t˜˜4˜m˚*å˚0A,˚˚AÍ˜0˜/÷Î˜˜÷+˚/”ã˜˜U˜˜0˜◊˜$˜Æ˜#˚˜)Ù˘0˜m‡m∫:±¯ Æ§¥Œ˜5”˚˚˝a˜≈ﬁ»ïû≠Ùœ±¥—€¯˚:˜¡XdmG˚C˜0˜?◊ÆtWÙú˚∫KafC˚M˜U˜Sœ≥iQ-y˜¯˙w°˜˜A˜*¯w˜d¯ë˚*¸ë?snNKs±Ú¶˚l˚OÃD˜A˜'◊ÿ˜)úã˜˜O˜˜+˜◊˜'˘ ˜¸!˜O˜˜˚˜+¯˜¸¢˝ad†v¯„˜˜z˜+¯Ë¯„˜¸⁄˚˜l¸„˜+¯„¸†v˘awÀ˜*˜j˘a˚*˝aú†v˘awû˘˘˘a˚/˚0¸≥âä˚.¯¥˚4˜Ü˝a˜#˚—ã˜%˜r˜%Á˜*˜Ü¯˜%˚*˚%˜*¸˜%˚*˚%”†v˜'˜¯Qwü˘;˘O˚ë˘a˚A˚ë˝a˜1Ω˜'˜ùπ˚'3˜§˚LÁ˜∞çúw˜˜I˜$˜'˜6˜≤˜"˚˜˜•˜#˚˜%’˘	˜lÚS√˚¨ˆ˚C∑Sôv†ã¥¿º¨◊Ê∫hBï˜#˜$Ñ ‚˚;˚A&8˚"˚*ıo˜nŸÿyÓt™vã^NYl&,Z∞ŸÉ˚"çCôd±aøSÂk˜ã˜@ã˜Áã˜$”x˜¯ˆw”¯÷˘˜é¯g˚,¸m/[^*;[¬Â¯e˚-¸p˚7ı*˜F˜TÒË˜D˜K†v˘aw–˜ ¯4˜˘ê˘a˚l˚¸…à˚¯…˚o˝a˜ ¯Ïç˜¸Ï˜(˜¯Ïç¸Ïú†v˘awö˘˘˘a˚=˚!˚À˚*˜À˚D˜å¸S˚¢˜+˜°”ã˜¯i˜◊˜'˜»˜,˘?¯˜n'˜˚S˚–˝a˜À˜J˜˜%˜{˚,˚(M0'˚&¯i˜$˜¿@˚/”†v˘aw–˜ ˜ƒ˜ ˘!˘a˚ ¸àâ˚±¯à˚1˝a˜ ¯îç˜∏¸îdã˜¯ﬂw◊¯é¯⁄˜˚¯¯ﬂ˚*˝a”†v˘aw‚˘˘e˚»¯=˜∑˜∏˚U˚•˚µ˜µ˚+˝a˜+˜á—”˜q˚œ˜∫†v˘aw˜∑œ¨Ÿç⁄¨‘˙4˘a˚+b˚Cb˚Bg˚Dâh˜UçÉB˜Ë˚3N˚æîøZ˚´âh˜Sêt7˜˘˚3˜_˝a˜ ±˜N∂˜N©˜Pç™˚O≥˚P¥˚M˜#d}˜;v¯=˜˜>w»˜ ˚ ˜˜É˜#z¯’˜•˜72˜˚E]rQeâ˜ë˚ ˝a˜ŒéˆSÆªr–˜·˜˜D˚#Å*]JE@[…ÏÙ∑«◊÷∑O%¸†v˘aw–˜ ˜e˘a˚ ˝a-†v¯}Ó˜w˜Å˜!˚˜Ë¯˘Z˚8Td w(–˜<¸}¸ã˜%À˜*˜j˜%˚*˚%”†v˜’˜˜§w“¯◊˘˘a˚*˚§˚´˜§˚*˝a˜*˜’˜´˚’¸ã˜%˜(Õ˜jû˜˚*˚%ﬂÑDvrTxV£ªƒıú†v˜ó˜˜h˜¯q˜)˘¯Ä˜4·˚˚‹˝a˜*˜ó˜@˜ÁÈ˜˚)âCfg@˚˜h˜
ÌÆo?˜x˜¯ä˜∑˘H˘t®=’º ¶·ãı˜m˚˜6˚v˚u˚˚4˚o˚n˜	˚3˜xÀŒù©¿ﬂ;B¯.N~Wvb@“>:‘FspÖlã˚AÍ˜0˜/÷Î˜˜÷+˚/-}˜˜€˜
≠˜$˜`˜!¯ü˜V˚!KjnSHg¡˜ı≥≈’∫©pPò˜!˜É+‘˚˚71$˚O˚?Â(˜/˜Âÿ˜ù˜É†v¯?˜
˚	˜
|wÀ˜ ˚ ˜˜E˜˜>˜ Î˘Ã¯˜C–˚O`qPfÁŒ_jûCF^pJgâ˜ÿ˚¸ßÎ˜ ˜◊–®Øƒ…¢n:˚“˜˜“Î”´∞…Ω•m@˚÷-˚i˜˘wï¯£¯≠¯ß˚'˚ ¸â˚¯˚/˜X¸æ{K{|UãÖàãçs˚äßûäõ˜	ûû˜_—˚—†v¯EÌ‹˜·˜ ˜—¯EÌ0†øëìµ≤˜çhÄãq#XZ%_?)◊¸E˜ ¯Ed}˜
8v¯ßwÕ˜ ˜[˜˚˜Ù¯≥¯ß¯˚˚«B`\IOm¨Ã˜›˚ ˚Ò˚ÕC˜÷æß»ØÙç@¸çv˘àwj˜Î˜ ˘u˚	˚v˝à˜¸†v¯ßwﬁ˜–˜ ˜e¯Ê˜˚ ˚˜ ¸Ê¯ß˚ ¸ßd†v¯?˜|wÃ˜˚˜ ˜]˜Ù¯¥¯˜Dœ˚C_rH`âÙÿ˚¸ßÏ˜ ˜ƒÿµπ—«®iE˚◊˚*ã˜˜ƒ˜ü¯^¯r˜˚™˜†˜¡˜¸B˚˜ë˚£˚ ˚d†v˜¡˜˜7˜◊¯ë¯›¯„˜¸ë˝a˜*˜¡˜Œ˜˚Œ˜7d}˜;v¯<˜˜?w≠˜$˜|˜˚˜z¯∏˘a¸˚˚ìâ ^d†D˚5˚ ˚;˚@‰˚˜œæ¶¡ÆçzH˙é˜ò&^Q=E^ ÏÛµ∆÷⁄µR d˚mı˜ ˜
˜…˜|w≥˜#˜z˜˚˜⁄¯º®¯ä˚<â¸ÀmX©D˚4!˚<˚?‚#˜!–¥£ƒ´éáL4hh>Ktò¥Å˚,#óﬁS˜'˜èí˜.Á˚˜Ñ*eR:G`«ÈÍ∂«Œ◊∑J1d†v¯@˜˜>wÃ˜˚˜ ˜]˜Ù¯µ¯˜C—˚CVnUoà˜ë˚˝aÏ˜ ˜≈ﬂ≥≤’∆ßjC˚◊-x˜˜˜˜é˜©˜˜d˜$˚˜Ù¯ù˜Ì˜ä9˜˚<˚(.-˚*˚ ·-˜ÀØõ∏Øçàá˚cHBã[p¢∫Ñ˚˚ú‹H˜˜8È˜˜{¯˚$˜?c[LId∏Ÿﬂ¥∂«œ≤];-x˜¯é˜´˜$˜_˜$¯ü˜Ó˜å=˜˚<˚;=˚˚å˚éÿ˚˜<˜=ÿ˜˜é˚$å˚RqK?@qÀ˜R˜P•À÷◊•K˚P-ã˜¯h˜
´˜˜]˜ ¯í˜˚»®ƒ˜œ ≈¿ª®¬ã⁄ã˜(„˚'ã˚'ã<6Ü˚9˜Óè•¨“«≥bL4Gk˚4˚*jSÑ˚-x˜˜mÔ˜O˜¶˜˚˜˜M˜ ˚˜$Í¯ò˜g‹d∆G£çÏ»Ø¢±Œ˜0ÿ˚˚1:˚&ä˜‹é≠≠≈¬ÆhTIel:v'Ú˜â≤q<K^]NHl∞‚Ü˚˚)âÊ3˜,˜(ÔË˜˜x˜4v˜û˜˜u˜¯◊˜x˘[¯˚Ω˚˜9¯˚ oQY*˚AÁ˜0˜4ŸÏ˜◊∆_B°˜(˜)x˚Ê˚C˚i˚˚(˚z˚v˜˚+˜YÌÃ´Ÿ»xô0-†v¯ßwò¯§¯±¯ß˚'˚¸â˚¯˚/˜T¸ß˜&-†v˜0˜¯Qw˜∆˜ ˚˜Ë¯°˜0˜<¯Q˚4˚ó¸D˚–˜´˚0˜ ˜0˚¯3ä'ä#%˚E»˜E˜∆-†v¯ßwö¯†¯Ø˚H˜¢˜B˜ô˚94˚.1˜.˚>˜B˚ô˚H˚¢˜<Á˜4Á˚4wü¯ßö˜,óíüòã˜£ó¸|ãı
˜ å
_˜™˘
endstream
endobj
84 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
85 0 obj
<</OP false/OPM 0/op false>>
endobj
92 0 obj
<</A 93 0 R/Border[0 0 0]/Rect[259.007 9.0 300.752 16.0]/Subtype/Link/Type/Annot>>
endobj
93 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
78 0 obj
[94 0 R]
endobj
79 0 obj
<</Length 13667>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.02499 Tc 0.00301 Tw 10.5 0 0 10.5 60 730.8196 Tm
[(weakness, delirium, syncope, hypotension, tachypnea, QT)70 (c)]TJ
-0.01601 Tc 0.01601 Tw 0 -1.23809 TD
(interval prolongation, and arrhythmias, indicating overac-)Tj
-0.006 Tc 0.005 Tw 0 -1.2381 TD
(tivity of muscarinic and nicotinic sites of autonomic and)Tj
0.006 Tw T*
(somatic nerves, as well as of the central nervous system.)Tj
0 Tc 0.011 Tw 0 -1.23809 TD
(This may be due to a significant upregulation of acetyl-)Tj
-0.021 Tc 0.021 Tw 0 -1.2381 TD
(choline receptors caused by decreased synaptic concentra-)Tj
0 Tc 0.149 Tw T*
(tion of acetylcholine due to abrupt discontinuation of)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(galantamine after prolonged exposure to the drug. )Tj
-0.00301 Tc 0.00301 Tw 1 -1.22381 Td
(Other causes for clinical deterioration were excluded.)Tj
0 Tc 0.01401 Tw -1 -1.22381 Td
[(There was no metabolic abnor)-25 (mality)65 (, electrolyte imbal-)]TJ
-0.01601 Tc 0.01601 Tw 0 -1.22381 TD
(ance, or signs of infection. Galantamine is the most likely)Tj
0 Tc 0.16499 Tw T*
(cause, given that it was the only medication recently)Tj
-0.024 Tc 0.024 Tw T*
[(restarted. The patient\325)55 (s condition resolved with discontinu-)]TJ
-0.004 Tc 0.004 Tw T*
(ation of galantamine and irbesartan. The latter may con-)Tj
-0.034 Tc 0.02299 Tw T*
[(t)-10 (ribute to hypotension but is unlikely to cause delirium, syn-)]TJ
-0.03101 Tc 0.02 Tw T*
[(cope, QT)70 (c interval prolongation, or arrhythmia \(MEDLINE)]TJ
-0.008 Tc 0.007 Tw T*
[(searched\). Drug interaction is a theoretical possibility)65 (, as)]TJ
-0.017 Tc 0.01601 Tw 0 -1.22382 TD
[(galantamine, irbesartan, and simvastatin under)20 (go metabo-)]TJ
-0.02499 Tc 0.01401 Tw 0 -1.22381 TD
[(lism via the CYP3A4 isoenzyme. However)40 (, the role of this)]TJ
-0.022 Tc 0.022 Tw T*
(enzyme in metabolism of irbesartan is minimal,)Tj
ET
BT
/T1_1 1 Tf
0 Tw 5 0 0 5 250.9888 488.3696 Tm
(14)Tj
ET
BT
/T1_0 1 Tf
0.022 Tw 10.5 0 0 10.5 258.9509 485.6196 Tm
(and sim-)Tj
-0.015 Tc 0.015 Tw -18.9477 -1.22381 Td
(vastatin was not ceased. Therefore, this mechanism is not)Tj
-0.02499 Tc 0.013 Tw T*
(likely to be significant.)Tj
-0.02299 Tc 0.022 Tw 1 -1.22381 Td
(Nausea, vomiting, and diarrhea, which were seen in our)Tj
0 Tc 0.036 Tw -1 -1.22381 Td
[(patient, are the most common adverse ef)20 (fects of AChIs)]TJ
-0.013 Tc 0.013 Tw T*
(linked to muscarinic enhancement. Urinary incontinence,)Tj
0 Tc 0 Tw T*
(hypotension, and bradycardia were other muscarinic ef-)Tj
-0.00101 Tc 0.00101 Tw T*
[(fects in our case. W)80 (eakness, tachypnea, initial \322nor)-25 (mal\323)]TJ
-0.02 Tc 0.02 Tw T*
(heart rate \(followed by bradycardia\) may be considered as)Tj
-0.01199 Tc 0.01199 Tw T*
[(mainly peripheral nicotinic ef)20 (fects, while CNS ef)20 (fects in-)]TJ
-0.01801 Tc 0.01801 Tw T*
(cluded delirium, restlessness, and agitation. There are few)Tj
-0.02499 Tc 0.02499 Tw T*
(case reports of delirium,)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 156.3089 347.5696 Tm
(15)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 10.5 0 0 10.5 164.6367 344.2696 Tm
(syncope,)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 6 0 0 6 199.5851 347.5696 Tm
(16)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.02499 Tw 10.5 0 0 10.5 207.9129 344.2696 Tm
[(and QT)70 (c interval pro-)]TJ
0 Tc 0 Tw -14.08694 -1.22381 Td
(longation)Tj
ET
BT
/T1_2 1 Tf
6 0 0 6 99.6621 334.7196 Tm
(7)Tj
ET
BT
/T1_0 1 Tf
0.015 Tw 10.5 0 0 10.5 105.4477 331.4196 Tm
[(associated with galantamine, and the mecha)2.4 (-)]TJ
-0.02499 Tc 0.013 Tw -4.32835 -1.22381 Td
[(nisms of these adverse ef)20 (fects remain unclear)55 (.)]TJ
-0.021 Tc 0.021 Tw 1 -1.22382 Td
[(Although exposure to anticholiner)20 (gic medications is as-)]TJ
-0.019 Tc 0.019 Tw -1 -1.22381 Td
(sociated with delirium,)Tj
ET
BT
/T1_2 1 Tf
-0.017 Tc 0 Tw 6 0 0 6 152.3537 296.1696 Tm
(17)Tj
ET
BT
/T1_0 1 Tf
-0.019 Tc 0.019 Tw 10.5 0 0 10.5 160.7524 292.8695 Tm
(and galantamine has been shown)Tj
-0.021 Tc 0.021 Tw -9.59547 -1.22381 Td
[(to produce ef)20 (fective reversal of this syndrome,)]TJ
ET
BT
/T1_2 1 Tf
-0.019 Tc 0 Tw 6 0 0 6 246.3565 283.3196 Tm
(18)Tj
ET
BT
/T1_0 1 Tf
-0.021 Tc 0.021 Tw 10.5 0 0 10.5 254.7294 280.0195 Tm
(in our pa-)Tj
0 Tc 0.16499 Tw -18.54566 -1.22381 Td
[(tient, galantamine precipitated agitated delirium. Irre)7 (-)]TJ
-0.017 Tc 0.017 Tw 0 -1.2238 TD
(versible inhibition of acetylcholinesterase by or)Tj
0 Tw 18.25565 0.00001 Td
(ganophos)Tj
0 Tc [-0.4 (-)]TJ
-0.017 Tc 0.01601 Tw -18.25565 -1.22381 Td
(phorous insecticides causes confusion and coma.)Tj
ET
BT
/T1_2 1 Tf
-0.01401 Tc 0 Tw 6 0 0 6 257.9933 244.7694 Tm
(19)Tj
ET
BT
/T1_0 1 Tf
-0.0166 Tc 10.5 0 0 10.5 266.4207 241.4695 Tm
(A)Tj
-0.017 Tc 0.95528 0 Td
(case)Tj
-0.02499 Tc 0.019 Tw -20.61439 -1.22381 Td
[(report described a 77-year)20 (-)-75 (old man with early Alzheimer)-35 (\325)56 (s)]TJ
-0.007 Tc 0.007 Tw 0 -1.22381 TD
(disease who developed paranoid delusion after 4 days of)Tj
-0.02499 Tc 0.013 Tw T*
(galantamine use.)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 126.4856 206.2195 Tm
(15)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01801 Tw 10.5 0 0 10.5 70.5 189.9195 Tm
[(All 3 AChIs used in Alzheimer)-35 (\325)55 (s disease, according to a)]TJ
-0.008 Tc 0.008 Tw -1 -1.2381 Td
(recent Cochrane review of pooled data from randomized)Tj
-0.015 Tc 0.015 Tw 0 -1.23809 TD
(controlled trials, have demonstrated a significantly higher)Tj
0 Tc 0.06599 Tw 0 -1.2381 TD
(incidence of syncope compared with placebo \(3.4% vs)Tj
0 Tw T*
(1.87%\).)Tj
ET
BT
/T1_2 1 Tf
6 0 0 6 93.238 141.2194 Tm
(1)Tj
ET
BT
/T1_0 1 Tf
0.216 Tw 10.5 0 0 10.5 101.132 137.9194 Tm
(An AChI edrophonium has been used as a)Tj
0.021 Tw -3.91733 -1.23809 Td
(provocative agent for inducing syncope during head-up)Tj
-0.02499 Tc 0.006 Tw T*
(tilt-table testing.)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 123.894 115.2195 Tm
(20)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.006 Tw 10.5 0 0 10.5 132.0242 111.9195 Tm
(In the majority of published studies, syn-)Tj
0.01199 Tw -6.85945 -1.2381 Td
(cope was associated with donepezil and was usually due to)Tj
-0.011 Tc 0 Tw 0 -1.23809 TD
(new-)Tj
-0.00999 Tc 0.00999 Tw 2.03191 0.00001 Td
(onset bradycardia. However)Tj
-0.0105 Tc 10.95421 0.00001 Td
(,)Tj
-0.00999 Tc 0.48946 0 Td
(in two-thirds of 16 pa)Tj
0 Tc 8.4774 0.00001 Td
(-)Tj
-0.008 Tc 0.008 Tw -21.95298 -1.23811 Td
(tients treated with donepezil and hospitalized for evalua-)Tj
0 Tc 0.103 Tw T*
(tion of syncope, its cause was considered unrelated to)Tj
0 Tw 0 -1.2381 TD
(donepezil.)Tj
ET
BT
/T1_2 1 Tf
0.002 Tc 6 0 0 6 103.4407 50.2195 Tm
(21)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.05 Tw 10.5 0 0 10.5 112.5865 46.9195 Tm
(There is one case report of syncope due to)Tj
-0.022 Tc 0.022 Tw 19.56319 65.13335 Td
(complete atrioventricular block that occurred after the first)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(administration of galantamine.)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 438.9686 721.1196 Tm
(16)Tj
ET
BT
/T1_0 1 Tf
-0.00999 Tc 0.00999 Tw 10.5 0 0 10.5 328.5 704.9197 Tm
(In our patient, the first syncopal episode was observed)Tj
-0.02299 Tc 0.02299 Tw -1 -1.22857 Td
(14 months after he started galantamine and was associated)Tj
-0.01199 Tc 0.011 Tw 0 -1.22857 TD
(with hypotension and sinus bradycardia. The next synco-)Tj
0 Tc 0.213 Tw T*
(pal episode occurred 3 weeks after galantamine was)Tj
-0.024 Tc 0.024 Tw T*
[(restarted and was associated with severe hypotension, QT)70 (c)]TJ
-0.00999 Tc 0.00999 Tw 0 -1.22858 TD
(interval prolongation, and arrhythmias. Although our pa-)Tj
-0.00101 Tc 0.00101 Tw 0 -1.22857 TD
(tient had coronary artery disease, he developed syncope)Tj
-0.02499 Tc 0.013 Tw T*
(only when he received galantamine. )Tj
0 Tc 0.231 Tw 1 -1.22857 Td
(The most extraordinary feature of our case is the)Tj
-0.019 Tc 0.019 Tw -1 -1.22857 Td
[(m)1 (a)1 (r)1 (k)1 (e)1 (d)1 ( )1 (Q)1 (T)71 (c interval prolongation with potentially serious)]TJ
-0.024 Tc 0.024 Tw T*
[(cardiac arrhythmias. Our patient had a QT)70 (c interval of 503)]TJ
-0.004 Tc 0.004 Tw T*
[(msec \(by Bazett\325)55 (s for)-25 (mula\), an increase of more than 60)]TJ
T*
(msec above the drug-free period. According to the Food)Tj
-0.00301 Tc 0.00301 Tw T*
(and Drug Administration and the Committee for Propri-)Tj
-0.022 Tc 0.022 Tw T*
[(etary Medicinal Products, any QT)70 (c interval over 500 msec)]TJ
-0.005 Tc 0.005 Tw T*
(or any increase of more than 60 msec is a cause for con-)Tj
-0.01801 Tc 0.01801 Tw T*
[(cer)-25 (n for the development of torsade de pointes. In 92% of)]TJ
-0.02299 Tc 0.02299 Tw T*
[(1)35 (16 torsade de pointes cases related to treatment with non-)]TJ
-0.007 Tc 0.007 Tw T*
[(cardiac drugs, QT)70 (c intervals were more than 500 msec.)]TJ
ET
BT
/T1_2 1 Tf
-0.005 Tc 0 Tw 6 0 0 6 546.0421 476.0198 Tm
(22)Tj
ET
BT
/T1_0 1 Tf
-0.03101 Tc 0.021 Tw 10.5 0 0 10.5 318 459.8198 Tm
[(Acquired or congenital QT)70 (c interval prolongation can result)]TJ
-0.028 Tc 0.01801 Tw T*
(in ventricular arrhythmias leading to syncope, seizures, and)Tj
-0.00999 Tc 0.021 Tw T*
[(sudden death. The Cochrane review of pool)-10 (e)-10 (d)-10 ( )-10 (d)-10 (a)-10 (t)-10 (a)-10 ( )-10 (f)-10 (r)-10 (o)-10 (m)]TJ
-0.021 Tc T*
(unpublished studies found that use of galantamine was as-)Tj
0 Tc 0.03799 Tw 0 -1.22856 TD
(sociated with a significantly higher rate of unexplained)Tj
-0.02499 Tc 0 Tw 0 -1.22857 TD
(death.)Tj
ET
BT
/T1_2 1 Tf
0 Tc 6 0 0 6 341.788 398.6199 Tm
[(1)79.2 (1)]TJ
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.011 Tw 10.5 0 0 10.5 349.6335 395.3199 Tm
(There has been one report of galantamine-associat-)Tj
-0.015 Tc 0.015 Tw -3.01271 -1.22857 Td
(ed QT)Tj
-0.0148 Tc 2.39789 0 Td
(c)Tj
-0.015 Tc 0.67915 0 Td
[(interval prolongation \(518 msec\) in a 47-year)20 (-)-75 (old)]TJ
-0.02499 Tc 0.01401 Tw -3.07703 -1.22857 Td
(schizophrenia patient.)Tj
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 6 0 0 6 404.5016 372.8199 Tm
(7)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01401 Tw 10.5 0 0 10.5 409.8647 369.5199 Tm
[(Another report described a 78)-25 (-year)20 (-)]TJ
-0.024 Tc 0.024 Tw -8.74901 -1.22857 Td
[(old man with Alzheimer)-35 (\325)56 (s dementia who developed a QT)70 (c)]TJ
0 Tc 0.011 Tw T*
[(interval of 477 msec a week after commencement of ri)1.1 (-)]TJ
-0.02499 Tc 0 Tw 0 -1.22858 TD
(vastigmine.)Tj
ET
BT
/T1_2 1 Tf
0 Tc 6 0 0 6 363.8767 334.1199 Tm
(8)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.024 Tw 10.5 0 0 10.5 369.3551 330.8199 Tm
(Our patient did not have the confounding fac-)Tj
-0.01401 Tc 0.01401 Tw -4.89096 -1.22857 Td
(tors present in these 2 cases: use of psychotropic drugs in)Tj
-0.02499 Tc 0.01601 Tw 0 -1.22857 TD
(the first and hypokalemia in the second. He did not receive)Tj
-0.01199 Tc 0.01199 Tw T*
[(any other drugs that may precipitate QT)70 (c interval prolon-)]TJ
0 Tc 0.006 Tw T*
[(gation and did not have electrolyte abnor)-25 (malities or hy-)]TJ
0.033 Tw T*
[(pothyroidism. In our patient, QT)70 (c interval prolongation)]TJ
-0.011 Tc 0.011 Tw T*
(was associated with nonsustained ventricular tachycardia)Tj
0 Tc 0.01401 Tw 0 -1.22858 TD
(revealed by Holter monitoring 3 days after galantamine)Tj
-0.02299 Tc 0.02299 Tw 0 -1.22857 TD
[(was discontinued. Three weeks later)40 (, Holter recording was)]TJ
-0.021 Tc 0.021 Tw T*
(unremarkable. In our case, polymorphic ventricular tachy)Tj
0 Tc 21.95305 0.00001 Td
(-)Tj
-0.00101 Tc 0.00101 Tw -21.95305 -1.22857 Td
(cardia \(torsade de pointes\) could not be ruled out, given)Tj
-0.02299 Tc 0.02299 Tw T*
(that there was no ECG monitoring during the first days af)Tj
0 Tc 21.95295 0.00001 Td
(-)Tj
-0.02499 Tc 0.013 Tw -21.95295 -1.22858 Td
(ter admission. )Tj
-0.017 Tc 0.017 Tw 1 -1.22857 Td
[(After or)20 (ganophosphate poisoning, QT)70 (c interval prolon-)]TJ
-0.009 Tc 0.009 Tw -1 -1.22857 Td
(gation with ventricular arrhythmias, including torsade de)Tj
-0.02499 Tc 0.02499 Tw T*
[(pointes, often occurs between the third and fifteenth day)65 (. It)]TJ
T*
(is unrelated to serum electrolyte imbalance and is associat)Tj
0 Tc 21.95278 0.00001 Td
(-)Tj
-0.013 Tc 0.013 Tw -21.95278 -1.22858 Td
[(ed with high mortality)65 (, especially sudden and unexpected)]TJ
-0.019 Tc 0 Tw T*
(death.)Tj
ET
BT
/T1_2 1 Tf
-0.017 Tc 6 0 0 6 342.1898 101.92 Tm
(19)Tj
ET
BT
/T1_0 1 Tf
-0.019 Tc 0.019 Tw 10.5 0 0 10.5 350.5913 98.62 Tm
(The syncope experienced by our patient may well)Tj
-0.01199 Tc 0.01199 Tw -3.10393 -1.22857 Td
(be related to QT)Tj
-0.0116 Tc 6.30447 0.00001 Td
(c)Tj
-0.01199 Tc 0.6823 0 Td
(interval prolongation with dysrhythmia)Tj
-0.02499 Tc 0.013 Tw -6.98677 -1.22858 Td
(of torsade de pointes.)Tj
-0.013 Tc 1 -1.23333 Td
(Although our patient had no family history of long QT)Tj
-0.01199 Tc 0.01199 Tw -1 -1.23334 Td
(interval syndrome or sudden cardiac death, a genetic car-)Tj
ET
0 0 0 0 k
318 745 234 10 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
-0.02499 Tc 0.013 Tw 8 0 0 8 347.0937 749.5293 Tm
(Prolonged QT Interval, Syncope, and Delirium with Galantamine)Tj
ET
0 0 0 0 k
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
10 0 0 10 267.483 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 400.608 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 413.7891 23.9116 Tm
[(2008 February)55 (, V)110 (olume 42    )]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 524.3189 25.4116 Tm
(n)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 10 0 0 10 537.5 23.9116 Tm
(281)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
BT
0 g
/GS2 gs
/T1_6 1 Tf
0 Tc 5 0 0 5 299.75243 11 Tm
( at UNIV OF MICHIGAN on April 18, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
80 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
81 0 obj
<</OP false/OPM 0/op false>>
endobj
94 0 obj
<</A 95 0 R/Border[0 0 0]/Rect[259.007 9.0 300.752 16.0]/Subtype/Link/Type/Annot>>
endobj
95 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
74 0 obj
[96 0 R]
endobj
75 0 obj
<</Length 10649>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
0.019 Tw 10.5 0 0 10.5 60 730.8196 Tm
[(Bazett\325)55 (s for)-25 (mula\) 4 days after discontinuation of galan-)]TJ
-0.022 Tc 0.022 Tw 0 -1.23809 TD
[(tamine and remained nor)-25 (mal thereafter \(T)70 (able 1\). A repeat)]TJ
0 Tc 0.07201 Tw 0 -1.2381 TD
[(24)-75 (-hour electrocardiographic monitoring 3 weeks later)]TJ
0.09801 Tw T*
(showed sinus rhythm with an average heart rate of 76)Tj
-0.015 Tc 0.015 Tw 0 -1.23809 TD
(beats/min \(minimum 49, maximum 126\), ventricular \(n =)Tj
0 Tc 0.002 Tw 0 -1.2381 TD
[(626\) and supraventricular \(n = 260\) and ectopy)65 (. He was)]TJ
0.035 Tw T*
[(dischar)20 (ged, with an MMSE score of 21/30 on his usual)]TJ
-0.01801 Tc 0.01801 Tw 0 -1.23809 TD
(medications except for galantamine and irbesartan. He re-)Tj
-0.02499 Tc 0.013 Tw 0 -1.2381 TD
(mained asymptomatic for 6 months.)Tj
ET
BT
/T1_1 1 Tf
0.011 Tw 10.5 0 0 10.5 60 598.8197 Tm
(Australian Reports)Tj
ET
BT
/T1_0 1 Tf
-0.00011 Tc 0 Tw 10.5 0 0 10.5 70.5 577.8197 Tm
(A)Tj
0 Tc 0.037 Tw 1.00885 0 Td
(summary of cases of cardiac, neurologic, and gas-)Tj
-0.02 Tc 0.02 Tw -2.00885 -1.2381 Td
(trointestinal disorders associated with 3 AChIs reported to)Tj
0 -1.23809 TD
[(ADRAC \(to May 31, 2007\) is shown in T)70 (able 2. No cases)]TJ
-0.021 Tc 0.021 Tw T*
(of torsade de pointes were reported. There have been 5 fa-)Tj
0 Tc 0.36501 Tw T*
(tal outcomes associated with galantamine, 1)Tj
-0.00011 Tc 19.3934 0.00001 Td
(1)Tj
0 Tc 0 Tw 1.11455 0 Td
(with)Tj
-0.006 Tc 0.006 Tw -20.50795 -1.2381 Td
(donepezil, and 3 with rivastigmine, including 3, 6, and 0)Tj
-0.02 Tc 0.02 Tw T*
[(sudden deaths, respectively)65 (. When the number of reported)]TJ
-0.008 Tc 0.008 Tw 0 -1.2381 TD
(cases was analyzed per 100,000 prescriptions written, an)Tj
-0.009 Tc 0.009 Tw T*
(estimated 8.47 cases of delirium, confusion, or agitation;)Tj
-0.01401 Tc 0.01401 Tw 0 -1.23809 TD
(3.76 of syncope; 2.82 of any type of arrhythmia or block;)Tj
0 Tc 0.063 Tw T*
(3.29 of vomiting; 3.76 of diarrhea; and 1.41 of sudden)Tj
-0.00101 Tc 0.00101 Tw 0 -1.2381 TD
(death were related to galantamine. For rivastigmine, the)Tj
-0.008 Tc 0.008 Tw 0 -1.23809 TD
(corresponding figures were 14.10, 5.37, 1.30, 7.38, 3.36,)Tj
0 Tc 0.07201 Tw T*
[(and 0, respectively)65.8 (,)-322.4 (and for donepezil 4.77, 1.28, 1.27,)]TJ
-0.015 Tc 0.015 Tw 0.00001 -1.2381 Td
[(2.13, 1.28, and 0.51, respectively)65 (. These data suggest that)]TJ
-0.02499 Tc 0.02499 Tw T*
(use of galantamine may be associated with the highest rate)Tj
-0.01801 Tc 0.01801 Tw T*
(of arrhythmia and sudden death, with rivastigmine having)Tj
0 Tc 0.043 Tw 0 -1.2381 TD
(the highest rate of delirium, syncope, and vomiting; no)Tj
-0.00301 Tc 0.00301 Tw 0 -1.23809 TD
(sudden death was reported. The rate of reported adverse)Tj
0 Tc 0 Tw T*
(ef)Tj
0.13699 Tw 0.75659 0.00001 Td
(fects with donepezil was lower than that with other)Tj
0.037 Tw 23.81484 38.09523 Td
(AChIs \(except that sudden death was not reported with)Tj
-0.02499 Tc 0.00301 Tw T*
(rivastigmine\). The total number of reports per 100,000 pre-)Tj
0 Tc 0.01199 Tw 0 -1.2381 TD
(scriptions was similar for galantamine and rivastigmine)Tj
-0.01401 Tc 0.01401 Tw T*
(\(52.3 and 57.1, respectively\) but was about 2 times lower)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(for donepezil \(25.9\).)Tj
ET
BT
/T1_1 1 Tf
0 Tw 10.5 0 0 10.5 318 650.8197 Tm
(Discussion)Tj
ET
BT
/T1_0 1 Tf
0.01801 Tw 10.5 0 0 10.5 328.5 629.8197 Tm
(Although galantamine is widely used in the treatment of)Tj
0 Tc 0.01601 Tw -1 -1.2381 Td
[(mild-to-moderate Alzheimer)-35 (\325)55 (s disease and known to be)]TJ
-0.022 Tc 0.022 Tw T*
(well tolerated,)Tj
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 6 0 0 6 374.7861 607.1197 Tm
[(1)76.4 (1)]TJ
ET
BT
/T1_0 1 Tf
-0.022 Tc 0.022 Tw 10.5 0 0 10.5 382.8135 603.8197 Tm
[(its choliner)20 (gically dependent gastrointesti-)]TJ
-0.01801 Tc 0.01801 Tw -6.17271 -1.2381 Td
[(nal adverse ef)20 (fects are well recognized and cardiac distur-)]TJ
-0.01401 Tc 0.01401 Tw T*
(bances have been reported.)Tj
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 6 0 0 6 428.2039 581.1197 Tm
(5)Tj
ET
BT
/T1_0 1 Tf
-0.01401 Tc 0.01401 Tw 10.5 0 0 10.5 433.7424 577.8197 Tm
[(T)71 (o our knowledge, this is the)]TJ
0 Tc 0.03 Tw -11.02308 -1.2381 Td
(first case report of a patient who developed withdrawal)Tj
-0.015 Tc 0.015 Tw T*
[(syndrome and multiple adverse ef)20 (fects when galantamine)]TJ
-0.02499 Tc 0.013 Tw T*
(was reintroduced.)Tj
-0.005 Tc 0.005 Tw 1 -1.23809 Td
(Galantamine is a reversible, competitive AChI and an)Tj
-0.02499 Tc 0.017 Tw -1 -1.2381 Td
(allosteric modulator of nicotinic acetylcholine receptors. In)Tj
0 Tc 0.013 Tw T*
(our case, at least 2 mechanisms of clinical deterioration)Tj
0.17 Tw 0 -1.2381 TD
(warrant discussion. First, galantamine discontinuation)Tj
0.011 Tw T*
(could lead to a withdrawal syndrome similar to that ob-)Tj
0 Tw 0 -1.23809 TD
(served with donepezil.)Tj
ET
BT
/T1_2 1 Tf
0.002 Tc 6 0 0 6 412.6833 464.1197 Tm
(12)Tj
ET
BT
/T1_0 1 Tf
0 Tc 10.5 0 0 10.5 421.3043 460.8197 Tm
[(W)41 (ithin 2 weeks of galantamine)]TJ
-0.013 Tc 0.013 Tw -9.8385 -1.23809 Td
(discontinuation, our patient\325)Tj
-0.01289 Tc 10.90105 0 Td
(s)Tj
-0.013 Tc 0.62598 0 Td
(condition deteriorated, with)Tj
-0.01801 Tc 0.01801 Tw -11.52703 -1.2381 Td
(obvious cognitive, functional, and behavioral decline, and)Tj
0 Tc 0.22501 Tw T*
(therefore, the medication was resumed. Since galan-)Tj
-0.021 Tc 0 Tw T*
(tamine\325)Tj
-0.0211 Tc 2.85154 0 Td
(s)Tj
-0.021 Tc 0.021 Tw 0.61779 0 Td
(half-life is about 6 hours,)Tj
ET
BT
/T1_2 1 Tf
-0.019 Tc 0 Tw 6 0 0 6 455.185 412.1197 Tm
(13)Tj
ET
BT
/T1_0 1 Tf
-0.021 Tc 0.021 Tw 10.5 0 0 10.5 463.5576 408.8197 Tm
(complete galantamine)Tj
0 Tc -13.86263 -1.2381 Td
(elimination \(5 half-lives\) will require approximately 30)Tj
-0.021 Tc 0.02 Tw T*
[(hours, when the ef)20 (fects of sudden withdrawal may appear)55 (.)]TJ
-0.02499 Tc 0.013 Tw T*
(Abrupt discontinuation of AChIs should be avoided. )Tj
-0.017 Tc 0.017 Tw 1 -1.2381 Td
(Second, when galantamine was restarted in our patient,)Tj
-0.01801 Tc 0.01801 Tw -1 -1.23809 Td
[(symptoms and signs of choliner)21.1 (gic excess \(\322toxicity\323\) de)]TJ
0 Tc 21.95295 0 Td
(-)Tj
-0.01199 Tc 0.01199 Tw -21.95295 -1.2381 Td
(veloped. These manifested as nausea, vomiting, diarrhea,)Tj
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
-0.024 Tc 0 Tw 10 0 0 10 60.5 23.9116 Tm
(280)Tj
ET
BT
/T1_3 1 Tf
0 Tc 5 0 0 5 84.2499 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 97.431 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 5 0 0 5 230.556 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 243.737 23.9116 Tm
[(2008 February)55 (, V)110 (olume 42)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0.013 Tw 8 0 0 8 60 749.5293 Tm
(AA Fisher and MW Davis)Tj
ET
0 0 0 0 k
60.5 48.5 491 238.998 re
f
0 0 0 1 K
0.5 w 
60.5 270.791 m
551.5 270.791 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tc 0 Tw 9 0 0 9 118.3628 276.5409 Tm
(T)Tj
-0.02499 Tc 0.011 Tw 0.51185 0.00001 Td
(able 2.)Tj
ET
BT
/T1_6 1 Tf
9 0 0 9 151.8784 276.5409 Tm
[(Main Adverse Ef)19.3 (fects Reported to Australian Adverse Drug Reactions Advisory Committee)]TJ
ET
228.5 256.291 m
303.5 256.291 l
S
BT
/T1_1 1 Tf
0 Tc 0 Tw 7.5 0 0 7.5 242.2613 260.5409 Tm
(Galantamine)Tj
ET
BT
/T1_1 1 Tf
5 0 0 5 287.265 263.2909 Tm
(a)Tj
ET
BT
/T1_1 1 Tf
7.5 0 0 7.5 364.7903 260.5409 Tm
(Donepezil)Tj
ET
BT
/T1_1 1 Tf
5 0 0 5 400.2047 263.2909 Tm
(a)Tj
ET
BT
/T1_1 1 Tf
7.5 0 0 7.5 476.7762 260.5409 Tm
(Rivastigmine)Tj
ET
BT
/T1_1 1 Tf
5 0 0 5 523.4443 263.2909 Tm
(a)Tj
ET
345.5 256.291 m
422.5 256.291 l
S
60.5 242.291 m
551.5 242.291 l
S
BT
/T1_1 1 Tf
-0.01401 Tw 7.5 0 0 7.5 90.8748 246.5409 Tm
(Adverse Effect)Tj
19.03599 0 Td
(A)Tj
7.645 0 Td
(B)Tj
8.053 0 Td
(A)Tj
7.54299 0 Td
(B)Tj
8.358 0 Td
(A)Tj
7.442 0 Td
(B)Tj
ET
465.5 255.291 m
540.5 255.291 l
S
BT
/T1_6 1 Tf
0 Tw 7.5 0 0 7.5 63.5 230.5409 Tm
(Bradycardia)Tj
22.63277 0.00001 Td
(13 )Tj
7.21132 0.00001 Td
(6.12)Tj
5.76401 Tw 8.6302 0.00001 Td
[(26 2.21)-6923 (6)-6172 (4.02)]TJ
0 Tw -38.47429 -1.33336 Td
(Syncope)Tj
23.203 0 Td
(8)Tj
6.642 0 Td
(3.76)Tj
8.644 0 Td
(15)Tj
7.141 0 Td
(1.27)Tj
8.868 0 Td
(8)Tj
6.728 0 Td
(5.37)Tj
5.82201 Tw -61.226 -1.33333 Td
[(Dizziness)-18355 (10 4.71)-7255 (7)-6028 (0.59)-6923 (7)-6171 (4.69)]TJ
0 -1.33334 TD
[(Confusion/delirium/agitation)-10298 (18 8.47)-6698 (56)-6029 (4.77)-6367 (21)-5616 (14.09)]TJ
0 Tw T*
[(Arrhythmia)-18370 (5)-6085 (2.35)-7255 (8)-6028 (0.68)-6923 (2)-6172 (1.34)]TJ
-0.01401 Tw 0 -1.33333 TD
(Bundle branch block)Tj
0 Tw 23.20257 0.00001 Td
[(1)-6086 (0.47)-7254 (1)-6028 (0.08)]TJ
-0.01401 Tw -23.20257 -1.33334 Td
[(Atrioventricular block)-29780 (6)-6028 (0.51)]TJ
0 -1.33334 TD
[(Hypotension/circulatory collapse )-8617 (6)-6086 (2.82)-7255 (5)-6028 (0.42)-6922 (2)-6172 (1.34)]TJ
0 -1.33333 TD
(Myocardial infarct/cardiac arrest)Tj
23.20257 0.00001 Td
(1)Tj
0 Tw 6.64152 0.00001 Td
(0.47)Tj
9.2 0.00001 Td
(7)Tj
6.58408 0.00001 Td
(0.59)Tj
8.86831 0.00001 Td
[(1)-6172 (0.67)]TJ
-54.49648 -1.33338 Td
(Nausea)Tj
22.64667 0.00001 Td
(12)Tj
7.19743 0.00001 Td
[(5.65)-6699 (25)-6028 (2.13)-6367 (17)-5690 (1)74 (1.41)]TJ
-29.84409 -1.33335 Td
[(V)55 (omiting)-19369 (7)-6085 (3.29)-6699 (25)-6028 (2.13)-6441 (1)74 (1)-6172 (7.38)]TJ
T*
[(Diarrhea)-19370 (8)-6085 (3.76)-6699 (15)-6028 (1.27)-6923 (5)-6172 (3.35 )]TJ
-0.01401 Tw 0 -1.33334 TD
[(Fatal outcome)-16882 (5)-6086 (2.35)-6772 (1)74 (1)-6028 (0.93)-6923 (3)-6172 (2.01)]TJ
T*
[(Sudden death)-16991 (3)-6085 (1.41)-7255 (6)-6028 (0.51)-6923 (0)]TJ
0 -1.33333 TD
[(T)111 (otal number of reports)-12001 (1)74 (1)74 (1)-5530 (52.28)-6143 (304)-5472 (25.9)-6923 (85)-5616 (57.06)]TJ
ET
60.5 74.291 m
551.5 74.291 l
S
BT
/T1_6 1 Tf
7.5 0 0 7.5 63.5 80.5409 Tm
(PBS prescription \(to May 2007\))Tj
25.11497 0 Td
(212,309)Tj
15.384 0 Td
(1,173,553)Tj
16.218 0 Td
(148,958)Tj
-56.71697 -2.26666 Td
(PBS = Pharmaceutical Benefits Scheme.)Tj
ET
BT
/T1_1 1 Tf
0 Tw 5 0 0 5 63.5 57.2909 Tm
(a)Tj
ET
BT
/T1_6 1 Tf
-0.00011 Tc 7.5 0 0 7.5 66.2795 54.5409 Tm
[(A)-264 (=)]TJ
0 Tc -0.01401 Tw 1.77875 0 Td
(absolute number of reported cases; B = number of reported cases per 100,\000 prescriptions.)Tj
ET
60.25 48.25 491.5 239.498 re
h
S
BT
0 g
/GS2 gs
/T1_7 1 Tf
0 Tw 5 0 0 5 299.75243 11 Tm
( at UNIV OF MICHIGAN on April 18, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
76 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
77 0 obj
<</OP false/OPM 0/op false>>
endobj
96 0 obj
<</A 97 0 R/Border[0 0 0]/Rect[259.007 9.0 300.752 16.0]/Subtype/Link/Type/Annot>>
endobj
97 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
70 0 obj
[98 0 R]
endobj
71 0 obj
<</Length 12497>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
0.006 Tw 10.5 0 0 10.5 60 730.8196 Tm
(facial trauma, and lacerations to his forehead, nose, and)Tj
-0.00101 Tc 0.00101 Tw 0 -1.23809 TD
[(right elbow following a fall. W)40 (itnesses reported that the)]TJ
-0.022 Tc 0.022 Tw 0 -1.2381 TD
(man had loss of consciousness. He was nauseated and had)Tj
-0.008 Tc 0.008 Tw T*
(vomited the previous day and developed weakness, diar-)Tj
-0.002 Tc 0.00101 Tw 0 -1.23809 TD
(rhea, and dizziness. He fell getting out of the bed on the)Tj
0 Tc 0.062 Tw 0 -1.2381 TD
[(admission day)65 (. Three weeks prior to admission he was)]TJ
0.04401 Tw T*
(restarted on galantamine prolonged release 8 mg in the)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
[(mor)-25 (ning after being of)20 (f the drug for 2 weeks.)]TJ
-0.015 Tc 0.01401 Tw 1 -1.2381 Td
[(About 1.5 years earlier)40 (, the patient was diagnosed with)]TJ
-0.03999 Tc 0.019 Tw -1 -1.2381 Td
[(m)-15 (i)-15 (l)-15 (d)-15 ( )-15 (d)-15 (e)-15 (m)-15 (e)-15 (n)-15 (t)-15 (i)-15 (a)-15 ( )-15 (of mixed etiology \(Alzheimer)-35 (\325)55 (s and vascular\))]TJ
-0.03799 Tc 0.02299 Tw T*
(and was treated with galantamine 8 mg daily with satisfacto-)Tj
-0.03 Tc 0.015 Tw 0 -1.2381 TD
(ry stabilization for the first 3 months and slow worsening in)Tj
-0.035 Tc 0.02 Tw 0 -1.23809 TD
[(the next year)55 (. He scored 26 of 30 on the Folstein Mini-Men-)]TJ
-0.015 Tc 0.011 Tw 0 -1.2381 TD
(tal State Examination \(MMSE\) before and 3 months after)Tj
-0.036 Tc 0.021 Tw T*
[(therapy started and 23 nine months later)55 (. Three months prior)]TJ
-0.035 Tc 0.02 Tw 0 -1.23809 TD
(to the current admission he had a syncopal episode with low)Tj
-0.02699 Tc 0.01199 Tw 0 -1.2381 TD
(blood pressure \(100/80 mm Hg\) but without orthostatic hy)Tj
0 Tc 21.9531 0.00001 Td
(-)Tj
-0.03999 Tc 0.00101 Tw -21.9531 -1.2381 Td
(potension. An electrocardiogram \(ECG\) showed sinus brady-)Tj
-0.015 Tc 0 Tw 0 -1.23809 TD
[(cardia of 59 beats/min, with nor)-25 (mal PR and QT)70 (c intervals)]TJ
-0.02299 Tc 0 -1.2381 TD
(\(T)Tj
0.007 Tw 0.82869 0 Td
(able 1)Tj
ET
BT
/T1_1 1 Tf
-0.021 Tc 0 Tw 6 0 0 6 92.7295 487.1197 Tm
(9,10)Tj
ET
BT
/T1_0 1 Tf
-0.022 Tc 0.007 Tw 10.5 0 0 10.5 102.6914 483.8197 Tm
(\). He was hospitalized, but the cause of syncope)Tj
-0.02699 Tc 0.01199 Tw -4.06585 -1.2381 Td
[(was not identified. T)70 (wo months later)40 (, at a routine check-up,)]TJ
-0.019 Tc 0.004 Tw 0 -1.23809 TD
(galantamine was discontinued by his physician because of)Tj
-0.03999 Tc 0.01601 Tw T*
[(the syncopal episode. W)42.4 (ithin 2 weeks of galantamine discon)]TJ
0 Tc 21.95293 0 Td
(-)Tj
-0.036 Tc 0.021 Tw -21.95293 -1.2381 Td
(tinuation, family members noted worsening in cognitive, be-)Tj
-0.033 Tc 0.01801 Tw T*
(havioral, and functional status. Galantamine was restarted at)Tj
-0.03999 Tc 0.013 Tw T*
(the same dose \(8 mg daily\).)Tj
-0.02299 Tc 0.02299 Tw 1 -1.2381 Td
(The patient had a history of coronary artery disease, hy-)Tj
-0.02499 Tc 0.01199 Tw -1 -1.23809 Td
(pertension, hypercholesterolemia, osteoarthritis, hiatus her)Tj
0 Tc 21.95294 0 Td
(-)Tj
-0.011 Tc 0.011 Tw -21.95294 -1.2381 Td
[(nia, and sur)20.4 (gical treatment for benign prostatomegaly)67.7 (.)]TJ
0 Tw 21.29671 0 Td
(At)Tj
-0.005 Tc 0.005 Tw -21.29671 -1.2381 Td
(the time of presentation, he was also receiving, for more)Tj
0 Tc 0.024 Tw T*
[(than 3 years, irbesartan 75 mg daily)65 (, clopidogrel 75 mg)]TJ
-0.011 Tc 0 Tw T*
(daily)Tj
-0.0114 Tc 1.8779 0 Td
(,)Tj
-0.011 Tc 0.011 Tw 0.48855 0 Td
[(simvastatin 20 mg daily)65 (, pantoprazole 40 mg daily)65 (,)]TJ
-0.00101 Tc 0.00101 Tw -2.36645 -1.2381 Td
[(e)1 (r)21 (gocalciferol 1000 IU daily)65 (, calcium carbonate 600 mg)]TJ
-0.02499 Tc 0.013 Tw T*
[(twice a day)65 (, and acetaminophen 1 g 2 times a day)65 (.)]TJ
-0.022 Tc 0.022 Tw 1 -1.23809 Td
(On admission, the patient was confused, restless, agitat-)Tj
-0.02499 Tc 0.015 Tw -1 -1.2381 Td
[(e)-10 (d)-10 (,)-10 ( )-10 (a)-10 (n)-10 (d)-10 ( )-10 (i)-10 (n)-10 (c)-10 (o)-10 (n)-10 (t)-10 (i)-10 (n)-10 (e)-10 (n)-10 (t)-10 ( )-10 (o)-10 (f)-250 (urine. His blood pressure was 84/46)]TJ
-0.035 Tc 0.005 Tw 24.57143 43.33333 Td
[(mm)-200 (Hg, pulse 79 beats/min, respiratory rate 18 breaths/ min,)]TJ
-0.022 Tc 0.01199 Tw T*
(temperature 36.5)Tj
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 11.5 0 0 11.5 387.6173 716.3197 Tm
(\373)Tj
ET
BT
/T1_0 1 Tf
-0.022 Tc 0.01199 Tw 10.5 0 0 10.5 391.1879 717.8197 Tm
(C, and room-air oxygen saturation 95%.)Tj
-0.024 Tc 0.01401 Tw -6.97027 -1.2381 Td
(He had deep lacerations of his forehead, nose, and right el-)Tj
-0.00999 Tc 0.03799 Tw 0 -1.2381 TD
(bow and loose front upper teeth, but no focal neurologic)Tj
0.06799 Tw 0 -1.23809 TD
[(deficit. Complete blood cell count biochemistry)65 (, thyroid)]TJ
0.039 Tw 0 -1.2381 TD
(function, cardiac troponin I, and C-reactive protein were)Tj
-0.035 Tc 0.013 Tw T*
[(nor)-25 (mal. No blood, urinary)65 (, or fecal infection was detected.)]TJ
-0.02499 Tc 0.02499 Tw 1 -1.23809 Td
[(The QT)70 (c interval was significantly prolonged regardless)]TJ
-0.01401 Tc 0.013 Tw -1 -1.2381 Td
[(of the for)-25 (mula applied \(T)70 (able 1\). Electrocardiographic 24)]TJ
-0.013 Tc T*
(hour Holter recording on the third admission day showed)Tj
-0.009 Tc 0.009 Tw 0 -1.23809 TD
(sinus rhythm with average heart rate 60 beats/min \(mini-)Tj
0 Tc 0.01199 Tw 0 -1.2381 TD
(mum 40, maximum 90\), frequent multifocal ventricular)Tj
-0.032 Tc 0.017 Tw 0 -1.23809 TD
[(e)-15 (c)-15 (t)-15 (o)-15 (pics, runs of ventricular beats, ventricular bigeminy and)]TJ
-0.03799 Tc 0.02299 Tw 0 -1.2381 TD
[(trigeminy)65 (, frequent supraventricular ectopics, aberrantly con-)]TJ
-0.015 Tc 0.08299 Tw T*
(ducted supraventricular run of 10 beats, supraventricular)Tj
-0.039 Tc 0.024 Tw 0 -1.23809 TD
[(bigeminy and trigeminy)65 (, supraventricular tachycardia, but no)]TJ
-0.015 Tc 0.08299 Tw 0 -1.2381 TD
[(pauses. Echocardiogram revealed nor)-22.7 (mal left ventricular)]TJ
-0.03999 Tc 0.004 Tw 0 -1.23809 TD
(size, mild segmental left ventricular dysfunction, and estimat-)Tj
0.013 Tw T*
(ed left ventricular ejection fraction of 51%. )Tj
-0.007 Tc 0.007 Tw 1 -1.2381 Td
(Computed tomography \(CT\) of the head did not show)Tj
0 Tc 0.082 Tw -1 -1.2381 Td
(any evidence of acute intracranial bleed or infarct, but)Tj
-0.00999 Tc 0.00999 Tw T*
(there was prominence of cerebral sulci and the ventricles)Tj
-0.017 Tc 0.017 Tw T*
(in keeping with cerebral atrophy)Tj
-0.0168 Tc 12.46004 0 Td
(,)Tj
-0.017 Tc 0.48308 0 Td
(and there were old lacu)Tj
0 Tc 9.00986 0 Td
(-)Tj
-0.01601 Tc 0.01601 Tw -21.95298 -1.2381 Td
(nar infarcts. CT of the cervical spine revealed fractures of)Tj
-0.015 Tc 0.015 Tw T*
(the spinous process of C4, right superior articular process)Tj
-0.007 Tc 0.007 Tw T*
(of C3, and left superior articular process of C5. Findings)Tj
-0.02499 Tc 0.013 Tw 0 -1.2381 TD
(from chest and abdominal X-rays were unremarkable.)Tj
0 Tc 0.19299 Tw 1 -1.23809 Td
(Galantamine and irbesartan were ceased. No other)Tj
-0.02499 Tc 0.024 Tw -1 -1.23809 Td
(changes in the patient\325)Tj
-0.0251 Tc 8.46684 0 Td
(s)Tj
-0.02499 Tc 0 Tw 0.61314 0 Td
(long-ter)Tj
-0.0251 Tc 2.99008 0 Td
(m)Tj
-0.02499 Tc 0.024 Tw 1.00216 0 Td
(medications were made.)Tj
-0.00999 Tc 0.00999 Tw -13.07222 -1.2381 Td
[(The patient was treated with a cervical collar)40 (, infusion of)]TJ
0 Tc 0.20599 Tw 0 -1.23809 TD
(NaCl 0.9% \(1.5 L/day\), prophylactic antibiotics, and)Tj
-0.007 Tc 0.006 Tw T*
(thromboembolic prophylaxis \(enoxaparin sodium 40 mg)Tj
-0.008 Tc 0.008 Tw 0 -1.2381 TD
(daily\). Lacerations were sutured and loose teeth were re-)Tj
-0.022 Tc 0.022 Tw 0 -1.23809 TD
(moved. His delirium resolved over 6 days, but he required)Tj
-0.024 Tc 0.024 Tw T*
(haloperidol for agitation \(0.25 mg intravenously 6 times in)Tj
-0.00011 Tc 0 -1.2381 TD
(6)Tj
0 Tc 0.13901 Tw 0.88904 0 Td
[(days\). The QT)70 (c interval shortened to 443 msec \(by)]TJ
ET
0 0 0 0 k
318 745 234 10 re
f
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 267.483 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 5 0 0 5 400.608 25.4116 Tm
(n)Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 413.7891 23.9116 Tm
[(2008 February)55 (, V)110 (olume 42    )]TJ
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 5 0 0 5 524.3189 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.024 Tc 10 0 0 10 537.5 23.9116 Tm
(279)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
0 0 0 0 k
60.5 48.5 491 181.582 re
f
0 0 0 1 K
0.5 w 
60.5 212.583 m
551.5 212.583 l
S
BT
0 0 0 1 k
/T1_4 1 Tf
0.011 Tw 9 0 0 9 84.5996 218.3328 Tm
[(T)74 (able 1.)]TJ
ET
BT
/T1_5 1 Tf
9 0 0 9 118.1152 218.3328 Tm
[(Electrocardiographic Characteristics and Corrected QT Intervals Calculat\ed by Dif)18 (ferent Correction Formulas)]TJ
ET
342.5 198.083 m
549.5 198.083 l
S
BT
/T1_4 1 Tf
0 Tc -0.01401 Tw 7.5 0 0 7.5 153.7645 196.3327 Tm
[(Heart Rate, )-3408 (PR,)-3970 (RR,)-4093 (QT)110 (,)]TJ
33.50779 0.80002 Td
[(QT)74 (c, msec, by formula)]TJ
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 484.6291 205.0828 Tm
(a)Tj
ET
60.5 184.083 m
551.5 184.083 l
S
BT
/T1_4 1 Tf
7.5 0 0 7.5 88.9105 188.3328 Tm
(Date)Tj
8.946 0 Td
[(beats/min)-3526 (msec)-3108 (msec)-3175 (msec)-3159 (Bazett)-3274 (Fridericia)-3473 (Framingham)-2984 (Hodges)]TJ
ET
BT
/T1_5 1 Tf
-0.01401 Tw 7.5 0 0 7.5 63.5 172.3328 Tm
(Feb 6, 2007)Tj
13.28898 0 Td
(59)Tj
7.529 0 Td
[(146)-3692 (1017)-3933 (425)-4332 (421)]TJ
24.66399 0 Td
(423)Tj
8.263 0 Td
(422)Tj
7.79099 0 Td
(423)Tj
-61.53598 -1.33333 Td
(May 14, 2007)Tj
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 108.7238 165.0828 Tm
(b)Tj
ET
BT
/T1_5 1 Tf
7.5 0 0 7.5 163.1614 162.3328 Tm
(83)Tj
7.52797 0.00001 Td
[(168)-4249 (723)-3932 (428)-4332 (503)-5479 (477)-6595 (471)-6124 (468)]TJ
-0.01401 Tw -20.81616 -1.33334 Td
[(May 18, 2007)-7258 (54)-6417 (144)-3914 (1)74 (1)74 (1)74 (1)-3932 (468)-4333 (443)-5478 (452)-6595 (451)-6124 (457)]TJ
0 -1.33334 TD
[(May 19, 2007)-7258 (63)-6417 (128)-4248 (952)-3933 (420)-4332 (430)-5479 (427)-6595 (427)-6123 (425)]TJ
0 -1.33333 TD
(May 22, 2007)Tj
0 Tw 13.28819 0.00001 Td
(55)Tj
7.52797 0.00001 Td
[(136)-3692.2 (1091)-3931.9 (456)-4332 (436)]TJ
24.66312 0.00003 Td
(443)Tj
8.263 0 Td
(442)Tj
7.791 0 Td
(447)Tj
-0.01401 Tw -61.53328 -1.33338 Td
(May 24, 2007)Tj
0 Tw 13.28819 0.00001 Td
(59)Tj
7.52797 0.00001 Td
[(136)-3693 (1017)-3932 (444)-4332 (440)]TJ
24.664 0 Td
(441)Tj
8.263 0 Td
(441)Tj
7.792 0 Td
(442)Tj
-0.01401 Tw -61.53516 -1.33335 Td
(Upper normal limit)Tj
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 124.1138 115.0828 Tm
(9)Tj
ET
BT
/T1_5 1 Tf
7.5 0 0 7.5 350.9921 112.3328 Tm
(483)Tj
7.147 0 Td
(460)Tj
8.263 0 Td
(457)Tj
7.791 0 Td
(457)Tj
ET
60.5 96.083 m
551.5 96.083 l
S
BT
/T1_5 1 Tf
-0.01401 Tw 7.5 0 0 7.5 63.5 102.3328 Tm
(Upper normal limit)Tj
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 124.1138 105.0828 Tm
(10)Tj
ET
BT
/T1_5 1 Tf
7.5 0 0 7.5 350.9921 102.3328 Tm
(457)Tj
7.14618 0.00001 Td
(445)Tj
-0.01401 Tw -45.47845 -2.40001 Td
(ECG = electrocardiogram. )Tj
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 63.5 77.0828 Tm
(a)Tj
ET
BT
/T1_5 1 Tf
0.048 Tc -0.034 Tw 7.5 0 0 7.5 66.25 74.3328 Tm
[(Bazett: QT)111 (c = QT/\(RR)]TJ
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 145.8564 77.0828 Tm
(1/2)Tj
ET
BT
/T1_5 1 Tf
-0.034 Tw 7.5 0 0 7.5 153.5297 74.3328 Tm
[(\); Fridericia: QT)111 (c = QT/\(RR)]TJ
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 251.6442 77.0828 Tm
(1/3)Tj
ET
BT
/T1_5 1 Tf
-0.034 Tw 7.5 0 0 7.5 259.3176 74.3328 Tm
[(\); Framingham: QT)111 (c = QT + 0.154 \(1 \320 RR\); Hodges: QT)110 (c = QT + 105 \()]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 514.1443 77.0828 Tm
(1)Tj
ET
BT
/T1_5 1 Tf
0.048 Tc 7.5 0 0 7.5 517.1656 74.3328 Tm
(/RR\3211\).)Tj
0 Tc -0.01401 Tw -60.12208 -1.2 Td
[(Upper normal limits of QT)111 (c interval were determined by Luo et al.,)]TJ
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 282.6186 68.0828 Tm
(9)Tj
ET
BT
/T1_5 1 Tf
-0.01401 Tw 7.5 0 0 7.5 287.3777 65.3328 Tm
(using 10,303 normal ECGs, and by Mason et al.,)Tj
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 448.2501 68.0828 Tm
(10)Tj
ET
BT
/T1_5 1 Tf
-0.01401 Tw 7.5 0 0 7.5 455.7888 65.3328 Tm
(using 46,129 normal ECGs.)Tj
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 63.5 58.0828 Tm
(b)Tj
ET
BT
/T1_5 1 Tf
-0.01401 Tw 7.5 0 0 7.5 66.5542 55.3328 Tm
(Day of hospital admission.)Tj
ET
60.25 48.25 491.5 182.082 re
h
S
BT
0 g
/GS2 gs
/T1_6 1 Tf
0 Tw 5 0 0 5 299.75243 11 Tm
( at UNIV OF MICHIGAN on April 18, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
72 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
73 0 obj
<</OP false/OPM 0/op false>>
endobj
98 0 obj
<</A 99 0 R/Border[0 0 0]/Rect[259.007 9.0 300.752 16.0]/Subtype/Link/Type/Annot>>
endobj
99 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
65 0 obj
[100 0 R]
endobj
66 0 obj
<</Length 10666>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 18.25 391 13 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.024 Tc 10 0 0 10 60 24.4116 Tm
(278)Tj
ET
BT
/T1_1 1 Tf
0 Tc 5 0 0 5 83.7499 25.9116 Tm
(n)Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 96.931 24.4116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 5 0 0 5 230.0559 25.9116 Tm
(n)Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 243.237 24.4116 Tm
[(2008 February)55 (, V)110 (olume 42)]TJ
ET
0 0 0 0 k
472 18 79.5 13 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tw 10 0 0 10 475.7004 24.1616 Tm
[(www)75 (.theannals.com)]TJ
ET
0 0 0 1 K
2 w 
225.299 709.926 m
373.096 709.926 l
S
BT
/T1_3 1 Tf
0.075 Tc 0.011 Tw 18 0 0 18 238.4009 712.5727 Tm
[(C)-25 (ASE REPOR)90 (TS)]TJ
ET
0.001 708.829 234.6 16.046 re
f
0 0 0 0 k
60 38.659 492 479.282 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
0 Tc 0 Tw 27.357 0 0 27.357 59.7366 497.7603 Tm
(A)Tj
ET
BT
/T1_5 1 Tf
-0.039 Tc 0.024 Tw 10.5 0 0 10.5 77.875 510.7603 Tm
(cetylcholinesterase inhibitors \(AChIs\))Tj
-0.03999 Tc 0.019 Tw 0 -1.2381 TD
[(a)-15 (r)-15 (e)-15 ( )-15 (u)-15 (s)-15 (ed in treatment of mild-to-mod-)]TJ
-0.021 Tc 0.006 Tw -1.70238 -1.23809 Td
[(erate Alzheimer)-35 (\325)56 (s disease.)]TJ
ET
BT
/T1_0 1 Tf
-0.02 Tc 0 Tw 6 0 0 6 164.5682 488.0604 Tm
(1,2)Tj
ET
BT
/T1_5 1 Tf
-0.021 Tc 0.006 Tw 10.5 0 0 10.5 174.152 484.7603 Tm
(These drugs)Tj
-0.015 Tc 0.092 Tw -10.87162 -1.23809 Td
(also improve cognition in patients with)Tj
-0.01601 Tc 0.00101 Tw T*
(other types of dementia, as well as those)Tj
-0.02699 Tc 0.01199 Tw 0 -1.23809 TD
(with schizophrenia, and may have neuro)Tj
0 Tc 15.1911 0 Td
(-)Tj
-0.034 Tc 0.019 Tw -15.1911 -1.2381 Td
(protective properties.)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0 Tw 6 0 0 6 141.4777 436.0604 Tm
(3)Tj
ET
BT
/T1_5 1 Tf
-0.03439 Tc 10.5 0 0 10.5 146.7392 432.7603 Tm
(A)Tj
-0.034 Tc 0.019 Tw 0.92248 0 Td
(Cochrane review)Tj
-0.015 Tc 0.302 Tw -9.18336 -1.2381 Td
[(concluded that there is no dif)20 (ference)]TJ
-0.03999 Tc 0.013 Tw T*
[(among AChIs with respect to ef)20 (ficacy)65 (.)]TJ
ET
BT
/T1_0 1 Tf
0 Tc 0 Tw 6 0 0 6 206.3149 410.0604 Tm
(1)Tj
ET
BT
/T1_5 1 Tf
0.127 Tw 10.5 0 0 10.5 70.5 393.7603 Tm
(AChIs are well tolerated.)Tj
ET
BT
/T1_0 1 Tf
0.00101 Tc 0 Tw 6 0 0 6 180.0401 397.0604 Tm
(1,4)Tj
ET
BT
/T1_5 1 Tf
0 Tc 10.5 0 0 10.5 191.5024 393.7603 Tm
(Among)Tj
-0.022 Tc 0.022 Tw -12.52404 -1.2381 Td
[(choliner)20 (gically mediated adverse ef)20 (fects,)]TJ
-0.02499 Tc 0.02499 Tw T*
(gastrointestinal symptoms \(nausea, vom-)Tj
0 Tc 0.048 Tw T*
(iting, diarrhea, anorexia\) predominate.)Tj
-0.01401 Tc 0.01401 Tw 0 -1.2381 TD
(Patients receiving AChIs rarely develop)Tj
0 Tc 0.186 Tw 0 -1.23809 TD
[(potentially serious cardiovascular ad)3 (-)]TJ
-0.015 Tc 0.015 Tw T*
[(verse ef)19.3 (fects such as syncope, bradycar)]TJ
0 Tc 15.19097 0.00002 Td
(-)Tj
-0.024 Tc 0.024 Tw -15.19097 -1.23811 Td
(dia, atrial arrhythmias, and sinoatrial and)Tj
-0.00999 Tc 0.00999 Tw T*
(atrioventricular block.)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0 Tw 6 0 0 6 150.9171 293.0603 Tm
(5)Tj
ET
BT
/T1_5 1 Tf
-0.00999 Tc 0.00999 Tw 10.5 0 0 10.5 156.4806 289.7603 Tm
(Seventeen cases)Tj
-0.01401 Tc 0.01401 Tw -9.18863 -1.2381 Td
(of cardiac dysrhythmias associated with)Tj
-0.009 Tc 0.009 Tw T*
(donepezil have been reported.)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0 Tw 6 0 0 6 183.384 267.0604 Tm
(6)Tj
ET
BT
/T1_5 1 Tf
-0.009 Tc 0.009 Tw 10.5 0 0 10.5 188.9529 263.7603 Tm
[(T)71 (wo pa-)]TJ
-0.006 Tc 0.006 Tw -12.28123 -1.2381 Td
(tients, one on galantamine)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0 Tw 6 0 0 6 168.7279 254.0604 Tm
(7)Tj
ET
BT
/T1_5 1 Tf
-0.006 Tc 0.006 Tw 10.5 0 0 10.5 174.3159 250.7603 Tm
(and another)Tj
0 Tc 0.02499 Tw -10.88723 -1.2381 Td
(on rivastigmine,)Tj
ET
BT
/T1_0 1 Tf
0 Tw 6 0 0 6 128.4997 241.0604 Tm
(8)Tj
ET
BT
/T1_5 1 Tf
0.02499 Tw 10.5 0 0 10.5 134.3897 237.7603 Tm
(developed prolonged)Tj
-0.021 Tc 0.021 Tw -7.08473 -1.23809 Td
(cardiac repolarization \(prolonged QT in)Tj
0 Tc 15.191 0.00001 Td
(-)Tj
-0.01199 Tc 0.01199 Tw -15.191 -1.2381 Td
(terval\), which may lead to life-threaten)Tj
0 Tc 15.19106 0.00001 Td
(-)Tj
-0.021 Tc 0.021 Tw -15.19106 -1.2381 Td
(ing polymorphic ventricular arrhythmias)Tj
-0.02499 Tc 0.013 Tw T*
(\(torsade de pointes\).)Tj
-0.03 Tc 0.019 Tw 1 -1.2381 Td
[(W)80 (e report a case in which galantamine)]TJ
-0.01401 Tc 0.004 Tw -1 -1.2381 Td
(was associated with QT interval prolon-)Tj
-0.019 Tc 0.009 Tw T*
(gation, syncope, delirium, vomiting, and)Tj
0 Tc 0.244 Tw 0 -1.2381 TD
[(d)10 (i)10 (a)10 (r)10 (r)10 (hea. W)80 (e also searched the Aus-)]TJ
-0.021 Tc 0.021 Tw T*
(tralian Adverse Drug Reaction Advisory)Tj
-0.024 Tc 0.024 Tw 0 -1.23809 TD
(Committee \(ADRAC\) database for simi-)Tj
-0.02499 Tc 0.013 Tw 0 -1.2381 TD
[(lar ef)21.5 (fects related to AChIs.)]TJ
ET
BT
/T1_6 1 Tf
0.011 Tw 10.5 0 0 10.5 318 94.3901 Tm
(Case Report)Tj
ET
BT
/T1_5 1 Tf
-0.006 Tc 0.006 Tw 10.5 0 0 10.5 328.5 73.3902 Tm
(An 85)Tj
0 Tw 2.4733 0.00001 Td
(-year)Tj
0 Tc 2.00379 0.00001 Td
(-)Tj
-0.006 Tc 0.006 Tw 0.40183 0.00001 Td
(old white man, who was a widower and a)Tj
0 Tc 0.017 Tw -5.87891 -1.23811 Td
(resident of an assisted living facility was brought to the)Tj
-0.024 Tc 0.024 Tw T*
[(emer)20 (gency department by ambulance because of agitation,)]TJ
ET
0 0 0 0 k
60 566.941 492 85 re
f
BT
0 0 0 1 k
/T1_7 1 Tf
-0.02499 Tc 0.011 Tw 16.8 0 0 16 60 623.0804 Tm
[(Pr)25 (olong)15 (ed QT Inter)-30 (val, Syncope)-20 (, and Delirium with Galantamine)]TJ
ET
BT
/T1_4 1 Tf
10.5 0 0 10 60 587.0804 Tm
(Alexander A Fisher and Michael W Davis)Tj
ET
0.5 w 
60 60.25 m
294 60.25 l
S
BT
/T1_4 1 Tf
8.5 0 0 8.5 60 48 Tm
(Author information provided at the end of the text.)Tj
ET
0 0 0 0.14999 k
239 118.042 313 399.899 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
-0.036 Tc 0 Tw 7 0 0 7 251 501.2782 Tm
(OBJECTIVE)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 288.4204 501.2782 Tm
(:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.00101 Tw 8.5 0 0 8.5 293.6549 501.2782 Tm
[(T)111 (o describe a case of QT interval prolongation, syncope, and delirium)]TJ
0 Tc 0.22701 Tw -5.01822 -1.29411 Td
(associated with galantamine use and to analyze similar cases related to)Tj
-0.013 Tc 0.013 Tw 0 -1.29412 TD
(acetylcholinesterase inhibitors \(AChIs\) reported to the Australian Adv\erse Drug)Tj
-0.02499 Tc 0.011 Tw T*
(Reaction Advisory Committee \(ADRAC\).)Tj
ET
BT
/T1_6 1 Tf
-0.02 Tc 0 Tw 7 0 0 7 251 454.2783 Tm
[(CASE)-397 (SUMMAR)37 (Y)]TJ
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 307.0682 454.2783 Tm
(:)Tj
ET
BT
/T1_4 1 Tf
-0.01401 Tc 0.01401 Tw 8.5 0 0 8.5 312.6178 454.2783 Tm
(An 85-year-old man with dementia was treated with prolonged)Tj
-0.013 Tc 0.013 Tw -7.24915 -1.29412 Td
(release galantamine 8 mg daily for 1.5 years. Three months prior to the \current)Tj
-0.022 Tc 0.022 Tw T*
(admission, he had a syncopal episode with low blood pressure and bradyca\rdia.)Tj
0 Tc T*
(T)Tj
0.065 Tw 0.55591 0 Td
(wo months later)Tj
-0.00011 Tc 7.13146 0 Td
(,)Tj
0 Tc 0.62088 0 Td
(galantamine was withdrawn, but within 2 weeks, the man)Tj
0.261 Tw -8.30825 -1.29413 Td
(developed marked cognitive, behavioral, and functional deterioration and\)Tj
-0.01601 Tc 0.01601 Tw T*
[(galantamine was restarted. Three weeks later)55 (, he developed syncope, delirium,)]TJ
0 Tc 0.067 Tw T*
(hypotension, and prolonged QT interval with serious cardiac arrhythmias,\ in)Tj
-0.017 Tc 0.017 Tw T*
(addition to vomiting and diarrhea. A complete blood cell count and bioch\emistry)Tj
0 Tc 0.27699 Tw T*
(panel performed on admission were normal. No infection was detected.)Tj
-0.015 Tc 0.015 Tw T*
(Galantamine and irbesartan were ceased. The delirium fully resolved in 6\ days,)Tj
0 Tc 0.075 Tw T*
[(and the QT interval shortened from 503 to 443 msec \(corrected by Bazett\\325)18 (s)]TJ
-0.02499 Tc 0.011 Tw T*
(formula\) 4 days after discontinuation of galantamine and remained norma\l. )Tj
ET
BT
/T1_6 1 Tf
-0.02299 Tc 0 Tw 7 0 0 7 251 319.2783 Tm
(DISCUSSION)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 292.9467 319.2783 Tm
(:)Tj
ET
BT
/T1_4 1 Tf
-0.03101 Tc 0.01601 Tw 8.5 0 0 8.5 298.4751 319.2783 Tm
[(I)-15 (n the ADRAC reports, galantamine was associated with 18 cases of)]TJ
-0.015 Tc 0.104 Tw -5.58531 -1.29412 Td
(delirium/confusion, 8 of syncope, 13 of bradycardia, 6 of other arrhythm\ias or)Tj
-0.037 Tc 0.022 Tw T*
(conduction abnormalities, and 6 of hypotension. Donepezil was associated\ with 56,)Tj
-0.015 Tc 0.011 Tw T*
[(15, 26, 15, and 5, and rivastigmine with 21, 8, 6, 2, and 2, respectivel\y)74 (, of these)]TJ
-0.019 Tc 0.004 Tw 0 -1.29411 TD
(reactions. Five fatal outcomes were reported in association with galanta\mine, 1)Tj
0 Tc 33.44433 0.00001 Td
(1)Tj
-0.015 Tc 0.12199 Tw -33.44433 -1.29413 Td
(with donepezil, and 3 with rivastigmine, including 3, 6, and 0 sudden de\aths,)Tj
0 Tc 0.16499 Tw 0 -1.29412 TD
[(r)15 (e)15 (s)15 (p)15 (e)15 (c)15 (t)15 (i)15 (v)15 (ely)74 (. This case, along with previously published reports and cases)]TJ
-0.02 Tc 0.02 Tw T*
(identified from the ADRAC database, illustrates that AChIs may lead to d\elirium,)Tj
-0.017 Tc 0.017 Tw T*
(syncope, hypotension, and life-threatening arrhythmias. The Naranjo prob\ability)Tj
0 Tc 0.25999 Tw T*
(scale indicated that galantamine was the probable cause of QT interval)Tj
-0.02499 Tc 0.011 Tw T*
(prolongation, syncope, and delirium in this patient.)Tj
ET
BT
/T1_6 1 Tf
-0.03 Tc 0 Tw 7 0 0 7 251 195.2783 Tm
(CONCLUSIONS)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 300.3924 195.2783 Tm
(:)Tj
ET
BT
/T1_4 1 Tf
-0.021 Tc 0.021 Tw 8.5 0 0 8.5 305.8704 195.2783 Tm
(Administration of galantamine and other AChIs requires vigilance)Tj
0 Tc 0.02699 Tw -6.45534 -1.29412 Td
(and assessment of risk factors that may precipitate QT interval prolonga\tion,)Tj
-0.02499 Tc 0.011 Tw 0 -1.29411 TD
(syncope, and delirium.)Tj
ET
BT
/T1_6 1 Tf
-0.036 Tc 0 Tw 7 0 0 7 251 159.2783 Tm
[(KEY)-377 (WORDS)]TJ
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 292.8581 159.2783 Tm
(:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.011 Tw 8.5 0 0 8.5 298.1792 159.2783 Tm
(delirium, galantamine, prolonged QT interval, syncope.)Tj
ET
BT
/T1_8 1 Tf
8.5 0 1.80673 8.5 251 144.2783 Tm
(Ann Pharmacother)Tj
ET
BT
/T1_4 1 Tf
0 Tw 8.5 0 0 8.5 322.581 144.2783 Tm
(2008;42:278-83.)Tj
0.011 Tw -8.42129 -1.76471 Td
(Published Online, 8 Jan 2008, )Tj
ET
BT
/T1_8 1 Tf
0 Tw 8.5 0 1.80673 8.5 360.8325 129.2783 Tm
[(www)55 (.theannals.com)]TJ
ET
BT
/T1_4 1 Tf
-0.0251 Tc 8.5 0 0 8.5 432.7881 129.2783 Tm
(,)Tj
-0.02499 Tc 0.011 Tw 0.51686 0 Td
(DOI 10.1345/aph.1K514)Tj
1 g
/T1_9 1 Tf
-0.278 Tc 0 Tw 1 0 0 1 -1000 1792 Tm
( )Tj
ET
BT
0 g
/GS2 gs
/T1_10 1 Tf
0 Tc 5 0 0 5 299.75243 11 Tm
( at UNIV OF MICHIGAN on April 18, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
26 0 obj
<</BaseFont/LORKSW+GillSans/Encoding 23 0 R/FirstChar 32/FontDescriptor 25 0 R/LastChar 84/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 708 0 500 0 0 0 0 0 0 0 0 0 823 510 0 604 458 604]>>
endobj
42 0 obj
<</BaseFont/QESCJA+GillSans-Bold/Encoding 39 0 R/FirstChar 32/FontDescriptor 41 0 R/LastChar 121/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 271 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 802 0 0 813 0 333 0 0 0 0 0 0 656 875 0 604 719 0 0 0 0 0 0 0 0 0 0 0 0 531 0 500 583 552 0 542 583 271 0 0 271 958 583 594 583 0 448 0 406 583 510 781 0 510]>>
endobj
46 0 obj
<</BaseFont/WZUNIQ+Helvetica-Oblique/Encoding 43 0 R/FirstChar 32/FontDescriptor 45 0 R/LastChar 119/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 556 0 500 0 556 0 0 556 0 0 0 222 833 556 556 0 0 333 500 278 0 0 722]>>
endobj
50 0 obj
<</BaseFont/QCENPR+Helvetica-Bold/Encoding 47 0 R/FirstChar 32/FontDescriptor 49 0 R/LastChar 32/Subtype/Type1/Type/Font/Widths[278]>>
endobj
47 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space]/Type/Encoding>>
endobj
49 0 obj
<</Ascent 750/CapHeight 717/Descent -205/Flags 262178/FontBBox[-170 -227 1001 963]/FontFile3 48 0 R/FontName/QCENPR+Helvetica-Bold/ItalicAngle 0/StemH 0/StemV 140/Type/FontDescriptor/XHeight 737>>
endobj
48 0 obj
<</Length 313/Length1 313/Subtype/Type1C>>stream
  QCENPR+Helvetica-Bold   @¯ ¯¯¯¯˚>˚w˙}˙W
 ãã
 ãã      ≤   Äçï002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki BoldHelsinki      ¸wü¯ßö˜,óíüòã˜£ó¸|ãı
˜ å
_˜™˘
endstream
endobj
43 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 46/period 65/A 80/P 97/a 99/c 101/e 104/h 108/l/m/n/o 114/r/s/t 119/w]/Type/Encoding>>
endobj
45 0 obj
<</Ascent 717/CapHeight 687/Descent -194/Flags 32/FontBBox[-214 -224 1198 931]/FontFile3 44 0 R/FontName/WZUNIQ+Helvetica-Oblique/ItalicAngle 0/StemH 0/StemV 88/Type/FontDescriptor/XHeight 737>>
endobj
44 0 obj
<</Length 1421/Length1 1421/Subtype/Type1C>>stream
  WZUNIQ+Helvetica-Oblique   E¯ ¯¯¯¯˚:˚t˙|˙7
 ã
 o
 ãã      ¸  !¨  l Äà002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki    " O  1 I B S N D P U F X  M T    < ~ Å √ ˝â¬!s∫ÎHÜñ´%ú†v˜d‚¯:wô˘˘ ˚ò˘a˚˚†˝aÓ÷˜d˜≥“˚d!˜ª˚r˜˜–ç-†v¯^€|wÃﬁ8‰˜è‚Ù¯Ä˜˜˜IŒ˚EZpM_âÙ’8¸üÏ‰˜∞˜¿ÃÂ’≠`.˚÷¸ú†v˜¬ﬁ˜é›·Ì˜ÁÓ˘¯ò˜6€˚˚◊˝aÌ˜¬˜u˜··˜(â6Y_+˚U˜é˜XÈºb;-†v¯_€˜FwÃ„˜è‚¯˜˜˜
KÕ˚HbtLYâ˜ú3˝a„˜±˜¬ Î–™f:˚È-|‘[v˜âÕ˜8‘Ø‰L€˜Ö„6‡µ¯§Àá~ÉäÑvÉî°˜¡Ê@¬˚˚HT˚
Ñ€—ï∞©Ÿ÷∑kSi{wlá˚$yπ$~SQ.0ÕOÌ◊√§«ƒˆQë§t√ûñçî°∫˚%˜HK>Q5Qf´ø¿Ø©ÿî˜òÜä≥ü˚—†v¯PÈ|wÿ›9„˜ﬂ¯PÊç~ÑåáQamB]â„9¸üË„˜ƒ‹√∆Ÿ˜K†v¯_⁄|wÃﬁ8„˜q„˜n„ˆ˘î˜˛˜KŒ%Lp|EJ≈o^¶IGYoNcâˆ’8¸üÓ„˜±Ù¡–ﬂæ´fO˚˛„˜”Ÿ¡…ŒÃ´c:˚Ê˚*{ÿ¯"⁄©È˜†‡7ﬂË¯q˜L7<y]_I1Z“˜˜¬’Áœ±h>ö‡˜}GÃ˚˚)*˚˚?˚8Á ˜"˜€÷˜ô-}◊¯$◊ÆÊ˜ƒÊ¯ù˜ö˜7'˜˚#˚#'˚˚7˚8Ó˚˜$˜$Ó˜˜80˚P=..PŸ˜˜∆ŸËË∆=˚¸Ñ◊¯’ﬂ„˜ï–mezó®˜Áﬂ’7˜&3˚&EA—˚Ï?¨g–úôåë≥-|◊˜@—˜/€≥Ë˜¥‚8ÊÙ¯ò˜}˜V:˜˚%˚1.˚ ˚K˚6Á'˜*¯˜ÿ»˜
ß4J{YeC.W√˜ÜÙ˜∏—˚∏Ïî«≈›Ô∞@;è”†v¯üwõ˘I˘Y¯ü4 ¸.â&¯.)&¸.â'¯.,˜+¸üÂÒ¯)çÙ¸)Ê¸ãı‚Û˜Sı#!¸@†v˘awŒ„˜/˘a3˝a˚*|÷˜2ŸV÷˜$◊´ﬂGﬂ˜y‡D„’¯c˜2‘c± ¶ˆ4°<üyòã±∑µ® ‹±pNê‡˜ ÇF√˚˚=J%I≥a›wŸrﬁv†}ãdW]k@2d©ŸÅ7éTíqùp´\”oÊã˜ãﬁ–ãÛu°¯üö˜)õôü˜°ñ¸}ö◊
„
_˜™˘
endstream
endobj
39 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma 68/D 71/G 73/I 80/P/Q 83/S/T 97/a 99/c/d/e 103/g/h/i 108/l/m/n/o/p 114/r 116/t/u/v/w 121/y]/Type/Encoding>>
endobj
41 0 obj
<</Ascent 716/CapHeight 682/Descent -221/Flags 262176/FontBBox[-177 -230 1167 929]/FontFile3 40 0 R/FontName/QESCJA+GillSans-Bold/ItalicAngle 0/StemH 0/StemV 145/Type/FontDescriptor/XHeight 728>>
endobj
40 0 obj
<</Length 2332/Length1 2332/Subtype/Type1C>>stream
  QESCJA+GillSans-Bold   A¯ ¯¯¯¯˚E˚zè˙5
 ãã
 ãã       ;±  ˆ }ãîCopyright (c) 1990 Adobe Systems Incorporated. All Rights Reserved.Gill Sans is a trademark of The Monotype Corporation Plc.Gill Sans BoldGill Sans    1 S P M O H F E  2 5 * U W B  4 Z D Q % J V N X I (    E Ö Ã Â'Búü3Lã∞ I¢Œk∞È)ò”¸ë†v˜¶˜˜2˜ﬁ˜>˜M˜Cﬁ˘>˝>˜>˜¶˜˜1œ˜ÎËE˜˚0˚˚«Á¨vQXoo=<˚^†v˜‚˜ÇwÀ˜%∞˜e¯a˚%¸a˜%˜[–‡´≠Ω¿¢§Ås±≥˜a™rñnãS[^+`âSÇ·˜«·∞˜/˜f˜/¯¡˜z˜E˚& ˚˚˚9˚1˚%˜,˜+Ò˜1√˜K˚/è&gSGTXÆ˜Û∂º ‘™O1¸†v˘>w ˜%˜d˘>˚%˝>˜%H†v¯	„3Ï«˜%˜A˜%ÿ˜a¯a˚%¸a˜%∏˜Ωƒ±¶ûØ¥™pJ˚≠˜%˜π˜+¥CP^uV]˚ ˚z·˜ˇ a¿ ˇ GaHˇ I·Hˇ õ˝pÏ5·ß˜˚˜1˜˜˜%˜ÚÄ¯¶¯a˚¶˚:c˚RÒ@6—[∆ÇâpÖR~Zj§y™ÇâÙ@%qvYdNøB˜V˜)Íªˆ¢ÑØm©Ò@?ÿ˚D]¿¡˜[››ÚÄ§§úÆ¥¶Ñ°{ßÕÍÄ˚ÌB∫Ø∞ªΩ¨fa[fc]]e±∏Ù@˜\¸lcpK>aûÆ≠µ†œ”¥yj)Ç·˜◊·∞˜*˜_˜¯í˜#ZG^zQ0Sª›Ü˜ﬂ˜<í˚Í˚˚"&'˚!˚$Ù-˜6Ø‚ã»ﬁ˚‘˜{Àë∞∞ƒ√±eLëHÇÏ3„˜±Ï˜hwÆ˜'˜Y˜%º¯†˘>˚%˚Öûddïa˚/)˚!˚Á%˜º±ò¨¥|f˜%º˚%˜pmrÄlG`√ﬂÁ∂¿‘•≠|†¸˜u˚1˜
¯‡˜"∫˜C¯D˜C˘œmEt˚ †A∂˜+πÚ˜ã˜+ã˜2˚˜R˚ïã˚àã˚)˚Gã˚Cã˚M˜,˚˜t˜7˜K˜Ç˜˜¸¸¯˜·ﬂ˜˜	ÓB˚˚,@˚˚5ﬁ˜–†v¯¡˜˜ß˜>˘H˘>˝,˚˜ã¸¡˜>¯¡˜ã˚—†v˘>w›˜>˜ê˘>˚>˝>˜>˚àÇˆ˜úÓŸ˜%¯¯a˚<˜%y˚U˚loÕ˚Z˚ﬁ_Î∏±ì†æÙwdoÑm^q®∏˜R˜<˚ óv¯jwç¯é˜kÇ‹˜h¯j˚.(˚í)˜í˚/˚Ç·˜ºÏ¨˜'˜˜%¯ß˜siÄâÅ|Çî¢˜f<≤˚BHxfO˚
∫πÕ©≈ üi`à˚UO:u˚Q¬T’Ωπô±√fï¢|ª≤ƒù£≥˚t⁄usn~pqv°¶π¥ü·™¸óvÍ˜Ω˚=ÌïŸ„ÔŒb∫P\hj]fõuÆ}ë[uTnq]Ç˜¯V˜∂˜C˜@˜C¯™˘∞5Fõ?˚2%=˚
˚â˜Ô¥ã˚chtJ@O¢Ã)˚'hœ∆l˜˜,˜◊˜˜Ç˚ÔnãÚ≠≤°»≈∆z_Ó˚ ˚\v˘>wå¯ê¯ë¯a˚,#˚Å*˜Å˚/˜H¸˚˚º˜.˚*ÇÚ˜óv™ˆ≥˜/¯c˜sKlÉh8T¡›‹√ø‚Ø∑Äw±˜ ù[Oó\˚,˚'˚!˚$Ù-˜6ººï†≈H˚ev˜qÏ˜õv∞È-Úƒ˜%˜[˜'ˆ˜^¯a˚%˝G˜%˜ëw≠∑¥˜ÂÏ˜(Ó˜-Ò˚Yb|ib0ßØ¢î™–≥X35_UDnqî†n˜,ã˜¯D˜÷˜>˜·˜C÷˘>˝>˜Æ˜§˜˜$˜X˜O˚˜/˚ç˚˚˜˜5 (˚	'X˚˚?˚¸†v¯awÂ˜4¬˜4˚,˜%Ë˜d¯a˚%¸a˜%0B˘G_gg__Øg∑∑ØØ∑∑gØ_HÇÏ3„¯	w«˜%˜A˜%x¯˜%¯a˚&∏˚∫^|ci_eh¢Ã˜±˚%˚ª˚ŸSÊ≈∏°¿π˜»†v¯	ÏÇw ˜%˜[˜%˜[˜%º˜d¯a˚%¸a˜%‹˜…µÆ±°±∂∏r@˚•˜%˜ªæ¨≤¶µ¿´fI˚¢˜%˜ºÙ@–"FVnFOÕkU´;npÜÄpºqqzrt˜óv¯jwä˘£¯˜Ü˜˚è–˜c¯j˚(*˚í%˜í3$˚í*˜í˚(˜d¸jœH†v¯ ı˜hw…˜%˜@˜%˜c˘>˚%˝>˜%˜∫º≠®†≠∏©kF˚õ˜%˜∫˜6æ7R\sVaâ˜7Ç˜"Û˜˜O˜"∫˜C˜é˜ì˚0˜>¯˘k˘¨G(¢%˚á˚<˚#˚d˚`˜=˚%˜ÇÙ˜˜≤¿æ˜´¯˚°˚ÙÓ;wYváa˚!,€˜Ã˜˜M¯ﬂﬂva‚Çî˘>î˚zî˜äó˜Ÿí¸∆îÓ
å
yXO	˜™˘
endstream
endobj
23 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 65/A 67/C 69/E 79/O/P 82/R/S/T]/Type/Encoding>>
endobj
25 0 obj
<</Ascent 716/CapHeight 682/Descent -230/Flags 32/FontBBox[-162 -230 1041 911]/FontFile3 24 0 R/FontName/LORKSW+GillSans/ItalicAngle 0/StemH 0/StemV 89/Type/FontDescriptor/XHeight 728>>
endobj
24 0 obj
<</Length 850/Length1 850/Subtype/Type1C>>stream
  LORKSW+GillSans   @¯ ¯¯¯¯˚6˚z˙•˙#
 ãã
 ãã   Ó   Í  ∑  & |ÖCopyright (c) 1990 Adobe Systems Incorporated. All Rights Reserved.Gill Sans is a trademark of The Monotype Corpration Plc.Gill Sans    $ " 4 &  3 1 0 5 
   M Ñ ÿ\òÔ¸≈ÇÂ¯úÂª˘$˘≤.DúE˚m˚1˚,˚d˚#˜˚Y˜îˆ‘§ÆŒˆY>7p>˚8˚ı˜-˜*˜˜˜0⁄”uZﬂú†v˜]„¯!wã˘/˜˛˘BF˚π˝BÔ·˜]˜∂Ê˚]Ô˚È¯¨˜˚ã˚h˚TÇ„¯†„≥Ê˜`Ê¯#˘´[WõW˚9D˚˚O˜ª{ã˚!eh[?HLÆÀY˚`ƒ«w’˜‹Ÿˆ˜m˚ªâã˜ª∏¨ π√{T≈˚*ã„˜h„˜b„÷Ì¯b˘>¸˝>¯ „˚æ˜h˜´„˚´˜b˜µ¸]†v˜º„˜jﬂÿÌ˜Yÿ˘>˝>Ì˜º¥Ω¥{˚ ÂÂ˚ ˜	\Ãz¢n∫W‡e M¥‘®¥∆ã⁄ã˜
5‘˚ãA7 Í±dKåRåmU"L˚ †v˜ª„˜g„—Ì˜{—˘>˝>Ì˜ªÒ˜2”ﬂˆ˜ G„˚)˚3˜‰¶UYG\dB˚˜AÇÂ¯úÂ∏¯ß∏˜È˚M˜!˚9˜s˜{˜˜:˜L˜R˚"˜4˚u˚q˚%˚5˚Q˜*˜˜˜,˜-˜˚˚*˚)˚˚˚-˚,˚˜˜)]†v¯Ê„˜ëÌ¯ﬂ˘>¸Œ3˜Ä¸ÊÌ¯Ê˜ÄÅï˘>ó˚âî˜ñó˜€ê¸∆ã€
‰Z 

yXO	˜™˘
endstream
endobj
67 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
68 0 obj
<</OP false/OPM 0/op false>>
endobj
100 0 obj
<</A 101 0 R/Border[0 0 0]/Rect[259.007 9.0 300.752 16.0]/Subtype/Link/Type/Annot>>
endobj
101 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
63 0 obj
<</CreationDate(D:20080123145847Z)/Creator(QuarkXPress\(tm\) 6.52)/ModDate(D:20150418043643-07'00')/Producer(QuarkXPress\(tm\) 6.52)/Title(Layout 1)/XPressPrivate(%%DocumentProcessColors: Black\n%%EndComments)>>
endobj
xref
0 102
0000000000 65535 f
0000042249 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000001838 00000 n
0000029411 00000 n
0000029841 00000 n
0000029634 00000 n
0000017173 00000 n
0000033313 00000 n
0000033602 00000 n
0000033399 00000 n
0000017019 00000 n
0000033857 00000 n
0000034289 00000 n
0000034081 00000 n
0000016635 00000 n
0000124949 00000 n
0000125269 00000 n
0000125067 00000 n
0000118425 00000 n
0000058305 00000 n
0000058870 00000 n
0000058667 00000 n
0000057646 00000 n
0000018603 00000 n
0000019346 00000 n
0000019141 00000 n
0000017823 00000 n
0000064557 00000 n
0000065033 00000 n
0000064820 00000 n
0000057202 00000 n
0000122139 00000 n
0000122538 00000 n
0000122326 00000 n
0000118690 00000 n
0000120271 00000 n
0000120639 00000 n
0000120428 00000 n
0000119071 00000 n
0000119581 00000 n
0000119881 00000 n
0000119668 00000 n
0000119430 00000 n
0000037818 00000 n
0000038235 00000 n
0000038020 00000 n
0000016241 00000 n
0000001882 00000 n
0000001970 00000 n
0000002288 00000 n
0000002557 00000 n
0000002838 00000 n
0000003107 00000 n
0000003388 00000 n
0000000016 00000 n
0000126457 00000 n
0000000097 00000 n
0000107681 00000 n
0000107707 00000 n
0000126196 00000 n
0000126254 00000 n
0000018514 00000 n
0000094849 00000 n
0000094874 00000 n
0000107423 00000 n
0000107481 00000 n
0000083865 00000 n
0000083890 00000 n
0000094591 00000 n
0000094649 00000 n
0000069863 00000 n
0000069888 00000 n
0000083607 00000 n
0000083665 00000 n
0000042548 00000 n
0000042573 00000 n
0000069605 00000 n
0000069663 00000 n
0000003645 00000 n
0000003670 00000 n
0000042290 00000 n
0000042348 00000 n
0000042393 00000 n
0000042492 00000 n
0000069708 00000 n
0000069807 00000 n
0000083710 00000 n
0000083809 00000 n
0000094694 00000 n
0000094793 00000 n
0000107526 00000 n
0000107625 00000 n
0000126299 00000 n
0000126400 00000 n
trailer
<</Size 102/Root 62 0 R/Info 63 0 R/ID[<AC7E45C73F2CD577463BA47748C58553><C20427E3D11DB2110A001A0A10000000>]>>
startxref
126685
%%EOF
